2021
Notice of Annual Meeting of Shareholders and Proxy Statement
About United Therapeutics

Our company was founded 25 years ago with the challenge of finding a way to cure or treat a rare, life-threatening illness suffered by our CEO’s daughter. That mission continues today, has grown to encompass a variety of rare diseases, and drives everything that we do. Early on, we developed a roadmap to success based on five strategic objectives:

- Develop the best medicines possible from our intellectual property
- Conduct the most insightful clinical trials of our medicines
- Achieve superior communication and awareness of our products among physicians
- Grow our business to be in the top quintile of our peers
- Achieve our goals by doing the right thing and using the highest ethical standards

Our Commitment to Corporate Social Responsibility

PATIENT-CENTRIC APPROACH

The parents of a child with pulmonary arterial hypertension founded United Therapeutics, so we take our commitment to patients personally. Through our relentless pursuit of life-changing therapies, medical devices, and transplantation technologies, and our patient support and assistance programs, we are striving to improve the lives of patients with PAH and other life-threatening diseases.

ENVIRONMENTAL STEWARDSHIP

We take sustainability seriously, as we believe that reducing our carbon footprint is a responsibility shared by all. Through our focus on constructing site net zero energy and LEED-certified buildings, we are taking a leadership role in driving the use of sustainable technologies forward.

OUR PEOPLE

We couldn’t be the creative company we are without attracting, enabling, and valuing diverse, hard-working, team-playing employees we call “Unitherians”. We have a company-wide minimum living wage, on-site subsidized day care, and a suite of health and wellness benefits to take care of our Unitherians holistically. Our Board and management teams lead our racial, ethnic, gender, and professional diversity initiatives.

AWARDS AND RECOGNITION

Fortune’s 2020 Great Places to Work

The Washington Post’s 2020 Top Places To Work

Triangle Business Journal 2020 Best Places to Work
LEAD INDEPENDENT DIRECTOR’S LETTER

To Our Fellow Shareholders,

No company can command its people to deliver the creativity, loyalty, and drive that create biotechnology magic and shareholder value. But since our founding, we have worked to set ourselves apart as a caring, daring, and happily different team that enables its people to give their best — and get our best.

Think this is corporate hype? Think again.

United Therapeutics was founded to find treatments for pulmonary arterial hypertension (PAH), following the PAH diagnosis of the daughter of our Founder, Chairperson, and CEO. Patient-centricity is real here.

We didn’t need the brutal events leading to the renewed focus on social justice to understand the value of a diverse team, both in creativity and in leadership. Our twelve-member board includes five women, three directors who self-identify as under-represented minorities, and one who self identifies as a member of the LGBTQ+ community. Our management team is similarly diverse — 47% female and 29% identify as racial or ethnic minorities.

That’s just the beginning. We adhere to a minimum “living wage,” enable every employee to become a shareholder, and provide an array of health, savings, education, work-life integration, family, and other benefits to treat our employees holistically and turn jobs into careers.

That isn’t all. Not only did we not lay off, furlough, or reduce the pay of any Unitherians as a result of the pandemic, despite initially having to stop enrollment of our clinical trials and put other projects on hold, we gave every employee multiple additional bonuses in 2020 to help them face the sometimes major challenges that new work protocols and family changes created.

Even that isn’t all. Later this year we will be asking you, our shareholders, to support our conversion into a public benefit corporation (PBC) to match the legal status of our subsidiary Lung Biotechnology PBC. We believe our charter should align with our values — and how we already run the company — and not the other way around.

And is all this working for our shareholders? We now have four approved therapies to treat PAH plus a drug for a rare pediatric cancer; we recently obtained FDA approval for the first-ever treatment of pulmonary hypertension associated with interstitial lung disease; we have a strong pipeline of studies in various fibrotic diseases; and we have exciting programs in the organ transplant space — including organ printing. The combination of our steady revenue streams, conservative budgeting, exceptional leadership, and a powerhouse of creative Unitherians helped us deliver a 72% stock price increase during 2020.

I am proud to be the Lead Independent Director of United Therapeutics, honored to be a member of our exceptional Board and team, and unabashed about asking for your voting support on the items described in this Proxy Statement so we can continue to redefine the biotech norm and deliver for you, our patients, our Unitherians, and our stakeholders.

Onward!

CHRISTOPHER PATUSKY, J.D., M.G.A.
Lead Independent Director
Vice Chair of the Board
Chair of the Compensation Committee
United Therapeutics at a Glance

WHAT IS UNITED THERAPEUTICS?

United Therapeutics is a profitable, 25-year old, $9B+ market cap, dare-to-be-different biotechnology company that is building on its expertise and success developing therapies for PAH to address other chronic, life-threatening medical conditions ranging from pulmonary fibrosis, to pediatric cancer, to organ manufacturing and transplantation. Our profit margins are among the strongest in the entire biotechnology industry.

WHAT DID WE DO IN 2020?

We continued to deliver strong operating results from our four PAH therapies and our pediatric cancer treatment, yielding revenues of ~$1.5 billion and net income of over $500 million. But this solid result was by no means a given.

Like many companies, we felt the impact of the COVID-19 pandemic. It delayed the launch of the Remunity® Pump for Remodulin® until February 2021. Enrollment of our clinical trials was temporarily paused as hospitals shut down. We felt pressure on our revenues, as it became difficult for patients to start advanced therapies, and our staff was limited to virtual interactions with healthcare providers. Our product development teams, however, quickly found ways to adapt clinical trial protocols and expand clinical site activation efforts, and we worked hard to ensure patients had uninterrupted access to our therapies.

We obtained approval of the Remunity Pump for Remodulin in 2020, and launched the product in February 2021. We believe this product will help us maintain and grow Remodulin revenues going forward. We submitted a supplemental new drug application for Tyvaso® in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD), which the FDA approved in March 2021 following the results of an exciting study published in the New England Journal of Medicine.

We also continued to listen to our shareholders — twice reaching out to those representing over 70% of our shares to offer engagement with our Board members — and steadily increased the detailed information we provide on our sustainability efforts, Board refreshment, and compensation practices. And we amended our certificate of incorporation to begin the destaggering of our Board of Directors.

HOW DID WE DO IN 2020?

Our solid 2020 results in the midst of a pandemic are a testament to the value of our focus on being a built-to-last, long-focused, and people-focused company. Successful R&D efforts led to a return to revenue growth in 2020, and strong revenues coupled with conservative budgeting generated substantial free cash flow. These contributed to our strong financial condition, including $3.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2020 ($2.2 billion net of $800 million in indebtedness).

This execution led to a significant rebound in our stock price. During 2020, our stock price grew by 72%, outperforming the 26% return generated by the Nasdaq Biotechnology Index.

WHERE ARE WE HEADING?

In addition to the already-launched label expansion for Tyvaso in PH-ILD and the Remunity Pump for Remodulin, both in 2021, we are striving toward additional potential product approvals/launches such as Tyvaso DPI™ and the Implantable System for Remodulin.

We expect to continue to grow revenue from our treprostinil-based therapies through label expansions, new indications, new formulations, and the introduction of new delivery devices. We are also working on a number of entirely new therapies to treat PAH and other rare diseases that we hope to launch over the next several years. Longer-term, we have set the ambitious goal of solving the acute shortage of transplantable organs through our innovative organ manufacturing programs, including ex-vivo lung perfusion, xenotransplantation, regenerative medicine, and organ printing.

Our conservative balance sheet not only places our company in a very strong position to weather successfully the continued economic effects of the pandemic, but also gives us strategic flexibility to continue to seek out and drive down “corridors of indifference” to help patients with PAH and other orphan lung diseases in need.

Finally, we started the process, which we hope our shareholders will approve later in 2021, to amend our charter to become a Delaware public benefit corporation, which is already the legal status of our subsidiary Lung Biotechnology PBC. We believe this step will align our charter with our existing values and operating model.
UNITED THERAPEUTICS CORPORATION
NOTICE OF 2021 ANNUAL MEETING OF SHAREHOLDERS

DATE AND TIME
Friday, June 25, 2021
10:30 a.m. Eastern Time

LOCATION
virtualshareholdermeeting.com/UTHR2021

WHO CAN VOTE
Shareholders as of April 30, 2021 are entitled to notice of, and to vote at, our 2021 Annual Meeting of Shareholders.

Voting Items

<table>
<thead>
<tr>
<th>Company Proposals</th>
<th>Board Vote Recommendation</th>
<th>For Further Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Election of the five directors named in the Proxy Statement</td>
<td>&quot;FOR&quot; each director nominee</td>
<td>Page 20</td>
</tr>
<tr>
<td>2 Advisory resolution to approve executive compensation</td>
<td>&quot;FOR&quot;</td>
<td>Page 41</td>
</tr>
<tr>
<td>3 Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan</td>
<td>&quot;FOR&quot;</td>
<td>Page 74</td>
</tr>
<tr>
<td>4 Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for 2021</td>
<td>&quot;FOR&quot;</td>
<td>Page 83</td>
</tr>
</tbody>
</table>

Shareholders will also consider and act upon such other business as may properly come before the Annual Meeting of Shareholders and any adjournment or postponement thereof. Proxy materials or a Notice of Internet Availability are being distributed to shareholders on or about May 7, 2021. This year’s Annual Meeting will be conducted solely virtually via live audio webcast. Our Board reached this decision after careful consideration and in light of ongoing developments related to COVID-19. A virtual format will enable shareholders to participate from any location and at no cost, while safeguarding the health of our shareholders, management, and Board. To attend the meeting online, vote your shares electronically, or submit questions, go to the website listed above. The Annual Meeting will begin at 10:30 a.m. Eastern Time on Friday, June 25, 2021, and you are encouraged to login early to avoid any delay due to technical issues. Please review the information in the Proxy Statement for additional information. Whether or not you expect to attend the meeting virtually, you are requested to vote your shares as promptly as possible so that your shares are represented at the meeting. All shareholders are extended a cordial invitation to attend this meeting. Our list of shareholders as of the Record Date will also be available for inspection for the ten days prior to the Annual Meeting. To inspect the list, please email our Investor Relations department at IR@unither.com.

By Order of the Board of Directors,

PAUL A. MAHON
Corporate Secretary
April 29, 2021

How to Vote

INTERNET
Before the meeting, go to proxyvote.com
During the meeting, go to virtualshareholdermeeting.com/UTHR2021

TELEPHONE
[800] 690-6903

MAIL
Mark, sign, date, and promptly mail the enclosed proxy card in the postage-paid envelope

Important Notice Regarding the Availability of Proxy Materials for United Therapeutics Corporation’s 2021 Annual Meeting of Shareholders to Be Held on Friday, June 25, 2021: United Therapeutics Corporation’s Proxy Statement and Annual Report on Form 10-K are available at: ir.unither.com/annual-and-proxy
# TABLE OF CONTENTS

**FORWARD-LOOKING STATEMENTS**

This Proxy Statement contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 (PSLRA). These statements, which are based on our beliefs and expectations as to future outcomes, include, among others, statements about our future operating results, business plans, objectives, pipeline advancements, benefits of our products, and any other statements that contain the words *believe*, *seek*, *expect*, *anticipate*, *forecast*, *project*, *intend*, *estimate*, *should*, *could*, *may*, *will*, *plan*, or similar expressions, and any other statements contained or incorporated by reference into this Proxy Statement that are not historical facts. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission (SEC), as well as risks stemming from COVID-19, that could cause actual results to differ materially from anticipated results. These statements may also be based on standards for measuring progress that are still developing and on assumptions that are subject to change in the future. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the SEC, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the PSLRA for forward-looking statements.

**WEBSITE REFERENCES**

Website references included throughout this Proxy Statement are provided for convenience. The content on the referenced websites are not incorporated herein and are not part of this Proxy Statement.

## LEAD INDEPENDENT DIRECTOR’S LETTER


## UNITED THERAPEUTICS AT A GLANCE


## NOTICE OF 2021 ANNUAL MEETING OF SHAREHOLDERS


## BUSINESS OVERVIEW

**Our Business**

2020 Performance in Review


## CORPORATE RESPONSIBILITY


## PROXY SUMMARY

**Voting Matters**

Governance Highlights

Executive Compensation Highlights


## OUR CORPORATE GOVERNANCE

**PROPOSAL 1: Election of Directors**

Selecting Directors

How We Select Our Director Nominees

Board Diversity

Board Skills

Proxy Access

Majority Voting

Policy on Overboarding

Board Declassification

Stock Ownership Guidelines

Board of Directors and Nominees

Nominees for Election at our 2021 Annual Meeting of Shareholders

Class II Directors Continuing in Office with Terms Ending in 2022

Class III Directors Continuing in Office with Terms Ending in 2023

Director Independence

Board Structure

Board Leadership

Committees of our Board of Directors

Corporate Governance Guidelines and Committee Charters

Board Roles and Responsibilities

Risk Oversight

Shareholder Engagement

Board Education

Meetings of our Board of Directors and Board Attendance at Annual Meetings of Shareholders

Shareholder Communication with Directors

Non-Employee Director Compensation

Overview

Equity-Based Awards

2020 Non-Employee Director Compensation
EXECUTIVE COMPENSATION

PROPOSAL 2: Advisory Resolution to Approve Executive Compensation

Letter from Our Compensation Committee

Compensation Discussion and Analysis
  Overview
  Company Introduction
  Our Named Executive Officers
  2020 Performance Highlights
  Shareholder Outreach and Responsiveness to our 2020 Say-on-Pay Vote

Overview of our 2020 Executive Compensation Program

Pay Element Overview

2020 Compensation Decisions

2020 Compensation Program Design

Key Governance Features of our Executive Compensation Program

Other Executive Compensation Policies and Practices

Compensation Committee Report

Compensation Tables
  Summary Compensation Table
  Grants of Plan-Based Awards in 2020
  Narratives to Summary Compensation Table and Grants of Plan-Based Awards in 2020 Table
  Outstanding Equity Awards at 2020 Fiscal Year-End
  Option Exercises and Stock Vested in 2020
  Pension Benefits in 2020
  Supplemental Executive Retirement Plan
  Potential Payments Upon Termination or Change in Control

Pay Ratio

PROPOSAL 3: Approval of The Amendment and Restatement of The United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan

AUDIT MATTERS

PROPOSAL 4: Ratification of The Appointment of Ernst & Young LLP as United Therapeutics Corporation’s Independent Registered Public Accounting Firm for 2021

Report of our Audit Committee

Principal Accountant Fees and Services

Policy on Audit Committee Pre-Approval of Audit Services and Permissible Non-Audit Services of our Independent Auditors

OTHER MATTERS

Certain Relationships and Related Party Transactions

Beneficial Ownership of Common Stock

Delinquent Section 16(a) Reports

Shareholder Proposals and Director Nominations

Other Business

Shareholders Sharing the Same Address

Annual Report

INFORMATION ABOUT THE MEETING, VOTING, AND PROXIES

Attending the Annual Meeting

General

Record Date and Outstanding Shares

Internet Availability of Proxy Materials

Solicitation

Voting Rights and Quorum

Proxy

ANNEX A - United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan

ANNEX B - Non-GAAP Financial Information
B U S I N E S S  O V E R V I E W

Our Business

We market four products for PAH and one product for pediatric high-risk neuroblastoma (NB). One of our PAH products, Tyvaso, has recently been approved to treat PH-ILD, making it the only approved therapy to treat this life threatening disease that we believe impacts at least 30,000 patients in the United States.

Innovation and Revenue Growth Despite Generic Challengers

Three of our PAH products are prostacyclin analogues based on the molecule treprostinil: Remodulin (delivered parenterally, via intravenous (IV) or subcutaneous (subQ) pumps), Tyvaso (an inhaled product), and Orenitram® (an oral tablet). Our fourth PAH product is Adcirca®, a PDE-5 inhibitor. Unituxin® is a monoclonal antibody for treatment of high-risk NB.

In 2018, generic versions of Adcirca were introduced, leading to a sharp decline in our revenue for this product, which is typical of the generic erosion curve for a small-molecule oral product. In addition, we saw the market entry of a generic version of Remodulin used in IV pumps in March 2019. Although many analysts predicted sharp declines for Remodulin, we expected and saw a resilient response, with relatively few U.S. patients choosing the generic version over branded Remodulin. Our U.S. Remodulin revenues have remained strong, and our overall revenues from our treprostinil-based products grew by 5% in 2020 compared to 2019. Revenues from two of our treprostinil-based products (Orenitram and Tyvaso) grew by 30% and 16%, respectively.

Going forward, we are actively working to improve the treprostinil molecule and each of its delivery systems to enhance convenience, safety, and patient outcomes. We are also actively studying additional indications for Tyvaso. We expect these efforts will result in revenue growth for each of our treprostinil-based products.

Remodulin: Next-Generation Parenteral Pump Systems

Our next-generation IV and subQ treprostinil pump systems are designed to improve patient convenience and potentially serve some of the 30-40% of PAH patients who refuse parenteral therapy because of site pain, the inconvenience of current pump designs or interference with lifestyle choices. We made substantial progress with our next-generation pump systems in 2020; the FDA cleared the pharmacy-filled Remunity Pump for Remodulin in February 2020 and we launched the Remunity Pump commercially in February 2021.

1. **IMPLANTABLE SYSTEM FOR REMODULIN**
   - Ease of use and reduced risk of bloodstream infections
   - Once-monthly refills or longer

2. **REMUNITY**
   - Small, lightweight, durable subQ pump with disposable cartridges
   - Flexible dosing via an acoustic volume sensing technology

3. **REMLIFE**
   - Next-generation ambulatory infusion pump with smartphone compatibility
   - Development-stage program

30-40% OF PAH PATIENTS REFUSE PARENTERAL THERAPY BECAUSE OF CONCERNS AROUND IV USE, SUBQ PAIN, OR LIFESTYLE INTERFERENCE

(1) Based on UT market research
(2) The FDA requires that certain conditions of Medtronic’s PMA approval of the Implantable System for Remodulin (ISR) must be satisfied prior to launch or sale of the ISR; accordingly, ISR labeling may be revised in the process of satisfying such conditions of approval.
Orenitram: FREEDOM-EV Label Expansion

In October 2019, the FDA approved a label expansion for Orenitram that incorporated the results of our FREEDOM-EV study. The FREEDOM-EV study showed that Orenitram, when taken with an oral PAH background therapy, decreased the risk of a clinical worsening event versus placebo by 25% (p=0.0391), driven by a 61% decrease in the risk of disease progression for patients taking Orenitram, when compared to placebo (p=0.0002). Orenitram is now indicated to delay disease progression and improve exercise capacity. We believe this will drive continued growth in Orenitram revenues.

Tyvaso: INCREASE, PERFECT, and TETON Studies in New Indications

In 2020, we announced the successful results of the INCREASE study of our Tyvaso inhaled treprostinil therapy in PH-ILD, and the FDA approved the addition of PH-ILD to the Tyvaso label in March 2021. We estimate there are over 30,000 U.S. patients with PH-ILD, who until now have had no approved therapies to treat their condition. In addition, we are conducting a pivotal study of Tyvaso in patients with PH associated with chronic obstructive pulmonary disease (PH-COPD) called the PERFECT study, and have recently commenced the TETON study of Tyvaso to treat idiopathic pulmonary fibrosis (IPF). We believe there are approximately 100,000 PH-COPD and 100,000 IPF patients in the United States. Presently, there are no FDA-approved therapies indicated to PH-COPD, and treatment options for IPF patients are extremely limited.

Treprostinil Label Expansion Efforts

<table>
<thead>
<tr>
<th>Study</th>
<th>Potential U.S. Population</th>
<th>Data Read-Out</th>
<th>FDA Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>FREEDOM-EV</td>
<td>45,000</td>
<td>✔</td>
<td>TBD</td>
</tr>
<tr>
<td>INCREASE</td>
<td>30,000</td>
<td>✔</td>
<td>TBD</td>
</tr>
<tr>
<td>PERFECT</td>
<td>100,000</td>
<td>Study ongoing</td>
<td>TBD</td>
</tr>
<tr>
<td>TETON</td>
<td>100,000</td>
<td>Study startup</td>
<td>TBD</td>
</tr>
</tbody>
</table>

Tyvaso DPI

We are developing a dry powder formulation of treprostinil called Tyvaso DPI for the treatment of PAH, under a license from MannKind Corporation (MannKind). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat® inhalation device technology used in MannKind’s Afrezza® (insulin human) Inhalation Powder product, which was approved by the FDA in 2014. We believe this product, which is a small, pocket-sized inhaler that does not need electricity, will have significant convenience advantages over current inhaled prostacyclin alternatives, which rely on the use of lengthy breathing sessions with nebulizers that need to be plugged in. Following successful pivotal development studies that demonstrated biocomparability between Tyvaso DPI and Tyvaso Inhalation Solution, we submitted an NDA to the FDA to approve this new therapy in April 2021 to treat both PAH and PH-ILD. We anticipate an expedited eight-month FDA review of this NDA as a result of our use of a priority review voucher we purchased in January 2021.

Prodrug Development: RemoPro™ and OreniPro™

We are conducting a series of phase 1 studies to develop a new prodrug of treprostinil called RemoPro, which is intended to enable subcutaneous delivery of treprostinil therapy without the site pain currently associated with subcutaneous Remodulin. As a prodrug, RemoPro is designed to be inactive in the subcutaneous tissue, which should decrease or eliminate site pain, and to metabolize into treprostinil once it is absorbed into the blood. We are also developing an oral prodrug version of Orenitram we call OreniPro, in order to provide increased tolerability and convenience through a once-daily dosing regimen.
We’re Moving Beyond Treprostinil...

We believe that treprostinil will be one of the standards of care in PAH for some time to come and anticipate significant growth through label expansions (such as PH-ILD for Tyvaso) and new formulations and delivery devices. In addition, we are working on programs beyond treprostinil that we think could have an outsized impact on patients with PAH and other lung diseases.

**Ralinepag in PAH.** Ralinepag is a next-generation, oral, selective, and potent prostacyclin receptor agonist in development for the treatment of PAH. We are conducting two phase 3 studies of ralinepag: [1] **ADVANCE OUTCOMES**, which is an event-driven study of ralinepag in PAH patients with a primary endpoint of time to first clinical event; and [2] **ADVANCE CAPACITY**, which studies the effect of ralinepag on exercise capacity in PAH patients with a primary endpoint of change in peak oxygen uptake via a cardiopulmonary exercise test. Both of these studies are global, multi-center, placebo-controlled trials of patients on approved oral background PAH therapies. We believe ralinepag’s once-daily dosing will make it highly competitive with the existing approved oral prostacyclin agonist, selexipag, which is a competitor’s product that generated U.S. revenues of more than $1.0 billion in 2020.

**Aurora-GT™.** We’re conducting a clinical study (called **SAPPHIRE**) of a gene therapy product called Aurora-GT, in which a PAH patient’s own endothelial progenitor cells are isolated, transfected with the gene for human endothelial nitric oxide synthase, expanded ex-vivo, and then delivered to the same patient. This product is intended to rebuild the blood vessels in the lungs that are destroyed by PAH. This is a registration stage study in Canada sponsored by Northern Therapeutics, Inc., a Canadian entity in which we have a 49.7 percent voting stake and a 71.8 percent financial stake. We have the exclusive right to pursue this technology in the United States.

...and Seeking a Cure

We believe that the ultimate solution for PAH patients and patients with many other life-threatening diseases is a cure through transplantation. Each year, end-stage organ failure kills millions of people. A significant number of these patients could have benefited from an organ transplant. Unfortunately, the number of usable, donated organs available for transplantation has not grown significantly over the past half century, while the need has soared. Our long-term goals are aimed at addressing this shortage. With advances in technology, we believe that creating an unlimited supply of tolerable manufactured organs is now principally an engineering challenge, and we are dedicated to finding engineering solutions.

We are heavily engaged in the early-stage research and development of a number of organ transplantation-related technologies including regenerative medicine, organ bio-printing, xenotransplantation, and ex-vivo lung perfusion.
# 2020 Performance in Review

## Strong Revenue Performance Despite COVID-19
- Overall revenue grew in 2020 compared to 2019
- U.S. treprostinil-based revenues reached an all-time high
- Orenitram revenue grew by 30% compared to 2019, with the FREEDOM-EV label expansion
- Tyvaso revenue grew by 16% in 2020 compared to 2019

## Industry-Leading Profitability
- Over $500 million in net income for 2020; diluted EPS of $11.54, and non-GAAP Diluted EPS* of $14.46
- 34.7% net profit margin and 57.1% EBITDASo margin*, compared to -3.2% average net profit margin and 16.3% average EBITDASo margin for our compensation peer group
- $1.6 million in 2020 revenue per employee, which ranks 5th among the companies in our compensation peer group (the top 25 companies, by revenue, in the Nasdaq Biotechnology Index)

## Continued Innovation and R&D Progress
- Readout of positive INCREASE study results, February 2020
- Continued progress on clinical studies supporting Tyvaso DPI, leading to April 2021 NDA submission with FDA
- FDA clearance of the pharmacy-filled Remunity Pump, February 2020
- Continued progress on phase 3 ralinepag clinical study, despite pandemic

## Strong Balance Sheet Poised for Future Investment
- $3.0 billion in cash, cash equivalents, and marketable investments at December 31, 2020
- $800 million in debt outstanding at December 31, 2020
- Strong balance sheet well-positioned to endure economic instability, and pursue strategic R&D and business development initiatives

*A reconciliation of our non-GAAP measures and other information relating to such measures can be found in Annex B.*

## Steady Performance During 2020 Despite COVID-19

The COVID-19 pandemic presented a number of challenges, causing us to pause enrollment of all of our clinical trials and delay the launch of the Remunity Pump, and making it more difficult to sell our therapies. We felt pressure on our revenues, as it became difficult for patients to start advanced therapies, and our staff was only able to interact virtually with healthcare providers. Our solid balance sheet and conservative budgeting algorithm mitigated these impacts, and we made no pandemic-related reductions in staffing, employee compensation, or research and development programs. Many of our employees were forced to adapt to a new work-from-home environment, while others continued to work in-person to keep our manufacturing and research and development efforts on track to ensure an uninterrupted supply of our therapies to patients. We are very proud of the work of our employees, and grateful for their efforts during these challenging times. Our many accomplishments in 2020 have put our company on a solid footing for an exciting year in 2021 and beyond.
Corporate Responsibility

Mission and Unitherian Culture

At United Therapeutics, we are crystal clear about our purpose and talk about it often — developing innovative therapies for unmet needs, with the ultimate objective of finding a cure for end-stage organ diseases by creating an unlimited supply of transplantable organs. We maintain a vibrant, entrepreneurial culture, instilling our employees with a sense of ownership and meaning that we believe gives us a competitive advantage in achieving our mission.

Our Patients

**Innovation:** In 2020, we reported the results of the first-ever successful pivotal study of a therapy in patients with PH-ILD, a condition impacting over 30,000 patients in the U.S. with no approved therapies until our Tyvaso therapy was approved in that indication this year.

**Patient Safety:** Nearly 1,800 volunteers participated in 19 of our clinical trials in 2019. We are subject to external audits by health authorities who verify that we are complying with applicable laws, regulations, and ethical standards. No regulatory inspections of our clinical trials resulted in required, voluntary, or official actions or monetary fines in 2019.

**Patient Support, Education, and Financial Assistance:** We rolled out our first copay assistance care program for patients taking Adcirca in 2010. During the past ten years, over 20,000 patients have enrolled in our ASSIST programs and received help in filling over 240,000 dispensed prescriptions.

Our People

**Diversity & Inclusion:** We are fully committed to diversity, equity, and inclusion — see details below.

**Communication:** Recent surveys showed that 93% of our participating employees “have a high degree of trust, are likely to be retained, and are highly engaged.”

**People Programs:** Our people programs are designed to demonstrate how much we value our employees, and to enable all employees to participate in our financial success. For example, all full-time domestic employees receive minimum annual compensation of $75,000, including salary and bonus eligibility. We also provide meaningful opportunities for employees to share in our success by making every full-time employee a shareholder through our long-term incentive programs. We offer market-leading benefit programs and provide access to a variety of health and wellness facilities and programs, such as on-site childcare centers and state-of-the-art fitness centers, and access to 24/7 employee assistance programs.

**COVID-19 Response:** We worked hard to support our employees during the pandemic, as discussed further below.

Our Planet and Communities

**Environmental Stewardship:** We operate eleven solar arrays that generate over 20% of the electricity that we consume on an annual basis. We also buy renewable energy credits to offset 100% of the electrical consumption at our Silver Spring, MD campus other than our site net zero Unisphere facility.

**Historical Environmental Data:** We provide information about our environmental footprint. As we expand our environmental, social, and governance (ESG) reporting efforts, we remain committed to taking groundbreaking steps to diminish our climate impact and enhance our disclosures.

**Our Community Programs:** In 2019, we held our annual Community Service Day events at both our RTP and Silver Spring locations. We had over 280 employees participate in our half and full day experiences which benefit local organizations in our communities. In 2020, in light of the pandemic we held a virtual Community Service Day where each employee was provided a cash stipend to donate to the non-profit charity of their choosing, and employees shared the details of their chosen organizations and any related service activities on our internal social media platform.
Our Principles & Other Priorities

**Ethics & Compliance:** Our Compliance Principles, based on our key tenet of “Do the Right Thing,” outline how we expect all Unitherians to behave.

**Workplace Safety:** We had 8 recordable/reportable incidents for our U.S. operations in 2020, with an overall incidence rate of 0.9 per 100 full-time workers. This is significantly below the incidence rate of 1.7 per 100 full-time workers for our industry.

**Supply Chain Management:** United Therapeutics maintains a rigorously compliant GxP Quality & Compliance program covering those aspects of our supply chain that could impact the quality and safety of our products. We use more than 700 pre-qualified raw material vendors and service providers to support clinical and commercial business operations.

For more details about our commitment to Corporate Responsibility, download our 2020 Corporate Responsibility report at corporateresponsibility.unither.com. The information on the sustainability website and in the 2020 Corporate Responsibility report are not incorporated by reference into, and do not form part of, this Proxy Statement.

Diversity, Equity, and Inclusion

Over the course of 2020, we strengthened our focus on Diversity, Equity & Inclusion (DE&I) at the Board level and throughout our company. We paused, listened to our employees, and took stock of where we are, and where we want to take DE&I together as an organization. Our goal is to ensure that DE&I continues to be ingrained into our DNA. To this end, in 2020 we:

- Engaged with an external consultant that specializes in fostering DE&I in workplaces
- Met with Unitherians across the organization in small group sessions to hear their voices, perspectives, and ideas about DE&I
- Established an Inclusion Advisory Group and a DE&I Executive Council, two working groups comprised of Unitherians whose purpose is to provide input, education, and oversight for our ongoing DE&I initiatives
- Enhanced our public disclosures with the publication of our first Corporate Responsibility Report in November 2020
- Developed a multi-year, company-wide training initiative designed to promote and enrich awareness of important diversity, equity, and inclusion topics. In 2020, all of our employees participated in these training sessions.

Support for Our Employees During the Pandemic

During the COVID-19 pandemic we have remained committed to supporting the health and wellness of our employees who are working hard to ensure we are able to maintain a continuous supply of medicines to our patients. Early in the pandemic we provided personal protective supply kits to all employees, and we moved quickly to transition all employees who could work remotely to a work-from-home model. For those employees required to come to our facilities, we remain focused on providing the safest possible working environment.

To further support our employees during this challenging time, we provided all employees with multiple cash bonuses to supplement their regular salaries and bonuses, which have not been impacted by the pandemic, and provided our employees with paid leave when they have been unable to work due to COVID-19 related issues. Throughout the pandemic, we have maintained consistent contact with our employees to keep them informed and feeling connected. We are committed to ensuring the safest possible work environment and acknowledging our employees’ contributions during this unprecedented time.
Creating a Sustainable Public Benefit Corporation

In 2021, we plan to seek shareholder approval to convert our company from a traditional Delaware corporation into a Delaware public benefit corporation (PBC). We believe this change will help align our legal form with our longstanding commitment to serve our patients; enhance our ability to recruit and retain top talent; reinforce our standing and credibility with regulators and stakeholders; attract more of the rapidly growing pools of duration, impact, and ESG-screened capital; and therefore enhance our ability to create excellent and sustainable value for our shareholders.

The fiduciaries of public benefit corporations must identify the specific public benefit mission they will pursue alongside their creation of shareholder value. They must also report on their promotion of this specific public benefit mission.

This proposed conversion is a logical extension for us. In 2015, we formed the first-ever PBC subsidiary of a public biopharmaceutical company, called Lung Biotechnology PBC, chartered in Delaware with the express purpose of “address[ing] the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply.” These technologies include xenotransplantation, regenerative medicine, organ bioprinting, and ex-vivo lung perfusion.

After operating our PBC subsidiary for six years, we are convinced that the time is right to convert United Therapeutics into a PBC. We have seen growing understanding and acceptance of the PBC form, most recently in the successful conversion of Veeva Systems Inc., a public company, to a PBC, following overwhelming approval by its shareholders.

We will seek shareholder approval during the fourth quarter of 2021 of a Board-approved PBC conversion, which we will effect by amending our charter to include a PBC purpose. We will provide more details as they develop, but we anticipate that our PBC purpose will be patient-focused, along the lines of the public benefit purpose of our Lung Biotechnology PBC subsidiary noted above. We plan to engage with shareholders and other stakeholders to discuss our plans to convert to a PBC in the coming weeks and months.

Our shareholders have expressed a keen interest in learning how United Therapeutics is working to both create a sustainable company and to address our ESG objectives, and we are steadily increasing the amount and granularity of our disclosures to meet these needs. See corporateresponsibility.unither.com. With a PBC conversion, we aim to continue our leadership in this area by becoming the first publicly traded biopharmaceutical company organized as a PBC. As a PBC we will be required to post reports on our progress toward fulfilling our PBC mission, which we believe will further enhance our disclosures and relationships with employees, stakeholders, patients, and shareholders.

What is a Public Benefit Corporation?

A Delaware PBC is a for-profit corporation. There are two primary differences between a PBC and a traditional Delaware for-profit corporation:

- A corporation organized as a Delaware PBC identifies in its certificate of incorporation one or more specific public benefits that it will seek to promote in addition to shareholders’ financial interests. The public benefits are actions or goals that are intended to have positive effects on a category of persons, entities, interests, or communities.
- In making decisions, directors of a PBC have an obligation to balance the financial interests of shareholders, the interests of stakeholders materially affected by the PBC’s conduct, and pursuit of the corporation’s public benefit purpose.

A Delaware PBC must also provide its shareholders with a statement, at least every other year, as to the PBC’s assessment of the success of its efforts to promote its public benefit purpose and the best interests of those materially affected by the PBC’s conduct.
Voting Matters

Shareholders will be asked to vote on the following matters at the Annual Meeting:

1. **Election of Directors**

   This year at our Annual Meeting, Professor Katherine Klein, Mr. Ray Kurzweil, Dr. Linda Maxwell, Dr. Martine Rothblatt, and Dr. Louis Sullivan are nominees for election as directors to serve one-year terms until our 2022 Annual Meeting of Shareholders or until their successors are duly elected and qualified or their office is otherwise vacated.

   Our Board recommends a vote **FOR** each director nominee. See page 20

2. **Advisory Resolution to Approve Executive Compensation**

   We are asking our shareholders to vote on an advisory resolution, commonly known as a “Say-on-Pay” proposal, to approve executive compensation as reported in this Proxy Statement.

   Our Board recommends a vote **FOR** this proposal. See page 41

3. **Approval of the Amendment and Restatement of The United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the Plan)**

   The Amendment and Restatement makes the following changes to the Plan:
   - Increases the maximum number of shares of our common stock that may be issued under the Plan by 1,000,000 shares
   - Extends the expiration date of the Plan to April 29, 2031
   - Expressly prohibits the payment of dividends on unvested awards for all equity types

   Our Board recommends a vote **FOR** this proposal. See page 74

4. **Ratification of the Appointment of Ernst & Young LLP as United Therapeutics Corporation’s Independent Registered Public Accounting Firm for 2021**

   The Audit Committee of our Board has appointed Ernst & Young LLP as our independent registered public accounting firm for the year 2021. We ask that our shareholders vote to ratify this appointment.

   Our Board recommends a vote **FOR** this proposal. See page 83
# Governance Highlights

## Board of Directors

<table>
<thead>
<tr>
<th>Name and Primary Occupation</th>
<th>Age</th>
<th>Director Since</th>
<th>Committee Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Director Nominations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katherine Klein, Ph.D.</td>
<td>64</td>
<td>2014</td>
<td></td>
</tr>
<tr>
<td>Professor of Management, The Wharton School</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vice Dean, Wharton Social Impact Initiative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ray Kurzweil</td>
<td>73</td>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>A Director of Engineering, Google</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linda Maxwell, M.D., M.B.A.</td>
<td>47</td>
<td>2020</td>
<td></td>
</tr>
<tr>
<td>Head and Neck Surgeon, Private Practice</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Founding and Executive Director, Biomedical Zone (Toronto)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martine Rothblatt, Ph.D., J.D., M.B.A.</td>
<td>66</td>
<td>1996</td>
<td></td>
</tr>
<tr>
<td>Founder, Chairperson, and Chief Executive Officer, United Therapeutics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Louis Sullivan, M.D.</td>
<td>87</td>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>President Emeritus, Morehouse School of Medicine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former Secretary, U.S. Department of Health and Human Services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class II Directors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christopher Causey, M.B.A.</td>
<td>58</td>
<td>2003</td>
<td></td>
</tr>
<tr>
<td>Principal, Causey Consortium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Giltner</td>
<td>57</td>
<td>2009</td>
<td></td>
</tr>
<tr>
<td>Former Portfolio Manager, Lyxor Asset Management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilda Mesa, J.D.</td>
<td>61</td>
<td>2018</td>
<td></td>
</tr>
<tr>
<td>Adjunct Professor, Columbia University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former Director, NYC Mayor’s Office of Sustainability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Judy Olian, Ph.D.</td>
<td>69</td>
<td>2015</td>
<td></td>
</tr>
<tr>
<td>President, Quinnipiac University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former Dean, UCLA Anderson School of Management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class III Directors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raymond Dwek, C.B.E., F.R.S.</td>
<td>79</td>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>Professor Emeritus and Director of the Glycobiology Institute, University of Oxford</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christopher Patusky, J.D., M.G.A.</td>
<td>57</td>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>Founder, Patusky Associates, LLC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vice Chair and Lead Independent Director, United Therapeutics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Governor Tommy Thompson, J.D.</td>
<td>79</td>
<td>2010</td>
<td></td>
</tr>
<tr>
<td>Former Governor of Wisconsin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former Secretary, U.S. Department of Health and Human Services</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AC – Audit Committee
CC – Compensation Committee
NGC – Nominating and Governance Committee

*AC – Member
CC – Chair
NGC – Independent*
Our Governance Best Practices

We have taken great strides over recent years to implement best corporate governance practices, often acting ahead of the curve in terms of our industry peers and the Russell 3000.

✅ **MAJORITY VOTING**

In 2015, we adopted a majority voting standard with a director resignation policy

- Only 47.4% of other Russell 3000 companies* have adopted majority voting for uncontested director elections
- Only 21.6% of our industry peers** have adopted majority voting for uncontested director elections and a director resignation policy

✅ **BOARD DESTAGGERING**

In 2020, we amended our Certificate of Incorporation to commence a destaggering process. Going forward, directors will be elected to one-year terms

✅ **DIVERSITY AND REFRESHMENT**

Diversity and refreshment are also key areas of focus where we are largely in-line with our peers or ahead of the curve. For example, our Board is 42% female, compared with 19% for the Russell 3000. In 2020, we refreshed our Board committees and enhanced our Board’s diversity with the addition of Dr. Linda Maxwell. Since 2014, we have added four new directors, all of whom are female and two of whom self-identify as members of a racial or ethnic minority

✅ **PROXY ACCESS**

In 2015, we also adopted a market-standard form of proxy access

- Only 21.3% of Russell 3000 companies* provide their shareholders a similar right
- Only 7.3% of our industry peers** provide their shareholders with proxy access

✅ **SHAREHOLDER FEEDBACK**

Our Nominating and Governance Committee has taken shareholder feedback on governance seriously — even commissioning external experts to study these issues and advise the Committee

✅ **ENHANCED DISCLOSURE**

In 2020, we issued our first corporate sustainability report. In this year’s proxy statement, we are providing enhanced disclosure concerning our Board’s skills and diversity

---

* Source: 2020 FactSet Research Systems Inc. database

** Industry peers are defined as U.S.-domiciled, NYSE- or Nasdaq-listed companies with the same first two primary Standard Industrial Classification code digits as our company (28: Chemicals and Allied Products), but excluding our company from peer results
Committee Refreshment

In 2020, we substantially refreshed the composition of our Board Committees, as follows:

- **Compensation**: Christopher Patusky and Raymond Dwek joined the Committee; Christopher Patusky was appointed Chair; Christopher Causey (formerly Chair) cycled off the Committee

- **Nominating and Governance**: Nilda Mesa joined the Committee; Christopher Causey was appointed Chair

- **Audit**: Christopher Causey and Judy Olian joined the Committee
Executive Compensation Highlights

Extensive Shareholder Engagement Resulted in Meaningful Compensation Program Changes

We actively and regularly engage with our shareholders on compensation matters, and have made significant changes to our compensation programs over the past several years as a result of those discussions. 2020 was no different. We engaged with shareholders before our 2020 Annual Meeting, reaching out to 38 of our largest shareholders that collectively held over 70% of our outstanding shares, and had discussions with shareholders representing over 30% of our outstanding shares. We also conducted engagement outreach following our 2020 Annual Meeting, again offering to engage with shareholders that collectively held over 70% of our outstanding shares (37 of our largest shareholders) and had discussions with ten shareholders that collectively held approximately 23% of our outstanding shares. During 2020 we reached out to 47 shareholders in aggregate that collectively held 74% of our outstanding shares and had discussions with 15 shareholders that collectively held 35% of our outstanding shares. Following our 2020 Annual Meeting, several shareholders declined our invitation for further discussions because they already shared their feedback during our spring shareholder outreach campaign just before our 2020 Annual Meeting.

The purpose of these meetings was to gather feedback regarding our executive compensation and governance policies, and to understand their say-on-pay votes in 2020. Our Compensation Committee Chair led the calls, along with our head of investor relations and a member of our human resources department. During the spring 2020 outreach, our Nominating and Governance Committee Chair joined the calls as well.

### Aggregate 2020 Engagement

<table>
<thead>
<tr>
<th>Offered Engagement</th>
<th>2020 Post-Annual Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>47 Shareholders</td>
<td>37 Shareholders</td>
</tr>
<tr>
<td>35 Shareholders</td>
<td>10 Shareholders</td>
</tr>
</tbody>
</table>

During our post-Annual Meeting outreach in 2020, we discussed specific proposed actions and disclosures that the Compensation Committee believed would be responsive to shareholders’ concerns regarding executive compensation. Following these discussions with shareholders, in direct response to their feedback, the Compensation Committee implemented the proposed actions, as described in this Proxy Statement. **Importantly, when we discussed our proposed actions and disclosures with shareholders following the 2020 Annual Meeting, every shareholder we spoke with confirmed that these actions and disclosures were appropriately responsive to their feedback.**

As detailed in our Compensation Discussion and Analysis, we believe that changes implemented following our shareholder engagement are directly responsive to feedback we have received from shareholders. Please see the details of the feedback received and specific actions we have taken on page 46.
Total Compensation Mix — Pay for Performance

The following charts illustrate the extent to which pay for our Chief Executive Officer and our other Named Executive Officers (as defined below under Compensation Discussion and Analysis—Our Named Executive Officers) is “at risk”, meaning payout levels are based entirely on performance due to the use of performance targets, in the case of our cash incentive program, or an inherent stock price performance criterion, in the case of stock options. For each chart, the amounts shown represent 2020 base salary (on an annualized basis, following the February 2020 salary increases), 2020 target cash bonus opportunity, and the annualized grant-date fair value of long-term incentive awards granted in March 2019, which was a four-year grant covering the period 2019-2022.

2020 CEO and Other NEOs Pay Mix

No Equity Awards Granted to NEOs in 2020

We implemented a new long-term incentive compensation program in 2019, awarding a four-year equity grant to our Named Executive Officers, which was granted instead of annual equity awards for the performance years 2019 through 2022. The four-year awards were granted in March 2019 and were divided equally into the following two forms of stock options:

- **Premium-Priced Performance Stock Options.** 50% of each Named Executive Officer’s equity award covering grants for 2019-2022 was granted with a premium-priced performance condition by virtue of an exercise price equal to 115% of our closing stock price on the date of the grant. Therefore, our stock price will have to grow by more than 15% above the share price on the grant date before our Named Executive Officers can realize any value from the award. These stock options will not vest (i.e., “cliff” vest) until the fourth anniversary of the grant date, promoting retention and a long-term view.

- **Market-Priced Stock Options.** 50% of each Named Executive Officer’s equity award covering grants for the period of 2019-2022 was granted with an exercise price equal to our closing stock price on the date of grant. These awards will vest in equal thirds on the second, third, and fourth anniversaries of the date of the grant, as a retention incentive.

While only the premium-priced options may count as “performance based” according to some, we view both of these tranches as performance-based, as both require significant and sustained stock price growth in order to enable our Named Executive Officers to realize any value from them. Both tranches have an eight-year term, which means they will need to grow and sustain the stock price more quickly than would be the case with a more typical ten-year term.

These awards are intended to compensate our Named Executive Officers over the four-year period of our current business plan. In response to shareholder feedback, we commit to not making any additional equity grants during this four-year period (2019-2022) to our existing Named Executive Officers. When viewed on an annualized basis, these awards meaningfully decreased overall compensation and decreased overall dilution when compared with the results if we had continued our previous program for four additional years. On an annualized basis, this program reduced our Chief Executive Officer’s total target direct compensation from the top quartile in 2018 to approximately the 50th percentile of our peer group.

The four-year awards are designed to incentivize and retain our Named Executive Officers over this critical four-year period, which aligns with a four-year business plan intended to drive substantial revenue growth despite generic competition, while reducing compensation on an annualized basis in response to requests by our shareholders.

Because we did not grant any equity awards in 2020, compensation to our Chief Executive Officer as reported in the Summary Compensation Table has been drastically reduced by 89%, to $4.8 million, compared to 2019.
Robust Goal-Setting

We continue to set difficult goals under our annual Company-Wide Milestone Program, which governs short-term cash bonuses for our Named Executive Officers. As one example, the chart below shows our revenue targets for the past three years, our actual revenue performance, and how this compares to the expectations of Wall Street analysts following our company, which is one of many factors considered when goals are set. Even as we managed through revenue declines in 2018-2019, we continued to set goals well above external expectations, and to deliver against those goals. As you can see below, we set our 2020 revenue target above 2019 target and actual revenues, and well above analyst consensus. In response to shareholder feedback following our 2020 Annual Meeting, we are including below additional prospective disclosure for 2021, demonstrating our commitment to incentivizing significant revenue growth in 2021.

A Look Ahead: 2021 Revenue Milestone — Incentivizing Significant Revenue Growth

In response to shareholder feedback, we are providing the following information regarding our 2021 revenue target. While we do not provide the actual target in advance because we do not provide formal financial guidance, we want to make clear that our executive compensation program incentivizes significant revenue growth in 2021:

- Threshold/minimum performance set above 2020 actual performance, **directly responsive to shareholder feedback — no revenue-based bonus unless revenue grows in 2021 compared to 2020**
- Threshold/minimum performance set above analyst consensus for 2021 revenues
- Target performance represents significant revenue growth compared to 2020 actual results
- Maximum performance for 2021 represents 18% revenue growth compared to 2020
1 Election of Directors

Our Board consists of twelve members and is in the process of declassifying. Currently it is divided into three classes, and historically one class was elected at each Annual Meeting to a three-year term. This year at our Annual Meeting, Professor Katherine Klein, Mr. Ray Kurzweil, Dr. Linda Maxwell, Dr. Martine Rothblatt, and Dr. Louis Sullivan are nominees for election as director to serve one-year terms until our 2022 Annual Meeting of Shareholders or until their successors are duly elected and qualified or their office is otherwise vacated. Each nominee other than Dr. Maxwell was previously elected by shareholders at our 2018 Annual Meeting to serve a three-year term as Class I directors. Dr. Maxwell was appointed to our Board in September 2020. Please see Board Declassification below for further details regarding our declassification process.

Directors are elected by a majority of votes cast at our Annual Meeting. A majority of votes cast means that the number of votes cast for the director nominee’s election must exceed the number of votes cast against that director nominee’s election. Broker non-votes and abstentions are not considered votes cast and therefore have no impact on the election of directors. Cumulative voting is not permitted in the election of directors. Proxies may not be voted for more than five nominees.

Each of our director nominees has consented to be named in this Proxy Statement and to continue to serve on our Board of Directors, if elected. We do not anticipate that any nominee will become unable or unwilling to accept their nomination or election. If such an event should occur, the persons named on the proxy card intend to vote for the election of such other person as is selected by our Board in such nominee’s stead. In the alternative, the persons named on the proxy card may simply vote for the remaining nominees, leaving a vacancy that may be filled at a later date by our Board of Directors, or our Board of Directors may reduce the size of our Board.

Our Board of Directors recommends that you vote FOR the election of each of the nominees.

Selecting Directors

We believe that our directors should possess the highest personal and professional ethics, integrity, and values, and should be committed to representing the best interests of our shareholders. We also endeavor to have a Board of Directors that, as a whole, represents a range of experiences in business, government, education, and technology and in other areas that are relevant to our business activities. As reflected in our Corporate Governance Guidelines, our Board and our Nominating and Governance Committee seek to achieve a diversity of occupational and personal backgrounds on the Board, including with respect to gender, race, and ethnic diversity. We assess the effectiveness of our efforts in this respect during the annual evaluation process conducted by our Nominating and Governance Committee. In addition, our Nominating and Governance Committee seeks to recommend director candidates who will enhance the quality of our Board’s deliberations and decisions, take their duties seriously, and promote the values and ethics to which we subscribe. Our Board also believes there are certain attributes every director should possess, which are described in the Director Nominations and Diversity section below. In evaluating incumbent directors for re-nomination to our Board, the members of our Nominating and Governance Committee consider a variety of factors. These include each director’s independence, financial literacy, personal and professional accomplishments, tenure on and contributions to our Board, and experience in light of our business goals.
How We Select Our Director Nominees

Succession Planning

Our Nominating and Governance Committee considers current and long-term needs of our evolving business and seeks potential director candidates in light of emerging needs, our current Board structure, tenure, skills, diversity, and experience.

Identification of Candidates

Our Nominating and Governance Committee engages in a search process for director candidates, led by its Chair.

Our Nominating and Governance Committee considers candidates recommended by members of our Board, executive officers, shareholders, and other sources, and evaluates shareholder nominees using the same criteria as it uses to evaluate all other candidates.

A shareholder who wishes to recommend a prospective nominee for our Nominating and Governance Committee’s consideration should submit the candidate’s name and qualifications to our Corporate Secretary at the address set forth under Shareholder Communication with Directors below.

Qualifications Sought

To be considered, each director candidate must meet the following minimum criteria:

- Personal and professional integrity
- A record of exceptional ability and judgment
- Ability and willingness to participate fully and work constructively in Board activities, including active participation in meetings of our Board and any committees to which they are assigned
- Interest, capacity and willingness, in conjunction with the other members of our Board, to serve the interests of our shareholders
- Reasonable knowledge of the fields of our operations, as well as familiarity with the principles of corporate governance
- Expertise needed to serve on one or more committees of our Board
- Independence, including the absence of any personal or professional relationships that would adversely affect the candidate’s ability to serve our best interests and those of our shareholders

In addition, our Nominating and Governance Committee is interested in candidates who possess the following skills:

- The ability to contribute to the variety of opinions, perspectives, personal and professional experiences and backgrounds, as well as other characteristics that differ among members of our Board
- A desire to contribute positively to the existing tone and collaborative culture among our Board members
- Professional and personal experiences and expertise relevant to achievement of our strategic objectives

Meeting with Candidates

Once our Nominating and Governance Committee identifies a potential director nominee, it screens the candidate, performs reference checks, and conducts interviews with the assistance of our General Counsel and our Chairperson and Chief Executive Officer.

If the outcome of that process is favorable, our Nominating and Governance Committee may recommend the candidate to our Board for consideration.

Decision and Nomination

Our Nominating and Governance Committee recommends, and our full Board approves, the director candidates who are best qualified to serve the interest of our shareholders. Our Nominating and Governance Committee’s evaluation of director nominees considers their ability to contribute these qualities and skills to our Board.

Election

Each year, shareholders consider and elect directors at our Annual Meeting of Shareholders. In addition, our Board may appoint directors to fill vacancies upon the recommendation of our Nominating and Governance Committee during the year, if deemed in the best interests of the company and our shareholders.
Re-Nomination Process

Our Nominating and Governance Committee appreciates the importance of critically evaluating individual directors and their contributions to our Board in connection with re-nomination decisions.

In considering whether to recommend re-nomination of a director for election at our Annual Meeting, our Nominating and Governance Committee conducts a detailed review, considering factors such as:

- The extent to which the director’s judgment, skills, qualifications, and experience (including those gained due to tenure on our Board) continue to contribute to our Board’s success
- Attendance and participation at, and preparation for, Board and committee meetings
- Independence
- Shareholder feedback, including the support received by those director nominees elected at our most recent Annual Meeting
- Outside board and other affiliations, including any actual or perceived conflicts of interest
- The extent to which the director continues to contribute to our Board’s diversity

Board Diversity

We believe it is important that our Board is composed of individuals reflecting the diversity represented by our employees, our patients, and our communities. In recent years, our Nominating and Governance Committee has taken this priority to heart in its nominations process, and the diversity of our Board has grown significantly. With the addition of Dr. Linda Maxwell in 2020, we have continued to expand the diversity of our Board, which is among the most diverse of our peers. In response to feedback from shareholders, we provide below enhanced disclosure regarding the diversity of our Board, utilizing the template included in a pending Nasdaq rule proposal.

<table>
<thead>
<tr>
<th>Board Size:</th>
<th>Total Number of Directors</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender:</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Number of directors based on gender identity</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Number of directors who identify in any of the categories below:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American or Black</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Alaskan Native or American Indian</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Asian</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hispanic or Latinx</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Native Hawaiian or Pacific Islander</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>White</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Two or More Races or Ethnicities</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>LGBTQ+</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Undisclosed</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>
Board Skills

In addition to the qualifications described above, we seek to maintain a diverse set of skills on our Board. In response to shareholder feedback, we are providing additional disclosure below regarding our Board members’ skills:

<table>
<thead>
<tr>
<th>Board Skill</th>
<th>Why This Skill is Important to Our Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Company Board Experience (non-UT)</td>
<td>Public companies face heightened public scrutiny and legal, regulatory, and accounting requirements unlike those faced by private companies</td>
</tr>
<tr>
<td>Executive Management Experience</td>
<td>Management of large organizations such as United Therapeutics can be extremely complex and challenging, and experience with executive management can help provide the context needed for overseeing our executive officers</td>
</tr>
<tr>
<td>Financial Expertise</td>
<td>It is extremely important that we manage our company in a fiscally conservative manner, and present our financial results in a clear, accurate, and reliable manner, navigating the complexity of evolving accounting standards and regulatory requirements</td>
</tr>
<tr>
<td>Legal</td>
<td>In our business we encounter extremely complex legal issues and challenges, including threatened and actual litigation</td>
</tr>
<tr>
<td>Government / Regulatory Experience</td>
<td>There are fewer industries more heavily regulated than the biopharmaceutical and medical device industries. Regulatory expertise helps ensure appropriate oversight of our compliance and regulatory functions, which are critical to our success</td>
</tr>
<tr>
<td>International</td>
<td>While most of our operations are U.S.-based, we conduct clinical trials and commercial distribution of our products worldwide</td>
</tr>
<tr>
<td>Science / Medicine</td>
<td>Our success is heavily dependent on our ability to successfully conduct insightful research and development efforts often involving cutting-edge technologies, and to manufacture our products using highly complex technologies</td>
</tr>
<tr>
<td>Healthcare Industry Experience</td>
<td>The healthcare sector presents unique challenges, and given our patient-centric mission experience in the healthcare field is extremely valuable</td>
</tr>
<tr>
<td>Environmental, Social, and Governance</td>
<td>We believe that ESG issues present important challenges, as well as the opportunity to build sustainable value for shareholders and other key stakeholders. We are committed to pursuing critically important ESG goals, while also delivering excellent financial performance for our shareholders</td>
</tr>
</tbody>
</table>

Proxy Access

We amended our bylaws in 2015 to implement proxy access, which allows shareholders to nominate and include in our Proxy Statement their own director nominees, provided that the shareholder(s) and the nominee(s) satisfy the requirements in our bylaws. Our Board carefully considered feedback we received from our shareholders in creating a thoughtfully designed and balanced approach to proxy access that mitigates the risk of abuse and protects the interests of all of our shareholders, while affording a meaningful proxy access right. Shareholders who wish to nominate directors for inclusion in our Proxy Statement in accordance with the procedures in our bylaws should follow the instructions under Other Matters—Shareholder Proposals and Director Nominations in this Proxy Statement.

Majority Voting

In June 2015, as part of our Board’s ongoing review of our corporate governance policies, we amended our bylaws to provide that director nominees are elected by a majority of votes cast in uncontested director elections. A majority of votes cast means that the number of votes cast for the director nominee’s election must exceed the number of votes cast against that director nominee’s election. In connection with this bylaw amendment, our Board also adopted a director resignation policy set forth in our Corporate Governance Guidelines, providing that any director who is not elected by a majority of the votes cast is expected to tender their resignation to our Nominating and Governance Committee. Our Nominating and Governance Committee will recommend to our Board whether to accept or
reject the resignation offer, or whether other action should be taken, considering all factors that the Nominating and Governance Committee believes are relevant. Our Board will act on our Nominating and Governance Committee’s recommendation within 90 days following certification of the election results. Any director who tenders their resignation pursuant to our director resignation policy will not participate in the proceedings of either our Nominating and Governance Committee or our Board with respect to their own resignation offer.

Policy on Overboarding

In 2020, we updated our Corporate Governance Guidelines to reduce our overboarding limit, such that directors are not permitted to serve on more than four public company boards (including our Board). This limit is below the limit of five boards contained in the guidelines of major proxy advisory firms, and satisfies the proxy voting criteria of our largest shareholders. In fact, this action was taken in direct response to feedback received during our shareholder outreach process in 2019. All of our directors satisfy our updated overboarding policy.

Board Declassification

At our 2020 Annual Meeting of Shareholders, our shareholders approved an amendment to our Amended and Restated Certificate of Incorporation to eliminate the classification of our Board. As a result, the classified nature of our Board is being phased out. As the term of each class of directors expires, they will be subject to re-election (if re-nominated by our Board) to a one-year term, instead of a three-year term. This year, all five Class I directors have been nominated for re-election to one-year terms.

Stock Ownership Guidelines

In 2011, our Board adopted Stock Ownership Guidelines applicable to our directors and our Named Executive Officers in order to further align the financial interests of our directors and Named Executive Officers with those of our shareholders, to foster a long-term management orientation, and to promote sound corporate governance. For non-employee members of our Board, our Stock Ownership Guidelines provide an ownership target equal to the lesser of 5,000 shares or a value equivalent to five times the annual cash Board retainer. The policy includes procedures for granting exemptions in the case of hardship. Ownership targets for our Named Executive Officers (including those serving on our Board) are described below under Compensation Discussion and Analysis—Other Executive Compensation Policies and Practices—Stock Ownership Guidelines.
Board of Directors and Nominees

The following presents information concerning persons nominated for election as directors at our Annual Meeting and for those of our directors whose terms of office will continue after our Annual Meeting, including their age as of the date of this Proxy Statement, membership on committees of our Board, principal occupations or affiliations during the last five years or more, director qualifications, and certain other directorships held. For additional information concerning the director nominees, including stock ownership and compensation, see the section entitled Non-Employee Director Compensation and the Other Matters—Beneficial Ownership of Common Stock table below.

Nominees for Election at our 2021 Annual Meeting of Shareholders

Each nominee was previously elected by shareholders at the 2018 Annual Meeting, except for Dr. Maxwell, who was appointed to the Board in September 2020 to fill a newly-created vacancy.

Katherine Klein, Ph.D.

Age: 64
Director Since: 2014

Committees:
None

Background

Professor Klein has served as the Vice Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School’s Edward H. Bowman Professor of Management since 2005. She also served as Professor of Management of The Wharton School from 2004 to 2005. Prior to joining Wharton, Professor Klein was on the faculty of the University of Maryland and a visiting professor at the Stanford Graduate School of Business. She received her B.A. from Yale University, and her Ph.D. in Community Psychology from the University of Texas at Austin. An award-winning organizational psychologist, Professor Klein has conducted extensive field research regarding a range of topics including team leadership, climate, conflict, social networks, and effectiveness; organizational change and technology implementation; employee diversity; and employee responses to stock ownership. She has taught executive education and consulted with and studied a variety of for profit and non-profit organizations including Charles Schwab, Rohm and Haas, North American Scientific, Medtronic, The Baltimore Shock Trauma Center, Penn Vet, the U.S. Census Bureau, and the Korean Management Association. Her research has been published in numerous top journals including Administrative Science Quarterly, Journal of Applied Psychology, the Academy of Management Journal, and the Academy of Management Review. She is also a former associate editor of the Journal of Applied Psychology and Administrative Science Quarterly. Professor Klein is a Fellow of the Academy of Management, the Society for Industrial and Organizational Psychology, the American Psychological Association, and the Association for Psychological Science.

Director Qualifications

As a professor and Vice Dean at one of the world’s leading business schools, Professor Klein brings valuable expertise in organizational behavior, social impact, and employee ownership culture, topics that are of vital importance to a growing biotech company like United Therapeutics. As we adapt to the needs of a larger company while balancing our goal of maintaining an entrepreneurial culture designed to foster continued high growth and innovation, Professor Klein provides valuable insight to our Board. Additionally, as Vice Dean of the Wharton Social Impact Initiative, Professor Klein is highly qualified to help guide United Therapeutics’ thinking about the social impact of its business operations.
Ray Kurzweil

Age: 73
Director Since: 2002
Committees: None

Background

Mr. Kurzweil is an inventor, entrepreneur, and author, and has created several important technologies in the artificial intelligence field. He has received the National Medal of Technology, the MIT Lemelson Prize, twenty-one honorary doctorates, a Grammy award for his contributions to music technology, and honors from three U.S. Presidents. In 2002, Mr. Kurzweil was inducted into the National Inventors Hall of Fame. Since 1995, Mr. Kurzweil has served as the Chief Executive Officer of Kurzweil Technologies, Inc., a technology development firm. Since January 2013, he has also served as a Director of Engineering for Google, a global technology and Internet search company.

Director Qualifications

Mr. Kurzweil brings to our Board extensive technological experience as an inventor and technology developer. His technical experience in the areas of artificial intelligence, telemedicine, and pharmaceutical research and development, and his experience in building businesses around his inventions, provide our Board with perspective in evaluating current and proposed technologies and business opportunities. Mr. Kurzweil also brings to our Board substantial corporate leadership experience from his role as Chief Executive Officer of Kurzweil Technologies, Inc.

Linda Maxwell, M.D., M.B.A.

Age: 47
Director Since: 2020
Committees: None

Background

Dr. Maxwell has been a head and neck surgeon in private practice since 2006, and is a medical educator, a published scientific author, and a health technology entrepreneur and innovator. Dr. Maxwell is Adjunct Professor of Surgery at the University of Toronto, Distinguished Visiting Professor at Ryerson University, and Associate Scientist at the Li Ka Shing Knowledge Institute in Toronto. She served as Founding and Executive Director of the Biomedical Zone in 2015 — Canada’s first and only hospital-embedded, physician-led business incubator for emerging health technology companies — and has guided a wide variety of startup companies through clinical development, capitalization, and commercialization. Dr. Maxwell also managed a life sciences tech transfer portfolio at the University of Oxford and the UK National Health Service, executing patent strategy, spin-out company formation, and early stage capital raising. She has also served as a healthcare innovation expert to various Canadian federal, provincial, and local government entities, as a member of the Department Audit Committee of the Public Health Agency of Canada, and as an advisor to the Canadian Medical Association and the Canadian Space Agency. She is a graduate of Harvard College and Yale Medical School, and holds an MBA from Oxford University. Dr. Maxwell completed surgical training at the University of Toronto and is double board certified in Otolaryngology-Head Neck Surgery and Facial Plastic Reconstructive Surgery. She holds an ICD.D designation, awarded by the Institute of Corporate Directors, University of Toronto, School of Management.

Other Public Company Boards

- Profound Medical Inc. (through November 2020)
- ImmuneBio, Inc.

Director Qualifications

Dr. Maxwell brings to our Board important expertise as a medical doctor, as a health technology entrepreneur, and innovator, and as an expert in corporate governance. Her experience in guiding emerging health technology companies through clinical development and commercialization is highly valued to an entrepreneurial biotech company like United Therapeutics. In addition, our Canadian operations have become increasingly important in recent years, so Dr. Maxwell’s knowledge of the Canadian regulatory environment will be very valuable to us.
Martine Rothblatt, Ph.D., J.D., M.B.A.

Age: 66
Director Since: 1996
Chairperson of the Board
Chief Executive Officer

Committees:
None

Background

Dr. Rothblatt founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previously, she created the satellite radio company SiriusXM. She is a co-inventor on eight of our patents. Her pioneering book, Your Life or Mine: How Geoethics Can Resolve the Conflict Between Private and Public Interests in Xenotransplantation, anticipated the need both for global virus bio-surveillance and a greatly expanded supply of transplantable organs.

Director Qualifications

Dr. Rothblatt brings to our Board extensive leadership and business experience at technology companies, as well as in depth knowledge of our company from her service as our founder, Chairperson and Chief Executive Officer. She also has substantial knowledge of medical ethics, having obtained her Ph.D. in medical ethics from the University of London.

Louis Sullivan, M.D.

Age: 87
Director Since: 2002

Committees:
Compensation
Nominating and Governance

Background

Dr. Sullivan was the founding President of Morehouse School of Medicine, from 1981 to 1989, served as President again from 1993 to 2002, and has served as President Emeritus since 2002. Dr. Sullivan was also one of the founders and served as Chair of Medical Education for South African Blacks, Inc., a member of the National Executive Council for the Boy Scouts of America, and a member of the Board of Trustees of Little League of America. Dr. Sullivan served as Secretary of the U.S. Department of Health and Human Services from 1989 to 1993. He is a physician certified in internal medicine with a sub-specialty certification in hematology. Dr. Sullivan currently serves on the board of directors of Emergent BioSolutions, Inc. (since 2005), a publicly-traded company. He also serves as Co-Chair of the Henry Schein Cares Foundation. Dr. Sullivan previously served on the boards of directors of a wide range of public companies, including General Motors Company, BioSante Pharmaceuticals, Inc., Bristol Myers Squibb Company, Cigna Corporation, 3M Company, Henry Schein, Inc., Household International (now HSBC), Equifax, and Georgia Pacific Corporation.

Other Public Company Boards

- Emergent BioSolutions, Inc.

Director Qualifications

Dr. Sullivan brings to our Board extensive experience in the healthcare industry as a public official from his service as Secretary of the U.S. Department of Health and Human Services, a physician certified in internal medicine, and a professor and an administrator at Morehouse School of Medicine. He also has substantial public company board experience gained from his service as a director of Emergent BioSolutions, Inc., as well as his extensive previous public company board service.
Class II Directors Continuing in Office with Terms Ending in 2022

Each Class II director was previously elected by shareholders at the 2019 Annual Meeting.

Christopher Causey, M.B.A.

<table>
<thead>
<tr>
<th>Age</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>58</td>
<td>Nominating and Governance (Chair)</td>
</tr>
<tr>
<td></td>
<td>Audit</td>
</tr>
<tr>
<td>Director Since</td>
<td>2003</td>
</tr>
</tbody>
</table>

**Background**

Mr. Causey has served as the Principal of the Causey Consortium, a professional services organization providing business strategy and marketing counsel to the healthcare industry, since 2002. Previously, Mr. Causey served as a senior marketing officer for a variety of healthcare companies. From 2001 to 2002, Mr. Causey served as Chief Marketing Officer for Definity Health Incorporated. He was also a member of the board of directors of Data Sciences International, Inc., a private company that develops wireless physiological monitoring solutions, from 2008 to 2013.

**Director Qualifications**

Drawing upon nearly 30 years of experience in strategic planning and marketing for health care delivery, financing and biotechnology organizations, including as Principal of Causey Consortium, Mr. Causey brings to our Board substantial experience in the health care and biotech industries. Our Board benefits from Mr. Causey’s extensive leadership experience as a senior health care marketing executive. Our Board of Directors has determined that Mr. Causey meets the financial sophistication requirements of Nasdaq’s listing standards.

Richard Giltner

<table>
<thead>
<tr>
<th>Age</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>57</td>
<td>Audit (Chair)</td>
</tr>
<tr>
<td></td>
<td>Nominating and Governance</td>
</tr>
<tr>
<td>Director Since</td>
<td>2009</td>
</tr>
</tbody>
</table>

**Background**

From 2009 until his retirement in 2010, Mr. Giltner was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale. From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He also held various other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010.

**Director Qualifications**

Mr. Giltner brings to our Board decades of experience in the financial sector, including international financial markets, financial derivatives, alternative investments and asset management. As our business continues to grow and expand, our Board benefits from Mr. Giltner’s global business and financial experience and his perspective as an institutional investor, as well as his leadership experience in international finance from his service in various management roles at Société Générale. Our Board of Directors has determined that Mr. Giltner is an audit committee financial expert as defined under the rules and regulations of the SEC and meets the financial sophistication requirements of Nasdaq’s listing standards.
Background

Professor Mesa has had a long and innovative career in environment, energy, and sustainability at the city, state, national, and global levels, and now writes and presents extensively on climate, energy, equity and urban systems relating to them. From 2014 to 2016, Professor Mesa served as Director of the New York City Mayor’s Office of Sustainability, where she led the pathbreaking OneNYC long term sustainability plan for the city. As chief sustainability officer for New York City, she oversaw programs in climate, energy, sustainability, air quality and public health, waste, green buildings, transportation, public education, and other initiatives. In 2016, she returned to Columbia University as an adjunct professor at the School of International and Public Affairs, as well as Director of the Urban Sustainability and Equity Planning Program with Columbia’s Center for Sustainable Urban Development at the Earth Institute, positions she continues to hold today. In 2006, she founded Columbia’s Office of Environmental Stewardship, one of the first in the United States for a university. She also served as Chief Administrative Officer at the Columbia Journalism School from 2012 to 2014. Before joining Columbia, Professor Mesa served in environmental leadership roles at the White House Council on Environmental Quality, the U.S. Air Force, the U.S. Environmental Protection Agency, and the California Attorney General’s office, and practiced law in both the public and private sectors. Her work has involved extensive international experience, including most recently a 2018 to 2020 appointment as a visiting professor and lecturer at the Paris Institute of Political Studies (Sciences Po), an international research university in France. She is the co-author of a book to be published next year on climate and collaboration, as well as a contributor to the recently published “Smarter New York City: How City Agencies Innovate.” [Columbia University Press]. She is a graduate of Harvard Law School and Northwestern University.

Director Qualifications

Professor Mesa brings to our Board extensive executive leadership experience, particularly in the area of environmental stewardship. As we continue to operate and grow our business in an environmentally sustainable fashion, we expect Professor Mesa’s insights to be extremely valuable. In addition, our Board benefits from her experience working in a variety of scientific, academic, government, legal, and international settings.
Background

Dr. Olian has served as President of Quinnipiac University since July 2018. Previously, she served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from 2006 to 2018. Her research and business expertise centers on aligning organizational strategies and design with human resource systems and incentives, and managing top management teams. She began her UCLA appointment after serving as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business. Dr. Olian serves or has been a member of various advisory boards (including the U.S. Studies Centre at the University of Sydney, Peking University Business School’s International Advisory Board, the Connecticut Governor’s Workforce Council, the Business-Higher Education Forum, New Haven Promise, and Catalyst, a leading global think tank for women in business) and served as Chair of the Loeb Awards for Business Journalism. Born and raised in Australia, Dr. Olian received her B.S. in Psychology from the Hebrew University, Jerusalem and her M.S. and Ph.D. in Industrial Relations from the University of Wisconsin, Madison. She was the Chair of AACSB International, the premier thought leadership and accreditation organization for leading global business schools, and currently serves on the board of directors of Ares Management, L.P., a publicly traded global alternative asset management firm, and Mattel, Inc., a publicly traded multinational toy manufacturing company.

Other Public Company Boards

- Ares Management, L.P.
- Mattel, Inc.

Director Qualifications

As the president of a prestigious university and former dean of one of the world’s leading business schools, Dr. Olian brings valuable expertise in managing and leading a large organization. Her academic expertise, which centers on the alignment of organizational strategies with human resource systems and incentives, provides valuable insight to a growing biotech company like United Therapeutics. In addition, her service as a director of Ares Management and Mattel provides valuable public company board experience. Our Board of Directors has determined that Dr. Olian meets the financial sophistication requirements of Nasdaq’s listing standards.
Class III Directors Continuing in Office with Terms Ending in 2023

Each Class III director was previously elected by shareholders at the 2020 Annual Meeting.

Raymond Dwek, C.B.E., F.R.S.

| Age: 79 | Committees: |
| Director Since: 2002 | Compensation |

**Background**

Professor Dwek is a Fellow of the Royal Society, London, and has served as Director of the Glycobiology Institute at the University of Oxford since 1988. He also served as Professor of Glycobiology at the University of Oxford from 1988 through 2009, and currently serves as Professor Emeritus. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in various positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and Nasdaq, and he served as a member of its Board of Directors until its sale in 2003. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis, and biology of sugar chains attached to proteins.

**Director Qualifications**

Professor Dwek has extensive scientific experience as both the head of the Department of Biochemistry at the University of Oxford, one of the world’s largest biochemistry departments, and as a biotechnology innovator at organizations such as the Glycobiology Institute and Oxford GlycoSciences PLC. In evaluating existing and potential new programs, our Board benefits from his scientific insight and experience in pharmaceutical research and development.

Christopher Patusky, J.D., M.G.A.

| Age: 57 | Committees: |
| Director Since: 2002 | Compensation (Chair) |
| | Audit |
| | Nominating and Governance |
| Vice Chair of the Board | |
| Lead Independent Director | |

**Background**

Mr. Patusky has more than 30 years of experience in the private, public and nonprofit sectors. After graduating from Harvard Law School, he clerked and practiced law from 1988 to 2000, focusing on litigation, intellectual property, and business startup. His legal work included co-leading a team that obtained the first approval from the Federal Communications Commission and the United Nation’s International Telecommunications Union of the use of stratospheric stations for delivery of telecommunication services worldwide. After receiving a master’s degree in governmental administration from the University of Pennsylvania in 2001, Mr. Patusky served from 2002 to 2007 as the Executive Director and member of the faculty of the University of Pennsylvania’s Fels Institute of Government. At Fels, he created and led the implementation of a first of its kind performance management system for the 270 schools of the Philadelphia School District, which was awarded an IBM Business of Government Award. From 2007 to 2011, Mr. Patusky was the Director of the Office of Real Estate and as a member of the Senior Policy Team at the Maryland Department of Transportation where he served on the Secretary’s sustainability committee while focusing his efforts on the Governor’s Transit Oriented Development (TOD) policy initiative, including drafting and lobbying passage of the Maryland TOD law, the authority he then used to advance real estate developments adjacent to Maryland’s transit stations. Since 2012, Mr. Patusky has served as the founding principal of Patusky Associates, LLC, which serves as a personal investment vehicle, and as an executive manager of Slater Run Vineyards, LLC, his family’s farm-based vineyard and winery.

**Director Qualifications**

Mr. Patusky brings to our Board extensive legal, regulatory, business, governance, financial, and international experience from his varied career. Our Board of Directors has determined that Mr. Patusky meets the financial sophistication requirements of Nasdaq’s listing standards.
Background

Before entering the private sector in 2005, Governor Thompson enjoyed a long and distinguished career in public service. As Secretary of the U.S. Department of Health and Human Services from 2001 to 2005, he was a leading advocate for the health and welfare of all Americans. He also served four terms as Governor of Wisconsin from 1987 to 2001. Governor Thompson currently serves as Interim President of the University of Wisconsin System, a position he has held since July 2020. Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP in Washington, D.C. from 2005 until January 2012, and as an Adjunct Senior Advisor from 2017 to 2020. From 2005 to 2009, he also served as the Independent Chair of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. He is currently a member of the boards of directors of the following public companies: Centene Corporation, Physicians Realty Trust [as Chair], and TherapeuticsMD, Inc. [as Chair]. He previously served on the boards of various other public companies, including Cancer Genetics Inc., CareView Communications, Inc., CNS Response, Inc., C.R. Bard, Inc., Cytori Therapeutics, Inc., SpectraScience, Tyme Technologies, Inc., and X Shares Advisors, and as the Chair of the board of directors of AGA Medical Holdings, Inc. from 2005 to 2010. Our Board has determined that Governor Thompson meets the financial sophistication requirements of Nasdaq’s listing standards.

Other Public Company Boards

- Centene Corporation
- Physicians Realty Trust
- TherapeuticsMD

Director Qualifications

Governor Thompson brings to our Board significant experience in the healthcare industry, both as a public official (former Secretary of the U.S. Department of Health and Human Services) and in the private sector (Deloitte Center for Health Solutions), as well as public company board experience and knowledge of legislative affairs. Governor Thompson’s legal experience from his private practice at Akin Gump also is useful in our Board’s oversight of our legal and regulatory compliance.

Director Independence

Our Board has made the following independence determinations:

- **General Independence**: Christopher Causey, Raymond Dwek, Richard Giltner, Katherine Klein, Ray Kurzweil, Linda Maxwell, Nilda Mesa, Judy Olian, Christopher Patusky, Louis Sullivan, and Tommy Thompson are independent in accordance with the Nasdaq listing standards.
- **Management Director**: Martine Rothblatt is not independent due her employment as our Chief Executive Officer.
- **Audit Committee Standards**: Christopher Causey, Richard Giltner, Judy Olian, Christopher Patusky, and Tommy Thompson meet the heightened independence standards for audit committee members set forth in rules promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act).
- **Compensation Committee Standards**: Raymond Dwek, Nilda Mesa, Christopher Patusky, and Louis Sullivan meet the heightened independence standards for compensation committee members under the Nasdaq listing standards.
- **Nominating and Governance Committee Standards**: Christopher Causey, Richard Giltner, Nilda Mesa, and Christopher Patusky meet the independence standards for nominating committee members under the Nasdaq listing standards.
Board Structure

Board Leadership

Our Board believes that it is important to evaluate and determine the most appropriate Board leadership structure so that our Board can both provide effective, independent oversight of management and facilitate its understanding of our business. To carry out this responsibility, our Corporate Governance Guidelines empower our Board to periodically evaluate and determine the appropriate leadership structure for our Board. In doing so, our Board has the flexibility to consider our specific circumstances and evolving needs at any given time.

Our Board has determined that at this time, the leadership structure best suited to support the dynamic demands of our business is to have Dr. Rothblatt, who founded our company, serve as Chairperson of our Board and Chief Executive Officer, and to appoint a Lead Independent Director with robust, well-defined responsibilities. Our Board believes that Dr. Rothblatt serving in the combined roles of Chairperson and Chief Executive Officer provides an efficient and effective leadership model for a growing entrepreneurial company like ours, as it fosters clear accountability, effective decision-making, and alignment on corporate strategy. In addition, because our Board works closely with our executive officers and members of senior management, there is a natural synergy in the combined Chairperson and Chief Executive Officer roles that facilitates our Board’s guidance of management. The Board will continue to monitor the appropriateness of this structure.

Our Board also believes that independent leadership is an important aspect of our Board’s leadership structure. As a result, the independent directors on our Board have designated Mr. Patusky as Lead Independent Director.

Lead Independent Director

• Our Lead Independent Director is selected annually by the independent directors
• Among other responsibilities, our Lead Independent Director:
  • coordinates the activities of our independent directors;
  • approves Board meeting schedules and agendas;
  • chairs all meetings of our Board when the Chairperson is not present, including executive sessions of our independent directors; and
  • serves as principal liaison between our independent directors and our Chairperson and senior management
• Our Lead Independent Director also has the authority to call executive sessions of the independent directors and is available for consultation and communication with major shareholders

A more detailed description of the responsibilities of the Lead Independent Director is included in our Corporate Governance Guidelines, which are available on our website at ir.unither.com/corporate-governance.

Committees of our Board of Directors

Our Board has three standing committees. A summary of each committee’s duties and each committee’s current composition can be found below. Additional detail on each committee’s duties can be found in each committee’s charter. Each committee’s charter provides that it may delegate responsibilities to subcommittees if it determines such a delegation would be in the best interest of our company. Committee charters can be found on our website at ir.unither.com/corporate-governance.

Audit Committee

<table>
<thead>
<tr>
<th>Members:</th>
<th>Primary Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Giltner</td>
<td>Representing and assisting our Board in its oversight responsibilities regarding our accounting and financial reporting processes, the audits of our financial statements, and system of internal controls over financial reporting, including the integrity of our financial statements, and the qualifications and independence of Ernst &amp; Young LLP, our independent registered public accounting firm</td>
</tr>
<tr>
<td>Christopher Causey</td>
<td>Retaining and terminating our independent auditors</td>
</tr>
<tr>
<td>Judy Olian</td>
<td>Approving related party transactions</td>
</tr>
<tr>
<td>Christopher Patusky</td>
<td>General oversight of risks related to our financial statements, internal controls, financial reporting processes, information technology, cybersecurity, and compliance with federal securities laws</td>
</tr>
<tr>
<td>Tommy Thompson</td>
<td></td>
</tr>
</tbody>
</table>

Meetings in 2020: 5

For additional information regarding the processes and procedures used by our Audit Committee, see the section entitled Report of our Audit Committee below.
### Compensation Committee

**Members:**
- Christopher Patusky (Chair)
- Raymond Dwek
- Nilda Mesa
- Louis Sullivan

**Meetings in 2020:** 7

Our Compensation Committee oversees our compensation plans and policies, reviews and approves compensation for our executive officers, oversees the administration of our equity incentive and share tracking awards plans and our Supplemental Executive Retirement Plan, and reviews and approves grants of stock options to our executive officers and the methodology and formulae for granting stock options and restricted stock units to other employees.

**Primary Responsibilities**
- Creating a system for awarding long-term and short-term performance-oriented incentive compensation to attract and retain senior management, and reviewing our compensation plans to confirm that they are appropriate, competitive, and properly reflect our goals and objectives while managing risk
- Assisting our Board in discharging its responsibilities regarding compensation of our executive officers
- Evaluating our CEO and setting our CEO’s compensation
- Overseeing human capital issues and diversity, equity, and inclusion matters

For additional information regarding the processes and procedures used by our Compensation Committee, see the section entitled **Compensation Discussion and Analysis** below.

### Nominating and Governance Committee

**Members:**
- Christopher Causey (Chair)
- Christopher Patusky
- Richard Giltner
- Nilda Mesa
- Louis Sullivan

**Meetings in 2019:** 7

**Primary Responsibilities**
- Proposing nominees for election to our Board
- Proposing nominees to fill vacancies on our Board and newly created directorships
- Reviewing candidates for election to our Board recommended to us by our shareholders
- Recommending committee membership and committee chairs
- Reviewing management succession plans
- Evaluating and overseeing issues and developments with respect to corporate governance, and making recommendations to our Board regarding corporate governance
- Overseeing our compliance program and our enterprise risk management program
- Overseeing our ESG disclosure program

### Corporate Governance Guidelines and Committee Charters

Upon the recommendation of our Nominating and Governance Committee, our Board maintains Corporate Governance Guidelines as a framework for the governance of our company. These guidelines are reviewed annually by our Nominating and Governance Committee, which recommends any changes to be submitted to the full Board for approval. Most recently, in March 2020, our Corporate Governance Guidelines were updated to, among other things, reduce the limit on the number of public company boards our directors may serve on, from five to four (including our Board). This change was made in direct response to shareholder feedback. Our Corporate Governance Guidelines, along with the charter for each Board committee, are available electronically in the Corporate Governance section of the Investors page of our website, located at ir.unither.com/corporate-governance, or by writing to us at United Therapeutics Corporation, Attention: Corporate Secretary, 1735 Connecticut Avenue N.W., Washington, D.C. 20009.
Board Roles and Responsibilities

Risk Oversight

Our Board is responsible for overseeing the risks facing our company. Our Board works directly with our executive officers and other members of our senior management team in carrying out its risk oversight function. Our directors take a proactive, interested, and detailed approach to their service on our Board and set expectations to promote our success through the achievement of business objectives while maintaining high standards of responsibility and ethics.

**BOARD**
- At its regularly scheduled meetings, our Board receives reports from our Chairperson and Chief Executive Officer, President and Chief Operating Officer, Chief Financial Officer, and General Counsel, and may also receive reports from the Committee Chairs, outside consultants, and other members of senior management, among others. These presentations often include identification and assessment of risks our company currently faces or may face in the future.
- Our Board is able to ask questions, discuss and provide guidance to management on the risks presented, as well as any risks that our Board identifies.
- Our Board implements its risk oversight function both as a whole and through delegation to various committees. These committees meet regularly and report back to the full Board.

**AUDIT COMMITTEE**
- Our Audit Committee’s responsibilities include general oversight of our company’s practices with respect to financial risk assessment and management, as well as the responsibility to review and discuss the company’s practices with respect to risk assessment and risk management, and risks related to matters including the company’s financial statements and financial reporting processes, and information technology and cybersecurity.

**COMPENSATION COMMITTEE**
- Our Compensation Committee’s duties include overseeing an assessment of the incentives and risks arising from or related to our compensation policies and practices, including but not limited to those applicable to our executive officers, and evaluating whether those incentives and risks are appropriate.

**NOMINATING AND GOVERNANCE COMMITTEE**
- Our Nominating and Governance Committee’s responsibilities include oversight of our company’s practices with respect to legal and regulatory compliance risk, as well as oversight of our enterprise risk management program.

**MANAGEMENT**
- Our senior management team is responsible for assessing risk on a daily basis. Our Board expects that our senior management team continually identifies, assesses, and manages the short-term and long-term risks faced by our company. If members of our senior management team identify risks that are material to United Therapeutics, our Board may convene a special meeting to discuss, assess, and address such risks.

In April 2021, our Compensation Committee reviewed a risk assessment conducted by management and our Compensation Committee’s independent compensation consultant, Radford, to determine whether the design of our employee compensation programs and the amounts and components of employee compensation might create incentives for excessive risk taking by our employees. Based on this review, our Compensation Committee concluded that the risks arising from our employee compensation programs are not reasonably likely to have a material adverse effect on our company. Our Compensation Committee believes that our compensation programs encourage employees, including our executives, to remain focused on a balance of the short-term and long-term operational and financial goals of our company, thereby reducing the potential for actions that involve an excessive level of risk. See the section entitled Compensation Discussion and Analysis below for information regarding certain risk mitigating features of our compensation programs.
Shareholder Engagement

How We Engage

Investor Relations and Senior Management
We provide institutional investors with many opportunities to provide feedback to our Board and senior management. We participate in investor conferences throughout the year, and regularly meet with our shareholders.

Board Involvement
Directors regularly and actively engage with our shareholders. For several years, our Compensation Committee Chair has actively sought to engage with our top 25+ shareholders at least once, and usually twice, per year. Our Nominating and Governance Committee Chair also engages with our shareholders on other governance topics.

2020 Engagement
We engaged with shareholders before our 2020 Annual Meeting, reaching out to 38 of our largest shareholders that collectively held over 70% of our outstanding shares and holding discussions with shareholders that collectively held over 30% of our outstanding shares. We also conducted engagement outreach following the Annual Meeting, again offering to engage with shareholders that collectively held over 70% of our outstanding shares (37 of our largest shareholders) and holding discussions with shareholders that collectively held approximately 23% of our outstanding shares. Overall, during 2020 we reached out to 47 shareholders that collectively held 74% of our outstanding shares and spoke with 15 of them that collectively held 35% of our outstanding shares. We note that following the 2020 Annual Meeting, several shareholders declined our invitation for further discussion because they had already shared their feedback during our spring shareholder outreach campaign just before our 2020 Annual Meeting.

Outcomes from Shareholder Engagement
We have considered shareholder feedback carefully, and modified our governance practices, executive compensation program, and disclosures to respond to this feedback. Some of the actions we have taken in response to shareholder feedback over the past several years include:

Governance
- Adoption of majority voting (2015)
- Adoption of proxy access (2015)
- Board decategorization (2020)
- Stricter overboarding limits for directors (2020)

ESG
- Commenced ESG disclosure program, resulting in the creation of our corporate responsibility website and our first annual corporate sustainability report (2020)
- Launched effort to convert into the first-ever public biopharmaceutical company organized as a public benefit corporation (2021)

Executive Compensation
- Renegotiated our Chief Executive Officer’s employment agreement to eliminate her entitlement to an annual stock option grant based on a market capitalization formula, and to eliminate an excise tax gross-up provision (2015)
- Shifted to 100% performance-based equity compensation program for our Named Executive Officers (2017)
- Reduced annualized total direct compensation for our CEO to approximately the 50th percentile of our peer group (2019)
- Reduced compensation for our CEO by 89% in 2020, compared to 2019 (2020)
- Addressed 2020 say-on-pay result through responsive changes and disclosures, as described under Compensation Discussion and Analysis (2021)

Enhanced Disclosure
- Complete revamp of our proxy statement, to enhance readability (2020)
- Added significant additional disclosure concerning our executive compensation decisions, and how they tie into our business strategy (2020 and 2021)
- Added disclosure concerning Board skills and diversity (2021)
Board Education

Our Board participates in a number of educational activities. Key members of management regularly provide scientific and business presentations to our Board to increase its understanding of the science behind our pipeline and our business activities. Experts regularly provide training sessions on key topics, particularly in complex legal, regulatory, and compliance areas. We joined the National Association of Corporate Directors, and encourage our Board members to take advantage of its numerous educational resources and programs.

Meetings of our Board of Directors and Board Attendance at Annual Meetings of Shareholders

Our full Board held six meetings during 2020. In addition, during 2020, our Audit Committee held five meetings, our Compensation Committee held seven meetings, and our Nominating and Governance Committee held seven meetings. Every director attended more than 75% of the total number of meetings of our Board and the committees on which they served during 2020, with 99% attendance on average. In accordance with applicable Nasdaq listing standards, the independent members of our Board met without management present four times during 2020.

Our Board encourages all of its members to attend our Annual Meeting of Shareholders, although attendance is not mandatory. All of our directors attended our 2020 Annual Meeting of Shareholders.

Shareholder Communication with Directors

Shareholders are encouraged to address any director communications to our Corporate Secretary by overnight or certified mail, signature acceptance or return receipt required, at: United Therapeutics Corporation, Attention: Corporate Secretary, 1735 Connecticut Avenue N.W., Washington, D.C. 20009. Our Corporate Secretary has the authority to disregard or take other reasonable action with respect to any inappropriate shareholder communications. After confirming the stock ownership of the author of the communication, our Corporate Secretary will review the appropriateness of a shareholder communication based on the relevance of the communication to Board duties and responsibilities. If deemed an appropriate communication, our Corporate Secretary will submit the shareholder communication to our Lead Independent Director, who may share it with the Nominating and Governance Committee or the full Board.
Non-Employee Director Compensation

Overview

In 2020, our non-employee director compensation program was comprised of three main elements:

- an annual cash retainer (payable quarterly) for service as a member of our Board
- additional annual cash retainers (payable quarterly) for service on Board committees and for service as Lead Independent Director
- stock options or restricted stock units (in either case, granted initially upon joining our Board, and thereafter on an annual basis) for service as a member of our Board

Directors may also be compensated for special assignments from our Board. In July 2019, at our request, Christopher Causey joined the board of a private company in which we own a minority equity interest. United Therapeutics pays him a stipend of $35,000 per year for this special assignment, which was approved by our Compensation Committee without his participation. Employee directors do not receive any compensation for service on our Board in addition to their regular compensation as employees.

Our Compensation Committee generally reviews non-employee director compensation levels approximately once every two years, and final decisions with respect to any changes in non-employee director compensation levels are made by our Board upon the recommendation of our Compensation Committee. In 2019, our Compensation Committee’s independent consultant reviewed the market competitiveness of our non-employee director compensation program relative to our compensation peer group and did not recommend any changes. Our current non-employee director compensation levels were established by our Board in February 2016. The following table outlines the non-employee director compensation levels in effect for 2020:

<table>
<thead>
<tr>
<th></th>
<th>Annual Cash</th>
<th>Value of Equity Based Awards[^3]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Initial</td>
</tr>
<tr>
<td>Board Membership</td>
<td>$60,000</td>
<td>$400,000</td>
</tr>
<tr>
<td>Lead Independent Director[^1]</td>
<td>$35,000</td>
<td>—</td>
</tr>
<tr>
<td>Committee Chair[^2]:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audit Committee</td>
<td>$25,000</td>
<td>—</td>
</tr>
<tr>
<td>Compensation Committee</td>
<td>$25,000</td>
<td>—</td>
</tr>
<tr>
<td>Nominating and Governance Committee</td>
<td>$25,000</td>
<td>—</td>
</tr>
<tr>
<td>Committee Membership[^3]:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audit Committee</td>
<td>$15,000</td>
<td>—</td>
</tr>
<tr>
<td>Compensation Committee</td>
<td>$15,000</td>
<td>—</td>
</tr>
<tr>
<td>Nominating and Governance Committee</td>
<td>$15,000</td>
<td>—</td>
</tr>
</tbody>
</table>

[^1]: Compensation for service as Lead Independent Director is paid in addition to amounts paid for membership on our Board and for any committee chair or membership.

[^2]: Committee chairs receive the compensation indicated for committee chair in lieu of the compensation for committee membership. Compensation for committee chair and committee membership is paid in addition to amounts paid for Board membership.

[^3]: Annual awards are generally granted once per year on the date of the first meeting of our Board following our Annual Meeting of Shareholders or for newly appointed directors, on or shortly following appointment to our Board.
Equity-Based Awards

Non-employee directors are eligible to receive equity-based awards under the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the 2015 SIP), as follows:

- **Form of Awards:** Initial grants and annual grants are paid in the form of stock options, restricted stock units (RSUs), or a combination of the two. For each grant, directors may elect to receive awards in any one of the following forms:
  - 100% stock options
  - 100% RSUs
  - 50% stock options / 50% RSUs

- **Value of Awards:** The aggregate value of each director’s annual equity-based award is $400,000. The aggregate value of an initial equity-based award upon joining our Board is $400,000, plus a pro rata portion of the annual equity-based award value based on the number of months remaining in our Board service year at the date of grant.

- **Deferral for RSUs:** For directors who elect RSUs, our Compensation Committee has implemented a deferral program enabling directors to defer delivery of shares of common stock following vesting of the RSUs.

- **Calculation Methodology:** Our Compensation Committee also sets the methodology for determining the precise numbers of stock options and/or RSUs for each grant. For the annual grants, generally occurring in June of each year, the following applies (subject to modification by our Compensation Committee in its discretion):
  - **Stock Options:** The number of stock options is calculated by dividing the equity value ($400,000, or $200,000, if the director has elected 50% options and 50% RSUs) by the fair value of each stock option, calculated in accordance with the Black Scholes Merton methodology utilized in calculating share-based compensation for financial reporting purposes. Black Scholes Merton inputs are the same as those used in our most recent quarterly report on Form 10-Q, except that the stock price input is the average closing price of our common stock over a recent time period prior to the date of grant (May 10 through June 10, in the case of annual grants).
  - **RSUs:** The number of RSUs is calculated by dividing the equity value ($400,000, or $200,000, if the director has elected 50% options and 50% RSUs) by the average closing price of our common stock over a recent time period prior to the date of grant (May 10 through June 10, in the case of annual grants)
  - **Rounding:** The resulting number of stock options or RSUs, calculated as above, is rounded to the nearest 10 shares

The grant-date fair value of RSUs and stock options reported in the Non-Employee Director Compensation table each year often varies from the $400,000 target for each director, because the methodology used to calculate the number of RSUs and/or stock options delivered is based on an average stock price over a specified, predetermined one-month period prior to the date of grant, whereas the amount reported in the table represents the grant date fair value of the RSUs and stock options on the date of grant. See 2020 Non-Employee Director Compensation below.

- **Exercise Price:** Stock options granted to non-employee directors have an exercise price equal to the closing price of our common stock as reported on the Nasdaq Global Select Market on the date of grant, or on the preceding trading day if the award is granted on a date when the Nasdaq is not open.

- **Grant Timing:**
  - The date of grant for a new non-employee director’s initial award, consisting of the initial membership award and a prorated amount of the annual award for the remainder of the board service year, is the date of a director’s appointment or election to our Board.
  - The date of grant for annual awards is the date of the first meeting of our Board following our Annual Meeting of Shareholders in the year of grant.

- **Vesting:** Non-employee director awards fully vest on the one year anniversary of the grant date, but only if the director attends at least 75% of the regularly scheduled meetings of our Board and their committee meetings from the date of grant until the date of our next Annual Meeting of Shareholders.

Previously, non-employee directors were also eligible to receive awards under the 2011 United Therapeutics Corporation Share Tracking Awards Plan (collectively with its predecessor plan adopted in 2008, the STAP), which settle only in cash. However, since the approval of the 2015 SIP on June 26, 2015, all equity-based awards for non-employee directors have been granted in the form of stock options and RSUs.
The following table lists the compensation earned in 2020 by each non-employee director:

<table>
<thead>
<tr>
<th>Name</th>
<th>Fees Earned or Paid in Cash (1)</th>
<th>Restricted Stock Units (2)</th>
<th>Stock Options (2)</th>
<th>All Other Compensation</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Causey</td>
<td>$100,000</td>
<td>—</td>
<td>$390,199</td>
<td>$35,000</td>
<td>$525,199</td>
</tr>
<tr>
<td>Raymond Dwek</td>
<td>$67,706</td>
<td>$402,394</td>
<td>—</td>
<td>$470,100</td>
<td></td>
</tr>
<tr>
<td>Richard Giltner</td>
<td>$100,000</td>
<td>$402,394</td>
<td>—</td>
<td>$502,394</td>
<td></td>
</tr>
<tr>
<td>Katherine Klein</td>
<td>$60,000</td>
<td>$201,197</td>
<td>$195,100</td>
<td>—</td>
<td>$456,297</td>
</tr>
<tr>
<td>Ray Kurzweil</td>
<td>$60,000</td>
<td>$201,197</td>
<td>$195,100</td>
<td>—</td>
<td>$456,297</td>
</tr>
<tr>
<td>Linda Maxwell</td>
<td>$18,424</td>
<td>—</td>
<td>$658,658</td>
<td>—</td>
<td>$677,082</td>
</tr>
<tr>
<td>Nilda Mesa</td>
<td>$79,606</td>
<td>$201,197</td>
<td>$195,100</td>
<td>—</td>
<td>$475,903</td>
</tr>
<tr>
<td>Judy Olian</td>
<td>$64,606</td>
<td>$402,394</td>
<td>—</td>
<td>$467,000</td>
<td></td>
</tr>
<tr>
<td>Christopher Patusky</td>
<td>$142,706</td>
<td>$201,197</td>
<td>$195,100</td>
<td>—</td>
<td>$539,003</td>
</tr>
<tr>
<td>Louis Sullivan</td>
<td>$90,000</td>
<td>$201,197</td>
<td>$195,100</td>
<td>—</td>
<td>$486,297</td>
</tr>
<tr>
<td>Tommy Thompson</td>
<td>$75,000</td>
<td>$201,197</td>
<td>$195,100</td>
<td>—</td>
<td>$471,297</td>
</tr>
</tbody>
</table>

\(1\) Includes (as applicable) annual cash retainer and fees for serving on our Board, the committees of our Board, as a committee chair, and as Lead Independent Director.

\(2\) On June 26, 2020, each of our non-employee directors (other than Dr. Maxwell, who was appointed to the Board on September 10, 2020) was granted stock options and/or RSUs. Each stock option had an exercise price of $119.76 per share and a grant date fair value of $37.81 per share, and each RSU had a grant date fair value of $119.76 per share. Upon her appointment to the Board on September 10, 2020, Dr. Maxwell received an equity award consisting entirely of stock options. Each stock option had an exercise price of $102.44 per share and a grant date fair value of $31.85 per share. Dr. Maxwell received 11,542 stock options for her new director sign-on grant, and 9,138 stock options reflecting a pro rata portion of her annual equity grant for the year in which she joined our Board. Amounts shown in these columns represent the aggregate grant date fair value of the stock options and RSUs granted in 2020, which were the only awards granted to non-employee directors in 2020, computed in accordance with applicable accounting standards. For a discussion of the valuation assumptions for stock options, see Note 8—Share-Based Compensation to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

The grant-date fair value of RSUs and stock options presented in this table differs from the $400,000 target for each director due to the methodology used to calculate the number of RSUs and/or stock options delivered, which is based on an average stock price over a specified one-month period prior to the date of grant.

\(3\) Consists of compensation paid to Mr. Causey in 2020 for his service on the board of directors of a private company in which we maintain a minority equity interest, excluding a portion that was paid retroactively in 2020 for his 2019 service.

Each non-employee director held the following number of stock options, STAPs and RSUs as of December 31, 2020:

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock Options</th>
<th>STAP Awards</th>
<th>RSUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Causey</td>
<td>51,380</td>
<td>6,000</td>
<td>—</td>
</tr>
<tr>
<td>Raymond Dwek</td>
<td>15,000</td>
<td>53,000</td>
<td>3,360</td>
</tr>
<tr>
<td>Richard Giltner</td>
<td>15,000</td>
<td>50,000</td>
<td>3,360</td>
</tr>
<tr>
<td>Katherine Klein</td>
<td>60,240</td>
<td>29,375</td>
<td>1,680</td>
</tr>
<tr>
<td>Ray Kurzweil</td>
<td>40,210</td>
<td>33,750</td>
<td>1,680</td>
</tr>
<tr>
<td>Linda Maxwell</td>
<td>20,680</td>
<td>—</td>
<td>1,680</td>
</tr>
<tr>
<td>Nilda Mesa</td>
<td>18,030</td>
<td>—</td>
<td>1,680</td>
</tr>
<tr>
<td>Judy Olian</td>
<td>45,930</td>
<td>—</td>
<td>3,360</td>
</tr>
<tr>
<td>Christopher Patusky</td>
<td>44,830</td>
<td>27,000</td>
<td>1,680</td>
</tr>
<tr>
<td>Louis Sullivan</td>
<td>35,590</td>
<td>30,000</td>
<td>1,680</td>
</tr>
<tr>
<td>Tommy Thompson</td>
<td>46,510</td>
<td>53,059</td>
<td>1,680</td>
</tr>
</tbody>
</table>
Advisory Resolution to Approve Executive Compensation

We are asking our shareholders to vote on an advisory resolution, commonly known as a “Say-on-Pay” proposal, to approve executive compensation as reported in this Proxy Statement. Our Board and our Compensation Committee strongly value the opinions of our shareholders, and we have made substantial modifications to our executive compensation program specifically to address concerns raised by shareholders in previous years. Our Compensation Committee, which is responsible for designing and administering our executive compensation program, has designed our executive compensation program to provide a competitive and internally equitable compensation and benefits package that reflects company performance, job complexity, and the value provided, while also promoting long term retention, motivation, and alignment with the long-term interests of our shareholders.

As described elsewhere in this Proxy Statement, we have evolved our compensation practices significantly in recent years, in large part in response to shareholder feedback. We were therefore very disappointed that shareholders did not approve our 2020 Say-on-Pay proposal following shareholder feedback in 2019 that we believed would lead to its support. Based upon our shareholder outreach efforts in both the spring and fall of 2020, we believe the changes and commitments disclosed below, which were made after the 2020 Annual Meeting and as a result of shareholder feedback, address the concerns evidenced by our negative Say-on-Pay outcome in 2020. **Shareholders with which we engaged following our 2020 Annual Meeting of Shareholders confirmed that the actions and disclosures described below are responsive to their concerns underlying our negative Say-on-Pay outcome in 2020.**

In connection with your vote on this proposal, we urge you to read the **Letter from Our Compensation Committee**, the Compensation Discussion and Analysis section of this Proxy Statement, the Summary Compensation Table, and other related compensation tables and narratives that follow, which provide detailed information on the compensation of our Named Executive Officers. Our Compensation Committee and our Board of Directors believe that the policies and procedures articulated in these sections of this Proxy Statement, including the modifications we have made to our executive compensation programs, are effective in achieving our goals, and that the compensation of our Named Executive Officers reported in this Proxy Statement has supported and contributed to both our recent and long term success.

In accordance with Section 14A of the Exchange Act, and as a matter of good corporate governance, we are asking shareholders to approve the following advisory resolution at the Annual Meeting:

RESOLVED, that the shareholders of United Therapeutics Corporation (our “Company”) approve, on an advisory basis, the compensation of our Company’s Named Executive Officers disclosed in the Compensation Discussion and Analysis, the Summary Compensation Table and the related compensation tables, notes and narrative in the Proxy Statement for our Company’s 2021 Annual Meeting of Shareholders.

This advisory resolution is non-binding on our Board of Directors. Although non-binding, our Board and our Compensation Committee will review and consider the voting results when making future decisions regarding our executive compensation program. Based on the results of our 2017 shareholder advisory vote on the preferred frequency of holding future advisory votes to approve executive compensation, our Board of Directors has adopted a policy providing for an annual advisory resolution to approve executive compensation. Unless our Board modifies its policy on the frequency of future “Say-on-Pay” advisory votes, the next “Say-on-Pay” advisory vote will be held at our 2022 Annual Meeting of Shareholders. **The affirmative vote of the holders of a majority of the outstanding shares of common stock present, online or by proxy, at our Annual Meeting, and entitled to vote on the matter, is required for approval of this proposal.** Abstentions have the same effect as an “against” vote. Broker non-votes, if any, have no impact on the vote.

Our Board of Directors recommends that you vote **FOR** the advisory resolution to approve executive compensation.
Letter from our Compensation Committee

Dear Fellow United Therapeutics Shareholders:

STRONG PERFORMANCE, REVENUE GROWTH, AND COMMITMENT TO OUR EMPLOYEES, PATIENTS, AND SHAREHOLDERS

2020 will unquestionably be a year to remember for all of us. United Therapeutics began this year with excitement, as we continued executing our strategy to grow our treprostinil-based revenues and better serve our patients through the development of expanded and improved therapies, devices, and technologies.

The COVID-19 pandemic brought unexpected and unimaginable challenges to the world. United Therapeutics responded quickly and decisively, ensuring our patients were not at risk of a disrupted supply of medicine, our employees were able to continue working seamlessly with the resources and support they needed, and our workplaces remained safe for essential employees who continued to report to worksites daily. For more insights on our pandemic response, see pages 9 and 11.

In the face of these challenges, United Therapeutics delivered — exceeding our overall revenue goal, delivering top quintile profitability, working hard to keep our manufacturing operations intact to ensure our patients had uninterrupted access to their critical medicines, advancing our development programs even with pandemic restrictions in place, and working hard to support our employees. Wall Street clearly recognized the company’s performance, as our stock price grew by 72% in 2020, compared to return from the Nasdaq Biotechnology Index of only 26%.

WE ARE ENGAGED, LISTENING, AND RESPONDING TO OUR SHAREHOLDERS

We seek and value the feedback and input of our shareholders. Over the past several years, we have conducted extensive and ongoing engagement with shareholders, and have greatly benefited from and appreciated this dialogue as we continue to evolve our compensation, ESG, and governance programs.

We were incredibly disappointed with our negative Say-on-Pay result last year. By way of background, our 2019 executive compensation program included a four-year, front-loaded equity award comprised of stock options. Although we felt this program was well-designed, and would address prior concerns raised by shareholders, our 2020 Say-on-Pay result revealed that further changes were needed, and we conducted significant outreach to learn more.

Throughout 2020, including both before and after our 2020 Annual Meeting, we reached out to 47 of our largest shareholders, collectively holding 74% of our outstanding shares, and had meetings with 15 shareholders collectively holding 35% of our outstanding shares. Additionally, we held discussions with the two largest proxy advisory firms to gather feedback. These efforts were led by the Chair of our Compensation Committee. Two key themes emerged from the shareholder feedback we heard during our 2020 shareholder outreach efforts (both before and after the 2020 Annual Meeting). First, shareholders were concerned about the structure of the four-year equity grant awarded to our Named Executive Officers in 2019, including concerns about our level of commitment not to grant additional equity during the ensuing four-year period (2019-2022). Second, shareholders wanted more transparency about our goal-setting process for short-term incentives. Our Compensation Committee discussed this feedback at multiple meetings, and ultimately took specific actions in response. These include a clear and firm commitment not to grant additional equity-based awards to our current Named Executive Officers until 2023, commitments regarding our next equity grants to our Named Executive Officers in 2023, and commitments concerning the robustness of our 2021 revenue goal. Shareholders we met with following the 2020 Annual Meeting gave us positive feedback about these changes and confirmed that the actions we are taking are responsive to their feedback and concerns. Please see the detailed discussion of our response to shareholders on page 46.

WE APPRECIATE YOUR SUPPORT

We have worked hard to address shareholder feedback regarding our executive compensation programs, and we want to personally thank those shareholders with which we had the opportunity to meet in 2020. We very much value the dialogue and look forward to continuing the conversation. Please review the Compensation Discussion and Analysis beginning on the following page for further information and detail about our executive compensation program. We look forward to your continued support of United Therapeutics generally, and your support of our Say-on-Pay proposal this year.

Sincerely,

Raymond Dwek
Compensation Committee Member

Nilda Mesa
Compensation Committee Member

Louis Sullivan
Compensation Committee Member

Christopher Patusky
Compensation Committee Chair
Compensation Discussion and Analysis

This Compensation Discussion and Analysis describes the compensation objectives and policies set by our Compensation Committee for our Named Executive Officers, including executive pay decisions and processes and all elements of our executive compensation program. In this Compensation Discussion and Analysis and elsewhere in this Proxy Statement, the term Compensation Committee refers to the Compensation Committee of our Board of Directors, and the terms we and our refer to United Therapeutics.

Overview

Below is a summary of introductory highlights regarding key 2020 compensation outcomes, performance metrics, and other achievements.

<table>
<thead>
<tr>
<th>UTHR: Industry leading 2020 total shareholder return (TSR)</th>
<th>Pipeline execution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compared to 2020 NBI* TSR 72%</td>
<td>• Successful INCREASE clinical study in a new indication with no approved therapies</td>
</tr>
<tr>
<td></td>
<td>• Filed sNDA to expand Tyvaso labeling to include PH-ILD</td>
</tr>
<tr>
<td></td>
<td>• FDA clearance of pharmacy-filled Remunity Pump for Remodulin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Returned to revenue growth trajectory</th>
<th>Strong performance despite COVID-19 challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲ 2% growth overall</td>
<td>• No COVID-19 based layoffs, furloughs, or pay reductions; provided COVID-related time-off programs and additional cash bonuses to support our employees</td>
</tr>
<tr>
<td>▲ 16% growth for Tyvaso</td>
<td></td>
</tr>
<tr>
<td>▲ 30% growth for Orenitram</td>
<td></td>
</tr>
<tr>
<td>• Continued to exceed analyst consensus revenue estimates</td>
<td></td>
</tr>
<tr>
<td>• Record number of U.S. treprostinil patients on therapy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Industry-leading profitability</th>
<th>Expended and strengthened our commitment to diversity and inclusion at the Board level and throughout the company, with leadership by our Compensation Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 35% Net Income Margin, 57% EBITDASO margin</td>
<td>• Board-level diversity — 5 of 12 directors are women; 3 of 12 identify as under-represented minorities</td>
</tr>
<tr>
<td>• EBITDASO margin was 2nd among our compensation peer group</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$1.6 million revenue per employee</th>
<th>Commenced ESG transparency program, with new website and first corporate responsibility report</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 5th highest in our compensation peer group</td>
<td></td>
</tr>
</tbody>
</table>

* NBI = Nasdaq Biotechnology Index

CEO Compensation at a Glance

- Our CEO’s compensation is predominately at-risk, performance-based (90%), when the 2019 four-year grant is viewed on an annualized basis
- Actual reported CEO compensation reduced by approximately 89% from 2019 to 2020
- 2020 total target direct compensation remained positioned at the 50th percentile, when the value of the four-year grant awarded in 2019 is viewed on an annualized basis
- During 2020, our CEO received:
  - A modest increase in base salary (3.5%), below the average salary increase for the rest of the company
  - No equity grants
  - No COVID-19 adjustments to incentive program targets, and no other discretionary adjustments in short-term or long-term incentives

No discretionary adjustments to executive compensation program as a result of COVID-19 or any other reasons

Responsiveness to 2020 Say-on-Pay results

- Extensive shareholder outreach after the 2020 Annual Meeting (reached out to holders of 70+% of our outstanding shares)
- 89% reduction in reported CEO compensation
- Annualized CEO total target direct compensation remained at approximately the 50th percentile of our peer group (when the 2019 four-year equity grant is annualized)
- Firm commitment to no additional NEO equity awards until 2023
- Additional responsive measures (see page 46)
Company Introduction

We were formed in 1996 to find a cure or treatment for a rare disease afflicting the daughter of our Founder, Chairperson and CEO. We now market and sell five therapies for rare diseases, including four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin® (treprostinil) Injection (Remodulin); Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Orenitram® (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca® (tadalafil) Tablets (Adcirca). We also market and sell an oncology product, Unituxin® (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity® Pump for Remodulin. We are actively advancing a pipeline of research and development projects that includes new indications, formulations, and delivery devices for our existing products, as well as new products to treat PAH, pulmonary fibrosis, and other conditions.

Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology PBC is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Our Named Executive Officers

Our 2020 Named Executive Officers (or NEOs) are:

Martine Rothblatt, Ph.D., J.D., M.B.A.
66, Founder Chairperson, Chief Executive Officer, and Director

Dr. Rothblatt founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previously, she created the satellite radio company SiriusXM. She is a co-inventor on eight of our patents. Her pioneering book, Your Life or Mine: How Geoethics Can Resolve the Conflict Between Private and Public Interests in Xenotransplantation, anticipated the need both for global virus bio-surveillance and a greatly expanded supply of transplantable organs.

Michael Benkowitz
49, President and Chief Operating Officer

Mr. Benkowitz joined United Therapeutics in 2011 as our Executive Vice President, Organizational Development. In this role, he was responsible for most companywide administrative functions, including human resources, and information technology, among others, and was also responsible for many of our business development efforts and oversight of several of our key collaborations. He was promoted to President and Chief Operating Officer in June 2016, when he also became responsible for all of our commercial and medical affairs activities.

James C. Edgemond
53, Chief Financial Officer and Treasurer

Mr. Edgemond joined United Therapeutics in January 2013 as Treasurer and Vice President, Strategic Financial Planning. Mr. Edgemond was promoted to Chief Financial Officer and Treasurer in March 2015. Prior to joining United Therapeutics, he was Vice President, Corporate Controller and Treasurer of Clark Construction Group from 2008 through January 2013. He also served in a variety of roles at The Corporate Executive Board Company from 1998 to 2008, serving as Executive Director, Finance from 2005 to 2008. He began his career as a public accountant at KPMG Peat Marwick LLP, from 1990 through 1998, where he served in a variety of roles, including as a Senior Manager prior to his departure.
2020 Performance Highlights

2020 continued the strategic transformation for United Therapeutics with several important milestones for our patients and our shareholders, including:

- **$1.48 billion in revenues**, marking a return to revenue growth despite generic competition and COVID-19. $1.6 million in revenue per employee, which ranked 5th out of companies in our compensation peer group.

- We advanced our key pipeline programs during 2020, including:
  - FDA clearance of the Remunity Pump for Remodulin.
  - Successful completion of the phase 3 INCREASE study of Tyvaso in patients with PH-ILD, an indication with no approved therapies.
  - Progressed our phase 3 BREEZE study for Tyvaso DPI, a drug device combination product being developed for treatment of PAH and PH-ILD.
  - Continued preparation for the launch of the Implantable System for Remodulin for PAH, pending Medtronic satisfying certain regulatory conditions.
  - Continued progress on additional clinical trials despite industry-wide COVID-19 related challenges.

- We reached record numbers of PAH patients in the United States being treated with our treprostinil-based therapies — once again reaching more patients than ever before.

- 72% TSR, compared to 26% TSR for the NBI.

These efforts in 2020 have already led to FOUR key developments in early 2021:

- **Commercial Launch of the Remunity Pump for Remodulin.** In February 2021, we launched commercial sales of this new subcutaneous delivery system for Remodulin.

- **FDA Approval of Tyvaso for PH-ILD.** In April 2021, the FDA approved our supplemental new drug application (sNDA) adding pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso is the first therapy ever approved by the FDA to treat this condition, which affects at least 30,000 patients in the United States alone.

- **Launched TETON Study in IPF.** Based on data from the INCREASE study, we launched a new phase 3 study of Tyvaso in patients with idiopathic pulmonary fibrosis (IPF), a condition impacting about 100,000 patients in the United States.

- **Submitted Tyvaso DPI NDA.** In April 2021, we submitted a new drug application (NDA) to the FDA for approval of Tyvaso DPI, a dry powder inhalation form of treprostinil, to treat both PAH and PH-ILD. We anticipate an FDA decision by the end of 2021, under an accelerated review as a result of our use of a priority review voucher we purchased in January 2021 for $105.0 million.

Shareholder Outreach and Responsiveness to our 2020 Say-on-Pay Vote

At our 2020 Annual Meeting, our shareholders did not approve our Say-on-Pay proposal, with only approximately 34% of the votes cast in favor of the proposal. We understand that there were elements of the structure and design of the four-year grant we made to NEOs in March 2019 that did not align with shareholder preferences, along with a perceived lack of commitment not to issue more equity during the four-year period the grant replaced. We have taken clear action to address and respond to the concerns we heard in 2020.

In the aggregate in 2020, we reached out to 47 shareholders that collectively held approximately 74% of our outstanding shares, and had discussions with 15 shareholders that collectively held over 35% of our outstanding shares. These discussions took place across two engagement efforts, one just before our 2020 Annual Meeting, and one following our 2020 Annual Meeting. Following our 2020 Annual Meeting, we offered to engage with shareholders that collectively held approximately 71% of our outstanding shares (37 shareholders), and had discussions with shareholders that collectively held approximately 23% of our outstanding shares (10 shareholders). These meetings were led by Christopher Patusky, our Lead Independent Director, who took on the role of Compensation Committee Chair in mid-2020 as part of our committee refreshment process. Where appropriate, participants also included representatives of our human
resources, investor relations, and legal departments. The purpose of these meetings was to gather feedback regarding our executive compensation and general governance policies, understand any concerns or feedback about our executive compensation programs and their Say-on-Pay vote, and gather feedback on actions and disclosures our Compensation Committee was considering in response to shareholder feedback. We also held meetings with the two largest proxy advisory firms in the fall of 2020, discussing similar topics.

Following these calls, our Compensation Committee met and discussed the feedback received and considered possible actions and enhanced disclosures in order to respond to shareholder feedback. The following chart summarizes the feedback received, and the actions and disclosures intended to address shareholder feedback. Shareholders we met with in our post-Annual Meeting outreach confirmed that they found these actions and disclosures to be responsive to their concerns.

In addition to the following actions, we have refreshed our Compensation Committee by adding Christopher Patusky as its chair, and Raymond Dwek as a member of the Committee.

<table>
<thead>
<tr>
<th>Aggregate 2020 Engagement</th>
<th>2020 Post-Annual Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>offered engagement (47 shareholders)</td>
<td>offered engagement (37 shareholders)</td>
</tr>
<tr>
<td>held discussions (15 shareholders)</td>
<td>held discussions (10 shareholders)</td>
</tr>
<tr>
<td>74%</td>
<td>71%</td>
</tr>
<tr>
<td>35%</td>
<td>23%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>What we heard:</th>
<th>Compensation Committee action following engagement:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholders were concerned with the structure of our 2019 four-year equity grant, including a perceived lack of commitment not to issue more equity during the four-year period covered by this grant</td>
<td>• Issued no equity awards to NEOs in 2020, resulting in an 89% decrease in reported compensation for our CEO</td>
</tr>
<tr>
<td></td>
<td>• Disclosed a firm commitment that there will be no new equity grants to our current NEOs until 2023 (see page 55)</td>
</tr>
<tr>
<td></td>
<td>• Disclosed a commitment to resume issuing equity awards annually in 2023 (i.e., granting one year of equity in 2023) (see page 55)</td>
</tr>
<tr>
<td></td>
<td>• Disclosed commitment that the 2023 equity grant will respond to shareholder feedback and will have the following guardrails (see page 55):</td>
</tr>
<tr>
<td></td>
<td>• The 2023 equity award will be at least 50% performance-based</td>
</tr>
<tr>
<td></td>
<td>• The performance-based equity award will include one or more performance conditions other than stock price appreciation</td>
</tr>
<tr>
<td></td>
<td>• The 2023 award will include a mix of equity vehicles, including the use of performance shares*</td>
</tr>
<tr>
<td>Shareholders expressed the need for more transparency in the goal setting process, especially when using goals set lower than prior year actual performance</td>
<td>• The 2020 revenue goal was set above 2019 actual performance (see page 52 for a discussion of the 2020 revenue goal)</td>
</tr>
<tr>
<td></td>
<td>• Advance commitments regarding our 2021 revenue goal (see pages 52-53):</td>
</tr>
<tr>
<td></td>
<td>• Our 2021 revenue goal has been set significantly above our 2020 actual performance</td>
</tr>
<tr>
<td></td>
<td>• Our minimum revenue performance level (i.e., threshold) for our CEO and other NEOs to receive any payout based on 2021 revenue performance has been set above our 2020 actual performance</td>
</tr>
<tr>
<td></td>
<td>• Enhanced disclosure about how our goals are set, including the methodology behind setting a cash profit-margin goal aligned with top quintile profitability (see pages 50-54)</td>
</tr>
</tbody>
</table>

* Performance shares are awards of either restricted stock or restricted stock units that include one or more performance-based vesting criteria.
Overview of our 2020 Executive Compensation Program

Compensation Program Objectives

Our executive compensation program is designed to retain and motivate our executive team, while achieving four critical objectives: pay-for-performance (with at-risk pay representing approximately 90% of overall Chief Executive Officer pay and approximately 83% of our other Named Executive Officers’ pay, when the 2019 four-year grant is viewed on an annualized basis); incentivize alignment with shareholder interests based on delivering operating performance and stock appreciation; balancing incentives over the short-term and long-term; and market competitiveness.

Pay Program Elements

We accomplish these objectives through the following compensation elements, as summarized below:

<table>
<thead>
<tr>
<th>Compensation Element</th>
<th>Pay-for-Performance</th>
<th>Shareholder Alignment</th>
<th>Balance Short- and Long-Term Perspectives</th>
<th>Market Competitiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base Salary</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Cash Incentive Awards</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Long-Term Incentives (Stock Options)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Benefits/Perquisites</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Supplemental Executive Retirement Plan [SERP]</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Severance/Change-of-Control Benefits</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Stock Ownership Guidelines</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>
Pay Element Overview

Our compensation program is broken into three elements: base salary, annual short-term incentive (cash bonus), and a long-term incentive program. A significant portion of target total compensation for our CEO and other NEOs is structured as “at risk” compensation, comprised of the annual short-term incentive cash bonus and long-term incentives in the form of stock options. In March 2019, our CEO and other NEOs were granted a one-time, four-year equity award which covered all equity awards for the years 2019-2022. The Compensation Committee will not grant any additional equity to our current NEOs during this four-year period. As such, our NEOs were not granted any additional equity in 2020. The below chart displays the breakdown of fixed and at-risk pay based on the annualized value of the four-year stock award granted in March 2019.

<table>
<thead>
<tr>
<th>Element / Percent of TDC</th>
<th>Why We Pay This Element</th>
<th>Key Characteristics</th>
<th>How We Determine Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Base Salary</td>
<td>Provides market</td>
<td>Cash</td>
<td>Market rate, internal</td>
</tr>
<tr>
<td></td>
<td>competitive levels of</td>
<td>Annual</td>
<td>pay equity, experience</td>
</tr>
<tr>
<td></td>
<td>fixed pay to attract</td>
<td></td>
<td>and critical skills</td>
</tr>
<tr>
<td></td>
<td>and retain our NEOs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEO</td>
<td>10.3%</td>
<td>17.4%</td>
<td></td>
</tr>
<tr>
<td>Other NEOs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonus</td>
<td>Provides competitive</td>
<td>Cash</td>
<td>50% Financial</td>
</tr>
<tr>
<td></td>
<td>incentives to achieve</td>
<td>Performance-Based</td>
<td>25% Cash Profits</td>
</tr>
<tr>
<td></td>
<td>difficult, annual</td>
<td>Annual</td>
<td>25% Revenues</td>
</tr>
<tr>
<td></td>
<td>company-wide performance criteria</td>
<td></td>
<td>50% Operational</td>
</tr>
<tr>
<td></td>
<td>Pay-for-Performance</td>
<td></td>
<td>25% Manufacturing</td>
</tr>
<tr>
<td></td>
<td>Shareholder Alignment</td>
<td></td>
<td>25% R&amp;D</td>
</tr>
<tr>
<td></td>
<td>Strategic alignment</td>
<td></td>
<td>Payout 0-150% of target</td>
</tr>
<tr>
<td></td>
<td>balancing a focus on</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>patients through</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>manufacturing and invent</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ory performance, and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>advancement of clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>programs with driving</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>revenue and profitability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEO</td>
<td>11.4%</td>
<td>13.0%</td>
<td></td>
</tr>
<tr>
<td>Other NEOs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stock Options</td>
<td>Strategic alignment</td>
<td>At-Risk</td>
<td>Market rate, internal</td>
</tr>
<tr>
<td></td>
<td>incentivizing</td>
<td>Performance-Based</td>
<td>pay equity, experience</td>
</tr>
<tr>
<td></td>
<td>achievement of four-</td>
<td>Four-Year Grant</td>
<td>and critical skills</td>
</tr>
<tr>
<td></td>
<td>year business plan</td>
<td>covering 2019-2022,</td>
<td>Substantial reduction</td>
</tr>
<tr>
<td></td>
<td>toward multiple-fold</td>
<td>with no other equity</td>
<td>in market positioning</td>
</tr>
<tr>
<td></td>
<td>increase in revenues,</td>
<td>awarded during this</td>
<td>on an annualized basis</td>
</tr>
<tr>
<td></td>
<td>driving shareholder</td>
<td>period</td>
<td></td>
</tr>
<tr>
<td></td>
<td>value.</td>
<td>50% premium-priced</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pay-for-Performance</td>
<td>cliff vesting at year 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shareholder Alignment</td>
<td>50% market-priced</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ratable vesting at</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>years 2, 3 and 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No intrinsic value</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>unless stock price</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>grows</td>
<td></td>
</tr>
<tr>
<td>CEO</td>
<td>78.3%</td>
<td>69.6%</td>
<td></td>
</tr>
<tr>
<td>Other NEOs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The following charts illustrate the extent to which pay for our Chief Executive Officer and our other Named Executive Officers is at risk, as payout levels are based entirely on performance. For each chart, the amounts shown represent 2020 base salary [on an annualized basis, following the February 2020 salary increases], 2020 target cash bonus, and the annualized grant-date fair value of long-term incentive awards granted in March 2019, which were granted 50% in the form of premium-priced performance stock options and 50% in the form of market-priced stock options.
2020 Compensation Decisions

Summary of 2020 Compensation

The components of our Named Executive Officers’ target total direct compensation are base salary and variable compensation, including cash incentives and long-term incentive compensation in the form of stock options. In 2020, we kept our commitment not to grant any additional equity to our CEO or other NEOs, based on the March 2019 grant which was designed to cover the 2019-2022 time-period (a four-year equity grant).

Summary 2020 Target Total Direct Compensation

<table>
<thead>
<tr>
<th>NEO</th>
<th>2020 Base Salary</th>
<th>% Increase Over 2019 Base Salary</th>
<th>2020 Cash Incentive Bonus Target as % of Base Salary</th>
<th>Change in Cash Incentive Bonus Target %</th>
<th>2020 Long-Term Incentive Award</th>
<th>2020 Total Target Direct Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt</td>
<td>$1,320,000</td>
<td>3.5%</td>
<td>110%</td>
<td>0% $</td>
<td>—</td>
<td>$2,772,000</td>
</tr>
<tr>
<td>James Edgemond</td>
<td>$700,000</td>
<td>3.7%</td>
<td>75%</td>
<td>0% $</td>
<td>—</td>
<td>$1,225,000</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>$915,000</td>
<td>3.4%</td>
<td>85%</td>
<td>0% $</td>
<td>—</td>
<td>$1,692,750</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>$880,000</td>
<td>3.5%</td>
<td>65%</td>
<td>0% $</td>
<td>—</td>
<td>$1,452,000</td>
</tr>
</tbody>
</table>

(1) Reflects increases in annual base salaries effective February 24, 2020 and first reflected in pay on March 13, 2020
(2) Represents the difference in cash incentive award target as a percentage of salary, between 2019 and 2020
(3) Reflects the fact that no equity was awarded in 2020 to our Named Executive Officers

Base Salary

Base salary is the fixed element of the compensation packages for our Named Executive Officers. Our Compensation Committee reviews and establishes base salary levels for our Named Executive Officers each year taking into consideration one or more of the following factors, depending on the circumstances: (1) a qualitative evaluation of individual performance, including contribution to the advancement of corporate objectives, impact on financial results, and strategic accomplishments; (2) our overall performance, financial condition, and prospects; (3) the annual compensation received by executives holding comparable positions at our peers; (4) our annual company-wide budget for salary increases; and (5) the input of our Chief Executive Officer (in the case of the other Named Executive Officers). Base salaries are also typically reviewed when there is a material change in the executive’s responsibilities during the year.

In early 2020, our Compensation Committee approved salary increases for our Named Executive Officers, as shown in the table above, effective February 2020. Salary increases were determined based on a review of competitive pay positioning, taking into consideration internal pay equity among Named Executive Officers and approximate the company-wide salary increases for our employees.

Cash Incentive Award Program

Each year, our Compensation Committee establishes cash incentive award targets for each of our Named Executive Officers, taking into consideration the same factors it uses to determine base salaries (other than our company-wide budget for salary increases). For 2020, our Compensation Committee established cash incentive award targets for our Named Executive Officers as a percentage of base salary, at the levels shown in the Summary 2020 Target Total Direct Compensation table above. These percentages were unchanged from 2019.
These stated incentive targets are comparable to those of executives holding similar roles and levels of responsibility at our peer group companies. Cash incentives are earned for achieving our Company-Wide Milestones (described below) and three of our four Milestones are subject to a threshold, or minimum, level of performance before earning credit for those Milestones. In addition, each of our Named Executive Officers had the opportunity to earn up to 150% of their respective target cash incentive award for 2020, based on above-target performance on our cash profit and revenue-based Milestones. We believe that by setting a threshold level of performance as well as a maximum under the plan we have aligned these policies with market norms and have also responded to feedback from our shareholders.

2020 Company-Wide Milestone Program

The Milestones (or performance goals) under our 2020 Company-Wide Milestone Program are intended to create company-wide incentives relating to significant corporate objectives, falling into two categories: (1) financial metrics, consisting of revenue and profitability targets; and (2) operational metrics, tied to manufacturing and research and development (R&D) objectives. Our Compensation Committee approved the specific goals and weightings based on management input at the beginning of the year and a desire to reflect core performance measures and priorities for the business for the fiscal year, including our commitment to compliance, and to set goals that translate most directly into short-, medium- and long-term value growth.

The goal-setting process for 2020 was rigorous, involving lengthy discussions and a review of multiple data points, including analyst consensus, product expectations, and overall market potential. The Milestone performance targets are difficult to meet and require significant leadership and execution excellence on the part of our Named Executive Officers. Based on these factors, our Compensation Committee established the following Company-Wide Milestones and weightings for 2020:

<table>
<thead>
<tr>
<th>Milestone Description</th>
<th>Weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milestone 1—Financial Performance—Cash Profits*: Achieve cash profits in the top quintile of our peer group as measured by a 50% cash profit margin</td>
<td>25%</td>
</tr>
<tr>
<td>Milestone 2—Financial Performance—Revenue: Superior financial performance as evidenced by achieving the net revenues for 2020 included in our long-range business plan ($1.46 billion)</td>
<td>25%</td>
</tr>
<tr>
<td>Milestone 3—Manufacturing: Adequate manufacturing capabilities, evidenced by a two-year inventory of Remodulin, Tyvaso, and Orenitram finished drug product and passing all GMP-related FDA inspections at our facilities without any issues that prevent the use or approval of any of our drug products</td>
<td>25%</td>
</tr>
<tr>
<td>Milestone 4—Research &amp; Development: Conduct insightful research and development programs, taking into account regulatory approvals, label extensions and the quantity and quality of trials that support our business goals</td>
<td>25%</td>
</tr>
</tbody>
</table>

* Cash profit margin is defined as cash profit divided by net revenues. Cash profit is defined as net income for 2020 as reported in our Annual Report on Form 10-K for the year ended December 31, 2020, adjusted to add the following expenses, net of relevant benefits (or subtracted, to the extent the expense item is a net benefit):

- Interest expense
- Non-cash charges (including, without limitation, amortization, and depreciation)
- Tax expense (including penalties and interest)
- Extraordinary, non-recurring and unusual items (including without limitation, license fees, milestone payments, gains/losses on acquisition/disposal of assets, asset impairments, restructuring costs, foreign currency adjustments, and discontinued operations)
- Legal expenses related to (1) intellectual property prosecution and defense; (2) litigation and government investigation and enforcement proceedings; and (3) amounts paid to settle/resolve legal disputes, litigation and government investigations and enforcement proceedings
- Share-based compensation expense

Our Compensation Committee carefully crafted these Milestones, which represent rigorous, objective standards by which to measure company and executive officer performance. Our Compensation Committee believes that all four Milestones are strategically important to our continued success and therefore should be weighted equally in determining incentive awards. Cash profits and revenue objectives are important to maintaining industry-leading financial performance. Our 2020 goals are tied to our long-term strategic objectives, which include aggressive revenue targets over near-term, medium-term and long-term time horizons, and are designed to achieve profitability at the top quintile of our peers. Our financial performance goal was established based on many factors, including market opportunity for each product, analyst expectations, and historical individual product performance. Our Compensation Committee also considered the continued impact of generic competition for Adcirca and Remodulin in setting revenue goals. Our total revenue goal for 2020 was determined by our Compensation Committee to be challenging, and was set at a level that was above analyst consensus expectations and above our 2019 net revenue performance. Our cash profit margin performance Milestone is set at a very high bar, incentivizing top-quintile performance relative to our peers and ensuring thoughtful and disciplined budget and spend management. The shift to a cash profit margin from an absolute cash profit number in 2020 also enhanced the rigor around this Milestone, ensuring that the Milestone objective would keep pace with revenue performance in the event of stronger than expected revenue performance. Our manufacturing Milestone is intended to ensure a continuous supply of our treprostinil-based therapies, which generate the vast majority of our revenues. Our R&D Milestone was intended to ensure that we have a robust pipeline of products capable of delivering future revenues sufficient to drive industry-leading growth.
The details of our framework for determining 2020 Milestone performance are provided below. As a general matter, under the terms of our Company-Wide Milestone Program, our Compensation Committee has the authority to exercise negative (downward) discretion in the event of partial attainment under any of the Milestones. The financial targets (cash profits and revenues) are set considering the market opportunity for our existing products, potential entrants of generic competition into the market during the performance period, analyst expectations, and our broader business plans. All of our targets were established prior to the COVID-19 pandemic, and no adjustments to these targets were made as the pandemic unfolded.

Financial Performance — Cash Profit Margin

<table>
<thead>
<tr>
<th>Threshold</th>
<th>Below Threshold</th>
<th>At Threshold</th>
<th>Target</th>
<th>Stretch/Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>0% credit</td>
<td></td>
<td>45%</td>
<td>50%</td>
<td>55%</td>
</tr>
</tbody>
</table>

Financial Performance — Revenues

<table>
<thead>
<tr>
<th>Threshold</th>
<th>Below Threshold</th>
<th>At Threshold</th>
<th>Target</th>
<th>Stretch/Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>0% credit</td>
<td></td>
<td>$1.3 billion</td>
<td>$1.46 billion</td>
<td>$1.6 billion</td>
</tr>
</tbody>
</table>

* Stretch goal to provide additional credit for above profit performance is applied based as discussed under Financial Multiplier below

Manufacturing

We award pro rata credit based on the number of quarters for which: (1) pre-specified inventory levels are achieved (i.e., two-year supply of Orenitram, Remodulin, and Tyvaso); and (2) we pass any GMP-related FDA inspections at our facilities without any issues that prevent the use or approval of any of our drug products. A minimum of two quarters is a threshold condition for any credit under this Milestone. Achievement of this Milestone requires operational and manufacturing excellence across multiple interrelated functions. Notably, our objective of maintaining a two-year supply of our PAH therapies has emerged as a critical competency as we successfully navigated the impacts of the COVID-19 pandemic, ensuring the patients we serve did not experience a disruption in drug supply.

Research & Development

Performance under the research and development Milestone is based on a system of R&D points, where expected points (i.e., the goal) are determined at the beginning of the year based on our pipeline, and progress is measured at the end of the year.

<table>
<thead>
<tr>
<th>Award pro rata credit</th>
<th>100% credit (at target)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 100% of Goal</td>
<td>100%+ of Goal</td>
</tr>
</tbody>
</table>

Financial Multiplier

For 2020, above-target cash incentive awards were possible (up to 150% of target) through the application of a Financial Multiplier, which is based only on the achievement of financial performance against the pre-established revenue and cash profit margin target and stretch/maximum goals, as follows:

<table>
<thead>
<tr>
<th>Metric</th>
<th>Range (Target to Stretch/Maximum)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash Profit Margin</td>
<td>50% 55%</td>
</tr>
<tr>
<td>Revenue Performance</td>
<td>$1.46 billion $1.6 billion</td>
</tr>
<tr>
<td>Multiplier for each</td>
<td>0% 25%</td>
</tr>
<tr>
<td>Metric*</td>
<td></td>
</tr>
</tbody>
</table>

* The Financial Multiplier is calculated independently for each metric, using linear interpolation between performance levels. Aggregate multiplier of up to 50% is applied to the entirety of the Milestone program attainment after determining individual performance for each individual Milestone.

2020 Milestone Performance

For 2020, our Compensation Committee determined that 100% of the Milestones were achieved, plus an additional 29% multiplier for above-maximum performance under our cash profit and revenue Milestones, as shown below:
A word about our financial performance goals in light of generic competition, the COVID-19 pandemic, and shareholder feedback

- **Revenue.** During our shareholder outreach, shareholders have sometimes requested more detail regarding our revenue goal-setting process, particularly in years (such as 2019) where goals were set below the prior year’s financial performance. **We are pleased to report that our goals for 2020 and 2021 were set above prior year performance.** At the time we established our 2020 Company-Wide Milestones, we were well into the challenges of generic competition for both Adcirca and Remodulin, and believed we could set a very aggressive revenue goal for our management team, far above analyst consensus (as shown below). This goal required strong performance and/or growth for Unituxin, Tyvaso, Orenitram, and Remodulin — despite generic competition for Remodulin — in order to create a revenue target that was higher than 2019 performance. Achievement of this goal would involve absorbing the continued expected revenue loss with Adcirca entering its third year with a generic competitor. While the entry of generic competition directly impacts our revenue performance, we believed at the time the goal was set that we were turning the corner and expected our management team to deliver 2020 revenue above 2019 target and actual performance. We did not alter this goal despite the onset of the COVID-19 pandemic, which made it more difficult for our team members to access physicians’ offices to promote our products, and made it more difficult for patients to see their doctors as needed to initiate and manage their therapy. Despite all these challenges, our team delivered remarkably, pivoting quickly to a new way of working, developing innovative and creative solutions for achieving their objectives, and delivering a revenue result exceeding the aggressive goal that was put in front of them. We believe that our four-year strategy is continuing to deliver, and feel strongly our management team can continue to deliver strong revenue growth in 2021, even as the challenges of the pandemic continue to make our work increasingly difficult and complex. **As such, we are disclosing that our 2021 revenue target, if achieved, will result in double-digit revenue growth. Further, in response to shareholder feedback, we are setting the threshold for revenue performance for 2021 above 2020 actual performance — ensuring that our executives will not receive any of their bonus attributable to revenue performance unless they deliver revenue performance that exceeds 2020.**
A Look Ahead: 2021 Revenue Milestone — Incentivizing Significant Revenue Growth

In response to shareholder feedback, we are providing the following information regarding our 2021 revenue target. While we do not provide the actual target in advance because we do not provide formal financial guidance, we want to make clear that our executive compensation program incentivizes significant revenue growth in 2021:

- Threshold/minimum performance set above 2020 actual performance, **directly in response to shareholder feedback** — no revenue-based bonus unless revenue grows in 2021 compared to 2020
- Threshold/minimum performance set above analyst consensus for 2021 revenues
- Target performance represents significant revenue growth compared to 2020 actual results
- Maximum performance for 2021 represents 18% revenue growth compared to 2020
- **Cash Profit.** We have always focused on market and peer leading profitability. This strength has been noted as standout in the face of the COVID-19 pandemic, as our strong free cash flow ensured that we maintained a healthy balance sheet even in the face of the challenges brought by the pandemic. While in previous years, we have set an absolute cash profit number as our goal, the driver of this objective has always been to achieve an industry-leading cash profit margin. In 2020, in order to provide shareholders with better clarity and visibility into the goal-setting process, we adjusted our goal setting from an absolute number to a cash profit margin to tie the performance objective directly to the formula we use to manage our budgeting processes. This also accomplished the objective of ensuring that our goal rigor stayed consistent even if there were an unexpected rise or drop in revenue. Our cash profit margin is a somewhat unique metric, in that it is designed to ensure we adhere closely to a carefully-crafted budgeting algorithm whereby our cash budget each year is set at no more than 50 percent of the prior year’s net revenue. This correlates to our 50 percent cash profit margin goal for 2020. This budgeting algorithm has historically led to top-quintile profitability. For comparative purposes, we have included the chart below to show how our budget discipline translated into top-quintile profitability in 2020. Because not all companies report the same non-GAAP financial measures, the chart below shows how our cash profit performance led to top-quintile performance in 2020 based on a uniform profitability metric: EBITDASO margin, or earnings before interest, taxes, depreciation, amortization, and share-based compensation expense, divided by revenues. The chart below includes all companies within our compensation peer group except for two companies whose EBITDASO margin was a negative number.

![Chart showing top-quintile profitability](chart.png)

---

**Additional detail regarding our research and development performance**

In evaluating performance under Milestone 4 [Research and Development], our Compensation Committee reviewed the clinical and registration-stage products being developed within our pipeline, the unmet medical need they are intended to address, and the significance of potential revenues if approved. The following is a list of these programs, several of which represent multi-billion-dollar revenue opportunities, and in some cases address potential indications for which there are no FDA-approved therapies:

- **FDA Approvals:** 12 points [full credit] awarded for achieving one **key FDA approval**, compared to a goal of one FDA approval. Specifically, the FDA cleared the pharmacy-filled version of the Remunity Pump for Remodulin

- **Late-Stage Clinical Programs:** Ten points [full credit] awarded for progressing **seven registration-stage programs** [compared to a goal of five programs], listed below:
  - **INCREASE**, a phase 3 study of Tyvaso for WHO Group 3 pulmonary hypertension associated with interstitial lung disease
  - **BREEZE**, a phase 3 study of Tyvaso DPI
  - **PERFECT**, a phase 3 study of Tyvaso for WHO Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease
  - **TETON**, a phase 3 study of Tyvaso for idiopathic pulmonary fibrosis
  - **ADVANCE OUTCOMES**, a phase 3 event-based study of ralinepag in PAH patients
  - **ADVANCE CAPACITY**, a phase 3 study of the effect of ralinepag on exercise capacity in PAH patients
  - Registration study of ex-vivo lung perfusion technology to increase the utilization of donated lungs for transplantation
Earlier-Stage Clinical Programs: Two points (full credit) awarded for progressing **one early stage development programs** (compared to a goal of one):
- Unexisome™, an exosome product for the treatment of bronchopulmonary dysplasia

New Product Candidates: One point (full credit) awarded for progressing **one new product candidate** into clinical development (compared to a goal of one):
- OreniPro, a once-daily prodrug form of Orenitram

2020 Cash Incentive Awards under the Company-Wide Milestone Program

The cash incentive awards earned by our Named Executive Officers and approved by our Compensation Committee for the 2020 performance year were as follows:

<table>
<thead>
<tr>
<th>NEO</th>
<th>2020 Base Salary (A)</th>
<th>2020 Cash Incentive Award Target as % of Base Salary (B)</th>
<th>2020 Milestone Attainment (C)</th>
<th>2020 Financial Multiplier (D)</th>
<th>Total Cash Incentive Bonus Earned (A × B × C × D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt</td>
<td>$1,320,000</td>
<td>110%</td>
<td>100%</td>
<td>129%</td>
<td>$1,873,080</td>
</tr>
<tr>
<td>James Edgemond</td>
<td>$700,000</td>
<td>75%</td>
<td>100%</td>
<td>129%</td>
<td>$677,250</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>$915,000</td>
<td>85%</td>
<td>100%</td>
<td>129%</td>
<td>$1,003,298</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>$880,000</td>
<td>65%</td>
<td>100%</td>
<td>129%</td>
<td>$737,880</td>
</tr>
</tbody>
</table>

Long-Term Incentive Compensation

2020 Long-Term Incentive Compensation

In light of the equity grants awarded in March 2019 intended to provide long-term equity incentive compensation to our NEOs for the period from 2019-2022, no equity was awarded to our CEO or other NEOs in 2020. We commit that no additional equity will be granted to our CEO or other current NEOs during the time period covered by this award (2019-2022). The next equity grant to our Named Executive Officers will be in 2023. Please see the section below titled A Look Ahead: 2023 Equity Incentive Compensation Program for commitments we are making on key design elements of our next equity incentive compensation program in 2023 in response to shareholder feedback following our 2020 Annual Meeting.

2019-2022 Long-Term Incentive Compensation

Our long-term incentive compensation program is structured to support our pay-for-performance and shareholder alignment objectives. As previously disclosed, we implemented a new long-term incentive compensation program in 2019 designed to motivate and retain our executive leadership team, while carefully and thoughtfully integrating shareholder feedback and alignment. We awarded a four-year grant of stock options to our Named Executive Officers, intended to cover four years of equity awards for the performance years 2019 through 2022, matching our then-current four-year business plan, execution of which was expected to yield significant revenue growth.

With the four-year grant in 2019, we firmly commit not to grant additional equity to our CEO or other current NEOs during the time period this grant is intended to cover (2019-2022), and our next equity grant to these executives will not occur before 2023.

The four-year grant consisted of two forms of stock options under the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan [the 2015 SIP]. One-half of these awards were in the form of premium-priced performance stock options, with an exercise price equal to 115% of our closing stock price on the date of grant. The vesting of the four-year awards was heavily weighted toward the end of the four-year period covered by the grant, with no vesting occurring during 2019 or 2020.

A Look Ahead: 2023 Equity Incentive Compensation Program

Based on feedback provided by shareholders during our 2020 shareholder engagements both before and after our 2020 Annual Meeting, we are providing the following commitments or “guardrails” concerning our 2023 equity incentive program. While it is too early to design an incentive compensation program that is two years away, we are committing that our equity incentive program will have the following features in 2023 to address concerns raised by shareholders regarding our 2019 four-year equity grant:

- A return to annual equity award granting practices, granting one year of equity in 2023 rather than a front-loaded, multi-year grant
- At least 50% of the award will be performance-based
- Performance-based awards will include one or more performance metrics other than stock price appreciation
- The 2023 equity program will include a mix of equity vehicles, including the use of performance shares

When discussing these commitments with shareholders during our post-Annual Meeting engagements, we received positive feedback and confirmed that these changes, coupled with our commitment not to award additional equity to our current NEOs during the remainder of the four-year period, were responsive to their concerns about our long-term incentive program.
**Vesting of 2018 Long-Term Incentive Awards**

In 2018, we awarded performance-based stock options to our Named Executive Officers with a performance vesting condition tied to achieving cash profit margin of at least 50% over a three-year period (2018-2020). These options were granted on March 15, 2018, with a cliff-vesting feature on the third anniversary of the date of grant, to the extent earned, and will expire on the tenth anniversary of the date of grant. Vesting of this grant was subject to a threshold performance criterion of 45% average cash profit margin, at which one-half of the target number of shares would have vested. Below this threshold, zero shares would have vested and between 45% and 50% average cash profit margin, the number of shares earned would have been determined by linear interpolation. Up to 200% of the target number of shares could be earned if the average cash profit margin equaled or exceeded 55%, with the number of shares earned between target and maximum determined by linear interpolation.

As a result of achieving an average cash profit margin of 59% during the 2018-2020 period, the 2018 long-term incentive award vested at maximum levels as of March 15, 2021, as shown in the table below.

<table>
<thead>
<tr>
<th>NEO</th>
<th>Threshold</th>
<th>Target</th>
<th>Max</th>
<th>Options Earned/Vested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt</td>
<td>71,276</td>
<td>142,551</td>
<td>285,103</td>
<td>285,103</td>
</tr>
<tr>
<td>James Edgmond</td>
<td>18,838</td>
<td>37,675</td>
<td>75,349</td>
<td>75,349</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>21,383</td>
<td>42,765</td>
<td>85,531</td>
<td>85,531</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>20,365</td>
<td>40,729</td>
<td>81,458</td>
<td>81,458</td>
</tr>
</tbody>
</table>

**2020 Compensation Program Design**

**Roles of Management, Compensation Committee, and Compensation Consultant**

**Role of Our Compensation Committee and Management**

Our Compensation Committee is composed entirely of independent directors, as defined by Rule 6505[a][2] of the Nasdaq listing standards. Our Compensation Committee meets as often as it determines necessary to carry out its duties and responsibilities through regularly scheduled meetings and, if necessary, special meetings. Our Compensation Committee also has the authority to take certain actions by written consent of all members. In 2020, our Compensation Committee met seven times. Our Compensation Committee reviews and oversees our compensation policies, plans, and programs and reviews and determines the compensation to be paid to our Named Executive Officers, with the input and advice from its independent compensation consultant. Our Compensation Committee also considers the input of our Chief Executive Officer in making compensation decisions related to our other Named Executive Officers.

**Role of Independent Compensation Consultant**

Our Compensation Committee has the authority to engage advisors to assist it in carrying out its responsibilities. In accordance with this authority, our Compensation Committee directly engaged Radford, part of the Rewards Solutions practice at Aon, plc, as its compensation consultant during 2020 to provide advice to our Compensation Committee on our executive and non-employee director compensation practices and policies. Our Compensation Committee, in its discretion, may replace its independent compensation consultant or hire additional consultants at any time. Radford performed additional services during 2020, namely consulting services for non-executive employee compensation matters and broad-based compensation survey data, and was paid fees for these services totaling approximately $33,900. In addition, Radford affiliates (Aon plc and its related entities) performed actuarial services relating to our SERP, insurance advisory services, and retirement plan advisory services, along with risk management consulting and insurance brokerage services for United Therapeutics during 2020, for which we paid approximately $469,759 during 2020. Additional insurance premiums and related fees were paid to Aon plc and passed through to insurance companies not affiliated with Aon plc. Our Compensation Committee approved these services and determined that they did not impair Radford’s independence. Our Compensation Committee considered the independence of Radford in light of SEC rules regarding conflicts of interest involving compensation consultants and Nasdaq listing standards regarding compensation consultant independence. Based on its review, our Compensation Committee determined that Radford was independent, and that Radford’s work did not raise any conflicts of interest. In making the foregoing determination, our Compensation Committee considered the following six factors, as well as other factors it deemed relevant: (1) the provision of other services to us by Radford; (2) the amount of fees Radford received from us, as a percentage of their total revenue; (3) the policies and procedures of Radford that are designed to prevent conflicts of interest; (4) the lack of any business or personal relationships of the Radford consultants with any member of our Compensation Committee; (5) the lack of any United Therapeutics stock owned by the Radford consultants performing services for our Compensation Committee; and (6) the lack of any business or personal relationships of the Radford consultants or Radford itself with any of our executive officers. During 2020, we paid Radford $269,107 in fees for determining or recommending the amount and form of compensation to our directors and executive officers.
Our Compensation Committee engaged Radford during 2020 to review and advise our Compensation Committee on all principal aspects of executive and non-employee director compensation. This included base salaries, cash incentive awards, and long-term incentive awards for our executive officers. Radford performed the following tasks for our Compensation Committee in 2020, among others:

- Reviewing and advising on the structure of our compensation arrangements for our Chief Executive Officer and our other Named Executive Officers
- Reviewing and advising on the structure of our compensation arrangements for our non-employee directors
- Providing recommendations regarding the composition of our peer group
- Analyzing publicly available proxy data for companies within our peer group and survey data relating to executive compensation
- Conducting pay and performance analyses relative to our peer group
- Updating our Compensation Committee on industry trends and best practices with respect to executive long-term incentive compensation program design, including types of long-term incentive compensation awards, size of long-term incentive compensation grants, and aggregate long-term incentive compensation grant usage
- Reviewing our equity incentive awards against our design/cost targets and against industry norms
- Reviewing the Compensation Discussion and Analysis and other compensation-related disclosures in our Proxy Statement
- Advising our Compensation Committee in connection with its risk assessment relating to our compensation programs
- Preparing for and attending shareholder engagement sessions
- Working on special or ad hoc projects for, or at the request of, our Compensation Committee as they arose

In the course of fulfilling these responsibilities, Radford regularly communicated with our Compensation Committee Chair outside of and prior to most Compensation Committee meetings. Our Compensation Committee regularly invites its independent compensation consultant to attend its meetings. In 2020, Radford representatives attended each of our Compensation Committee’s seven meetings.

While our Compensation Committee considered its independent consultant’s recommendations in 2020, our Compensation Committee’s decisions, including the specific amounts paid to our executive officers and directors, were its own and may reflect factors and considerations in addition to the information and recommendations provided by its independent consultant.
Compensation Peer Group

On an annual basis, our Compensation Committee reviews Named Executive Officer compensation levels relative to a peer group of industry and labor market competitors. For 2020, we defined our peer group as the top 25 companies other than United Therapeutics, ranked by revenue, in the Nasdaq Biotechnology Index. This was the same peer group selection methodology we used the prior year. Our 2020 peer group was selected in 2019, and was used to develop market data as an input into our compensation program for 2020. This peer group includes only companies that are U.S.-based or based in jurisdictions with similar compensation disclosure requirements as U.S. companies. Our methodology for selecting compensation peers uses an objective metric, which our Compensation Committee believes results in a peer group that includes biopharmaceutical and biotechnology companies that are similar to us in terms of financial performance, shareholder value creation, and drug development and commercialization, and generally reflects the universe of companies from which we recruit, and against which we retain, executive talent.

Each year, a number of peers are added or removed from the list and replaced with other companies for various reasons, including merger and acquisition activities. We have provided below for reference the profile of our compensation peer group for 2020, showing changes made from our 2019 peer group. For clarity, the 2019 peer group was selected in 2018 and used for setting 2019 compensation policies. The 2020 peer group was selected in 2019 and used for setting 2020 compensation policies.

<table>
<thead>
<tr>
<th>2019 PEER GROUP</th>
<th>ADDITIONS FOR 2020</th>
<th>DELETIONS FOR 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acorda Therapeutics</td>
<td>Exelixis</td>
<td>Acorda Therapeutics</td>
</tr>
<tr>
<td>Akorn</td>
<td>Illumina</td>
<td>Bruker</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>Incyte</td>
<td>AMAG Pharmaceuticals</td>
</tr>
<tr>
<td>Alkermes</td>
<td>Jazz Pharmaceuticals</td>
<td>Bio-Techne</td>
</tr>
<tr>
<td>AMAG Pharmaceuticals</td>
<td>Mylan N.V.</td>
<td>BioMarin</td>
</tr>
<tr>
<td>Amgen</td>
<td>Myriad Genetics</td>
<td>Biogen</td>
</tr>
<tr>
<td>Biogen</td>
<td>Neurocrine</td>
<td>Bio-Marin</td>
</tr>
<tr>
<td>BioMarin</td>
<td>Opko Health</td>
<td>Celgene</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>PRA Health Sciences</td>
<td>Endo International</td>
</tr>
<tr>
<td>Bruker</td>
<td>Regeneron</td>
<td>Gilead</td>
</tr>
<tr>
<td>Celgene</td>
<td>Shire</td>
<td></td>
</tr>
<tr>
<td>Endo International</td>
<td>Syneos</td>
<td></td>
</tr>
<tr>
<td>Gilead</td>
<td>Vertex</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2020 PEER GROUP</th>
<th>Ionis Pharmaceuticals</th>
<th>Shire</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akorn</td>
<td>Jazz Pharmaceuticals</td>
<td>Regeneron</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>Mylan N.V.</td>
<td>Seattle Genetics</td>
</tr>
<tr>
<td>Alkermes</td>
<td>Myriad Genetics</td>
<td>Syneos Health</td>
</tr>
<tr>
<td>Amgen</td>
<td>Nektar Therapeutics</td>
<td>Vertex</td>
</tr>
<tr>
<td>Biogen</td>
<td>Gilead Sciences</td>
<td></td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>Horizon Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Illumina</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Incyte</td>
<td></td>
</tr>
</tbody>
</table>
The following chart shows how United Therapeutics ranks within its 2020 peer group on a variety of metrics. These metrics were based on available data at the time the peer group was approved, generally reflecting the trailing twelve-month period ending March 31, 2019.

<table>
<thead>
<tr>
<th>United Therapeutics ($ in millions)</th>
<th>Percentile</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$1,601.2</td>
<td>42nd%</td>
</tr>
<tr>
<td>Operating Income</td>
<td>($157.4)</td>
<td>9th%</td>
</tr>
<tr>
<td>Adjusted Operating Income(1)</td>
<td>$642.6</td>
<td>58th%</td>
</tr>
<tr>
<td>Net Income</td>
<td>($149.9)</td>
<td>14th%</td>
</tr>
<tr>
<td>Adjusted Net Income(1)</td>
<td>$650.1</td>
<td>67th%</td>
</tr>
<tr>
<td>ROIC(1)</td>
<td>21.7%</td>
<td>78th%</td>
</tr>
<tr>
<td>Return on Equity(1)</td>
<td>27.7%</td>
<td>65th%</td>
</tr>
<tr>
<td>Return on Assets(1)</td>
<td>11.9%</td>
<td>83rd%</td>
</tr>
<tr>
<td>Market Cap Per Employee(2)</td>
<td>$5.5</td>
<td>46th%</td>
</tr>
</tbody>
</table>

(1) In the case of United Therapeutics, each of these figures has been adjusted to reflect a one-time, $800.0 million up-front payment in January 2019 to Arena Pharmaceuticals, Inc.

(2) Market capitalization per employee as of May 2019 when the peer group was approved.

Our Compensation Committee’s approach to peer group selection is to apply an objective external measure for selecting companies. This results in a number of peers being larger than United Therapeutics based on revenue as well as a number of peers being smaller. Our goal each year is to place our company within the peer group statistics of the 25th to 75th percentile for revenue as close to the median as possible while managing changes each year due to sector volatility, industry consolidation, and differences in business and organization models. Furthermore, our Compensation Committee views it as critical to measure ourselves against industry-leading peers (including those that are both larger and smaller than we are) because, in addition to being companies with which we compete for talent, many of these larger and smaller companies are also our business competitors. By placing our company at around the 50th percentile of our peer group for revenue, we believe our peer group reflects companies of similar scope and complexity.
Key Governance Features of our Executive Compensation Program

Our Compensation Committee periodically assesses the effectiveness of our compensation policies and practices in achieving its pay-for-performance objective while aligning the interests of executive officers with those of shareholders, balancing short-term and long-term elements, and maintaining market competitiveness. Our Compensation Committee also reviews risk mitigation and governance items, which are designed to help ensure that our compensation programs are functioning to achieve such objectives. In conjunction with this assessment and review, we have adopted the following best practices:

✓ WHAT WE DO

- Design our executive compensation program to align pay and performance
- Maintain an appropriate balance between short-term and long-term compensation, which discourages short-term risk taking at the expense of long-term results
- Grant performance-based long-term incentive awards
- Maintain stock ownership guidelines to align executive officer and share ownership with that of our directors and our shareholders
- Prohibit hedging and pledging by executives and directors*
- Employ a compensation recovery, or clawback, policy**
- Conduct annual risk assessments of our compensation policies and practices
- Hold Compensation Committee executive sessions without management
- Engage an independent compensation consultant who reports directly to the compensation committee

✗ WHAT WE DON'T DO

- No backdating of stock options
- No repricing of stock options without shareholder approval
- No liberal share recycling under 2015 Stock Incentive Plan
- No vesting prior to the first anniversary of grant, subject to limited exceptions
- No discounted or reloaded stock options
- No excessive perquisites
- No excise tax gross ups
- No guaranteed bonus payments

* Pursuant to our insider trading policy, directors, officers, and employees are prohibited from purchasing our securities on margin, engaging in "short" sales of our common stock, or buying or selling puts, calls, futures contracts, or other forms of derivative securities relating to our securities. In addition, our Board has adopted a policy prohibiting our directors and executive officers from pledging of shares of our common stock.

** Our Board has the authority, to the extent permitted by governing law, to make retroactive adjustments to any cash award or equity award-based incentive compensation paid to our Named Executive Officers and certain other senior managers where the payment was predicated upon the achievement of certain financial results that were subsequently the subject of a restatement.

Other Executive Compensation Policies and Practices

Equity Incentive Awards Grant Timing Policy

Our equity incentive award grant timing is designed so that equity-based awards are granted after the market has had an opportunity to react to our announcement of annual earnings. As such, as a general matter equity-based awards to our employees and Named Executive Officers are typically granted on March 15th each calendar year (or the preceding trading day if markets are not open on March 15th). We also believe this timing helps us avoid broad internal communication of highly confidential financial results prior to public announcement of our annual financial results. Our Compensation Committee may also approve equity-based awards at other times, in connection with significant personnel events, such as new hire, promotion, new directorship, achievement of a significant corporate objective, or appointment to a Board committee. In addition, our Compensation Committee is permitted the flexibility to grant awards on the 15th day of any month (or the preceding trading day if markets are not open on the 15th).

All equity incentive awards granted to our Named Executive Officers and other employees have an exercise price equal to at least the closing price of our common stock on the Nasdaq on the date of grant or, if the award is granted on a date when the Nasdaq is not open, an exercise price equal to at least the closing price of our common stock on the Nasdaq on the preceding trading day.

Benefits and Perquisites

The benefits offered to our Named Executive Officers are substantially the same as those offered to all employees, with the exception of the supplemental executive retirement plan (SERP) discussed in the section entitled Supplemental Executive Retirement Plan below. We provide a tax-qualified retirement plan (a 401(k) plan) and medical and other benefits to executives that are generally available to other full-time employees. Under our 401(k) plan, all employees are permitted to contribute up to the maximum amount allowable under applicable law (i.e., $19,500 in 2020 or $26,000 for eligible participants who are age 50 or older). We make matching contributions equal to 40% of eligible employee contributions with such matching contributions vesting 33 1/3% per year based on years of service, not the amount of time an employee has participated in the 401(k) plan. Therefore, once an employee completes three years of service, their
account is fully vested, and any future matching funds will vest immediately. The 401(k) plan and other generally available benefits programs allow us to remain competitive for executive talent. We also provide limited perquisites to our Named Executive Officers, including participation in either our vehicle lease program, which covers the monthly lease payment and cost of insurance and maintenance on vehicles, or a monthly car allowance of up to $1,000. Our Compensation Committee believes that the availability of these benefit programs generally enhances executive recruitment, retention, productivity, and loyalty to us.

For additional details on certain benefits and perquisites received by our Named Executive Officers, see the Summary Compensation Table below.

**Supplemental Executive Retirement Plan**

We maintain our SERP for select executives to enhance the long-term retention of individuals who have been and will continue to be vital to our success. Currently, only our Named Executive Officers and two other members of senior management participate in the SERP. The SERP provides each participant with a lifetime annual payment after retirement (or at their election, a lump-sum payment) of up to 100% of final average three-year gross salary less estimated social security benefit, provided that they is employed by us or one of our affiliates until age 60. Participants in the SERP are prohibited from competing with us or soliciting our employees for a period of twelve months following their termination of employment or, if earlier, upon attainment of age 65. Violation of this covenant will result in forfeiture of all benefits under the SERP.

Additional details regarding the SERP, including provisions in connection with a participant’s death or disability or change in control, are provided under the Pension Benefits in 2020 table below.

**Post-Employment Obligations for Named Executive Officers**

Each of our Named Executive Officers is eligible for certain severance payments in the event their employment terminates under specified circumstances, including in connection with a change in control, as provided in their employment agreements as well as the terms of the SERP, the 1997 United Therapeutics Corporation Amended and Restated Equity Incentive Plan [EIP], the 2015 SIP, and the STAP. These payments vary based on the type of termination but may include cash severance, stock option and STAP vesting acceleration, SERP vesting acceleration, and/or continuation of health and other benefits.

Our Compensation Committee approved these arrangements in order to promote the loyalty and productivity of our Named Executive Officers and to align executive and shareholder interests by enabling executives to consider corporate transactions that are in the best interests of our shareholders and our other constituents without undue concern about whether the transaction may jeopardize their employment. Our Compensation Committee wants our Named Executive Officers to be free to think creatively and promote the best interests of our company without worrying about the impact of those decisions on their employment.

Details regarding severance and change in control arrangements for our Named Executive Officers are contained in the text following the Potential Payments Upon Termination or Change in Control table below.

**Stock Ownership Guidelines**

As noted above under Our Corporate Governance—Selecting Directors—Stock Ownership Guidelines, in 2011 our Board adopted Stock Ownership Guidelines in order to further align the financial interests of our directors and Named Executive Officers with those of our shareholders, to foster a long-term management orientation, and to promote sound corporate governance. Our Stock Ownership Guidelines set targets for each Named Executive Officer according to the lesser of a multiple of base salary or fixed number of shares of common stock as follows:

<table>
<thead>
<tr>
<th>Title of NEO</th>
<th>Ownership Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairperson and Chief Executive Officer</td>
<td>Lesser of 6x base salary or 100,000 shares</td>
</tr>
<tr>
<td>President and Chief Operating Officer</td>
<td>Lesser of 3x base salary or 30,000 shares</td>
</tr>
<tr>
<td>Chief Financial Officer and Treasurer</td>
<td>Lesser of 3x base salary or 20,000 shares</td>
</tr>
<tr>
<td>Executive Vice President and General Counsel</td>
<td>Lesser of 3x base salary or 30,000 shares</td>
</tr>
</tbody>
</table>

The policy provides procedures for granting exemptions in the case of hardship.
Policy Regarding Tax Deductibility of Executive Compensation

For fiscal year 2017 and prior years, Section 162(m) of the Internal Revenue Code (the Code) generally limited the deductibility of compensation to $1 million per year for certain of our Named Executive Officers, unless compensation in excess of the limit qualified as "performance-based compensation." Following the changes to the tax laws effective as of January 1, 2018 that eliminate the exception for "performance-based compensation," we expect we will be unable to deduct compensation payable to Named Executive Officers in excess of $1,000,000.

While our Compensation Committee considers the impact of this tax treatment, the primary factor influencing program design is the support of our business objectives. Generally, whether incentive compensation will be deductible under Section 162(m) of the Code will be a consideration, but not the decisive consideration, with respect to our Compensation Committee’s compensation determinations. Accordingly, our Compensation Committee retains flexibility to structure our compensation programs in a manner that is not tax-deductible in order to achieve a strategic result that our Compensation Committee determines to be more appropriate.

Compensation Committee Report

The Compensation Committee of our Board of Directors has reviewed and discussed the Compensation Discussion and Analysis contained within this Proxy Statement with management and, based on such review and discussions, our Compensation Committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated into United Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2020.

Submitted by the Compensation Committee:

CHRISTOPHER PATUSKY (Chair)
RAYMOND DWEK
NILDA MESA
LOUIS SULLIVAN
## Compensation Tables

### Summary Compensation Table

The following table shows compensation information for 2018, 2019, and 2020 for our Named Executive Officers, calculated in accordance with SEC regulations.

<table>
<thead>
<tr>
<th>Name and Principal Position</th>
<th>Year</th>
<th>Salary ($)</th>
<th>Stock Options ($)</th>
<th>Non-Equity Incentive Plan Compensation ($)</th>
<th>Change in Pension Value and Nonqualified Deferred Compensation Earnings ($)</th>
<th>All Other Compensation ($)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt, Chairperson and Chief Executive Officer</td>
<td>2020</td>
<td>1,352,435 (1)(7)</td>
<td>—</td>
<td>1,873,080</td>
<td>1,575,757</td>
<td>10,400</td>
<td>4,811,672</td>
</tr>
<tr>
<td></td>
<td>2019</td>
<td>1,218,038 (7)</td>
<td>40,010,000</td>
<td>1,753,125</td>
<td>2,643,874</td>
<td>10,000</td>
<td>45,635,037</td>
</tr>
<tr>
<td></td>
<td>2018</td>
<td>1,208,447 (7)</td>
<td>12,796,803</td>
<td>2,021,250</td>
<td>—</td>
<td>9,800</td>
<td>16,036,300</td>
</tr>
<tr>
<td>James Edgemond, Chief Financial Officer and Treasurer</td>
<td>2020</td>
<td>722,115 (4)</td>
<td>—</td>
<td>677,250</td>
<td>1,790,415</td>
<td>20,000</td>
<td>3,209,780</td>
</tr>
<tr>
<td></td>
<td>2019</td>
<td>645,192</td>
<td>13,003,250</td>
<td>632,813</td>
<td>1,668,041</td>
<td>19,600</td>
<td>15,968,896</td>
</tr>
<tr>
<td></td>
<td>2018</td>
<td>645,833</td>
<td>3,382,085</td>
<td>731,250</td>
<td>467,161</td>
<td>16,400</td>
<td>5,242,729</td>
</tr>
<tr>
<td>Michael Benkowitz, President and Chief Operating Officer</td>
<td>2020</td>
<td>944,423 (4)</td>
<td>—</td>
<td>1,003,298</td>
<td>3,160,903</td>
<td>16,994</td>
<td>5,125,618</td>
</tr>
<tr>
<td></td>
<td>2019</td>
<td>845,577</td>
<td>15,003,750</td>
<td>940,313</td>
<td>2,829,195</td>
<td>17,171</td>
<td>19,636,006</td>
</tr>
<tr>
<td></td>
<td>2018</td>
<td>833,333</td>
<td>3,839,015</td>
<td>1,083,750</td>
<td>835,680</td>
<td>17,480</td>
<td>6,609,258</td>
</tr>
<tr>
<td>Paul Mahon, Executive Vice President and General Counsel</td>
<td>2020</td>
<td>908,077 (4)</td>
<td>—</td>
<td>737,880</td>
<td>2,432,869</td>
<td>22,400</td>
<td>4,101,226</td>
</tr>
<tr>
<td></td>
<td>2019</td>
<td>812,692</td>
<td>12,003,000</td>
<td>690,625</td>
<td>3,038,484</td>
<td>22,000</td>
<td>16,566,801</td>
</tr>
<tr>
<td></td>
<td>2018</td>
<td>820,000</td>
<td>3,656,242</td>
<td>799,500</td>
<td>—</td>
<td>21,800</td>
<td>5,297,542</td>
</tr>
</tbody>
</table>

(1) Increases in base salaries for each of our Named Executive Officers became effective on March 1, 2018, February 25, 2019, and February 24, 2020.

(2) Amounts shown represent the aggregate grant date fair value of stock options granted in each reported year, computed in accordance with applicable accounting standards. For a discussion of valuation assumptions for stock options for 2020 see Note 8 — Share Based Compensation to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The stock options were awarded under our 2015 SIP. The value of 2018 stock option awards with performance conditions are reported at target, calculated using the Black Scholes Merton value in accordance with GAAP. For awards granted in respect of the 2018 performance years, the number of shares actually earned exceeded target for “stretch” performance, and vested in March 2020 at maximum. If the maximum number of shares were used in calculating the Black Scholes Merton value of these awards, the grant date fair value would be as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>Year</th>
<th>Number of Shares (at target)</th>
<th>Grant-Date Fair Value (at target)</th>
<th>Number of Shares (at maximum)</th>
<th>Grant-Date Fair Value (at maximum)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt</td>
<td>2018</td>
<td>285,102</td>
<td>$12,796,803</td>
<td>498,930</td>
<td>$22,464,680</td>
</tr>
<tr>
<td>James Edgemond</td>
<td>2018</td>
<td>75,350</td>
<td>$3,382,085</td>
<td>131,861</td>
<td>$5,937,136</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>2018</td>
<td>85,530</td>
<td>$3,839,015</td>
<td>149,679</td>
<td>$6,739,404</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>2018</td>
<td>81,458</td>
<td>$3,656,242</td>
<td>142,552</td>
<td>$6,418,505</td>
</tr>
</tbody>
</table>

(3) Amounts shown for each year represent the total cash awards earned by each Named Executive Officer under our Company-Wide Milestone Program for the respective year, although the awards were not paid until March of the following year. The payouts were determined based on our attainment of specific, pre-established performance Milestones. For example, the amounts reported for 2020 reflect cash earned in respect of 2020 performance but paid in March 2021. For information on the amounts earned for 2020, see the section entitled Cash Incentive Award Program in the Compensation Discussion and Analysis above.

(4) Amounts shown represent the change in the actuarial present value of retirement benefits under the SERP calculated in accordance with GAAP under SEC requirements. The assumptions used in calculating the change in the actuarial present value of SERP benefits are described in the footnotes to the Pension Benefits in 2020 table below. The change in pension value from year to year as reported in the table will vary based on these assumptions and may not represent the value that a Named Executive Officer will accrue or receive under the SERP. The change in the amounts reported for 2020 compared to 2019 was primarily driven by the decrease in the discount rate and the lump sum interest rate. We note that there were no changes in the terms of our SERP in 2020 versus 2019.

(5) The amounts shown represent the aggregate incremental cost that can be attributed to lease, insurance, and maintenance payments made on vehicles used by a Named Executive Officer or for monthly automobile allowances, travel expenses for family members to our functions.
(collectively, the perquisites), and "matching contributions" under our 401(k) Plan equal to 40% of each participant’s qualifying salary contributions.

(6) We changed pay timing and pay periods in 2019 (from semi-monthly and paying current to bi-weekly and paying one week in arrears). This resulted in less pay actually received in 2019 (there were only 25 pay dates in calendar year 2019 with the change in timing) and with the timing of pay dates in 2020, there are 27 actual pay dates in 2020 rather than 26, which resulted in an increase in reported wages.

(7) Our Canadian subsidiary paid a portion of Dr. Rothblatt’s total base salary in Canadian dollars. The value of this portion in U.S. dollars has been estimated for the purposes of disclosure here by using the average exchange rate for each respective year. In 2018, 2019, and 2020, our Canadian subsidiary paid the equivalent of US$92,614, US$90,436, and US$281,984 of Dr. Rothblatt’s total base salary, respectively.

Grants of Plan-Based Awards in 2020

<table>
<thead>
<tr>
<th>Name</th>
<th>Grant Date</th>
<th>Estimated Future Payouts Under Non-Equity Incentive Plan Awards</th>
<th>All Other Option Awards: Number of Securities Underlying Options (2)</th>
<th>Exercise or Base Price of Stock Option Awards ($/Sh)</th>
<th>Grant Date Fair Value of Stock Option Awards ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt</td>
<td>N/A (1)</td>
<td>N/A, 1,452,000, 2,178,000</td>
<td>—</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>James Edgemon</td>
<td>N/A (1)</td>
<td>N/A, 525,000, 787,500</td>
<td>—</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>N/A (1)</td>
<td>N/A, 777,750, 1,166,625</td>
<td>—</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>N/A (1)</td>
<td>N/A, 572,000, 858,000</td>
<td>—</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(1) Actual cash incentive awards earned under the program in 2020 are reported in the Summary Compensation Table under the column entitled “Non-Equity Incentive Plan Compensation.” While there are threshold performance criteria and payout levels for 75% of the cash incentive program (based on the Milestones related to cash profits, revenues, and manufacturing), there is no threshold performance level for the entirety of the program because the R&D Milestone does not contain threshold / minimum performance criteria.

(2) In light of the four-year equity grant of stock options in March 2019 covering the 2019-2022 period, no equity-based awards were granted to the Named Executive Officers in 2020.

Narratives to Summary Compensation Table and Grants of Plan-Based Awards in 2020 Table

Named Executive Officer Employment Agreements

The material terms of each Named Executive Officer’s employment agreement are described below.

Dr. Rothblatt

In April 1999, we entered into an employment agreement with Dr. Rothblatt. This agreement was amended from time to time and we entered into an Amended and Restated Executive Employment Agreement with Dr. Rothblatt effective January 1, 2009 in order to clarify the effectiveness of certain prior amendments, and to make other immaterial amendments. This agreement was further amended effective January 1, 2015, to remove her entitlement to an annual grant of stock options based on a market capitalization growth formula and to provide us flexibility to grant her incentive-based compensation in a variety of forms at our Compensation Committee’s discretion. The amendment also eliminated Dr. Rothblatt’s right to an Internal Revenue Code Section 280G excise tax gross up payment, among other changes.

Dr. Rothblatt’s employment agreement provides for an initial five-year term, which is automatically extended for an additional year at the end of each year unless either party gives at least six months’ notice of termination. If either party provided such a notice of termination, it would result in a four-year remaining term. We note that this rolling five-year term has no bearing on potential severance payments upon termination, which are described under Potential Payments Upon Termination or Change in Control.

Dr. Rothblatt’s compensation in 2020 was paid pursuant to this employment agreement, which entitles her to a minimum base salary of $180,000, annual cash and long-term incentive compensation and participation in employee benefits generally available to other executives. The level of Dr. Rothblatt’s base salary is subject to annual review and increase by our Compensation Committee. Her annual salary was reviewed in early 2020, and beginning February 24, 2020, was set at $1,320,000. Her employment agreement also requires us to pay the cost of leasing, maintaining, and insuring an automobile for Dr. Rothblatt.

Dr. Rothblatt’s employment agreement prohibits her from engaging in activities competitive with us for five years following her last receipt of compensation from us. She is also subject to a permanent confidentiality obligation. For information regarding severance and change in control arrangements for Dr. Rothblatt, see the text following the Potential Payments Upon Termination or Change in Control table below.
Mr. Edgemon, Mr. Benkowitz, and Mr. Mahon

We have entered into employment agreements with each of Messrs. Edgemon, Benkowitz, and Mahon. The agreement for Mr. Mahon provides for an initial five-year term, which is automatically extended for an additional year at the end of each year. Either party may terminate the agreement a certain time period prior to an annual renewal, which would result in a four-year remaining term. The agreements for Messrs. Benkowitz and Edgemon provide an initial term of three years, following which the agreement continues from year to year for one-year terms unless either party provides written notice to terminate a certain time period prior to the end of the then current term. Each employment agreement provides for an annual minimum base salary, which is subject to annual review and increase by our Compensation Committee. Annual salaries for each of these executives were reviewed in early 2020, with raises becoming effective February 24, 2020. The following table outlines these details for each executive:

<table>
<thead>
<tr>
<th>Name</th>
<th>Month/Year of Agreement</th>
<th>Minimum Base Salary under Agreement</th>
<th>Base Salary as of February 24, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Edgemon</td>
<td>March 2015</td>
<td>$400,000</td>
<td>$700,000</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>June 2016</td>
<td>$650,000</td>
<td>$915,000</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>June 2001</td>
<td>$300,000</td>
<td>$880,000</td>
</tr>
</tbody>
</table>

Under these agreements, each executive is eligible to participate in our broad-based employee benefit plans. In accordance with our executive automobile policy, Messrs. Edgemon, Benkowitz, and Mahon each receives either a monthly car allowance of $1,000 per month or the use of a company owned or leased vehicle.

Each of these employment agreements prohibits the executive from accepting employment, consultancy or any other business relationships with an entity that directly competes with us or from engaging in the solicitation of our employees on behalf of a competitor for a period of time following employment, and outplacement benefits with a value of $10,000.

Messrs. Edgemon and Benkowitz are each party to a change in control severance agreement providing benefits in the event of his termination following a change in control. In particular, these benefits include a cash severance payment equal to two times base salary, plus two times the highest of [1] the cash incentive award paid to the individual for the year immediately preceding the year in which the change in control occurs, [2] the cash incentive award payable to the individual for the year immediately preceding the year in which the termination of employment occurs, or [3] the individual’s annual target cash incentive award. This cash severance would become payable in lieu of any severance payment under the respective employment agreements unless severance under the employment agreement would result in a greater benefit. The change in control severance agreement also provides for continuation of medical benefits for 24 months following termination, and outplacement benefits with a value of $10,000.

For further information regarding severance and change in control arrangements for these Named Executive Officers, see the text following the Potential Payments Upon Termination or Change in Control table below.

Summary of Terms of Plan-Based Awards

Stock Options under the 2015 SIP

In March 2018 and March 2019, our Named Executive Officers were granted stock options under our 2015 SIP. No equity-based awards were granted to our Named Executive Officers in 2020.

Stock options granted under the 2015 SIP in 2018 vest in one-third increments on the first three anniversaries of the date of grant (in the case of Milestone Performance Options granted with respect to 2018 performance, to the extent earned), or cliff vest on the third anniversary of the date of grant to the extent earned based on performance (in the case of Cash Profit Performance Options as described in our 2019 Proxy Statement), in each case subject to the Named Executive Officer’s continued employment. Each stock option granted in 2018 has a ten-year term. Stock options granted under the 2015 SIP in 2019 cover four years of equity compensation (2019 through 2022), and have been designed such that: [1] overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if we had continued with the previous equity compensation program for four additional years; [2] the Named Executive Officer will be incented to achieve our business objectives over the four-year period; and [3] vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. 50% of the 2019 option grant was granted with an exercise price equal to the closing price of our common stock on the date of grant, and vests in equal installments on March 15, 2021, 2022 and 2023. The other 50% is has an exercise price equal to 115% of the closing price of our common stock on the date of grant, and cliff vests (100%) on March 15, 2023. All of the 2019 stock options have an expiration date of the eighth anniversary of the date of grant. For information regarding acceleration of vesting upon certain employment termination events, see the text following the Potential Payments Upon Termination or Change in Control table below.
Outstanding Equity Awards at 2020 Fiscal Year-End

The following table sets forth information regarding unexercised stock options or STAP awards held by each of our Named Executive Officers as of December 31, 2020.

<table>
<thead>
<tr>
<th>Name and Grant Date</th>
<th>Award Type</th>
<th>Number of Securities Underlying Unexercised Options or STAP Awards:</th>
<th>Equity Incentive Plan Awards:</th>
<th>Option or STAP Award Exercise Price ($)</th>
<th>Option or STAP Award Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Exercisable</td>
<td>Unexercisable</td>
<td>Number of Securities Underlying Unexercised Unearned Options (#)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12/31/2013</td>
<td>Stock Option[1][2]</td>
<td>1,000,000</td>
<td>—</td>
<td>113.08</td>
</tr>
<tr>
<td></td>
<td>12/31/2014</td>
<td>Stock Option[1][2]</td>
<td>723,869</td>
<td>—</td>
<td>129.49</td>
</tr>
<tr>
<td></td>
<td>03/15/2016</td>
<td>Stock Option[1][2]</td>
<td>294,000</td>
<td>—</td>
<td>120.26</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[4]</td>
<td>1,000,000</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[5]</td>
<td>1,000,000</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[7]</td>
<td>1,000,000</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2018</td>
<td>Stock Option[4]</td>
<td>2,400,000</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td></td>
<td>03/15/2019</td>
<td>Stock Option[9]</td>
<td>4,000,000</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td></td>
<td>03/15/2019</td>
<td>Stock Option[10]</td>
<td>500,000</td>
<td>—</td>
<td>117.76</td>
</tr>
<tr>
<td>James Edgermond</td>
<td>01/14/2013</td>
<td>STAP Award[8]</td>
<td>5,000</td>
<td>—</td>
<td>52.12</td>
</tr>
<tr>
<td></td>
<td>03/14/2014</td>
<td>STAP Award[3]</td>
<td>2,411</td>
<td>—</td>
<td>94.96</td>
</tr>
<tr>
<td></td>
<td>03/13/2015</td>
<td>STAP Award[3]</td>
<td>25,000</td>
<td>—</td>
<td>163.30</td>
</tr>
<tr>
<td></td>
<td>03/13/2015</td>
<td>STAP Award[3]</td>
<td>15,160</td>
<td>—</td>
<td>163.30</td>
</tr>
<tr>
<td></td>
<td>03/15/2016</td>
<td>Stock Option[3]</td>
<td>49,000</td>
<td>—</td>
<td>120.26</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[4]</td>
<td>45,000</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[5]</td>
<td>18,750</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[7]</td>
<td>32,205</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[5]</td>
<td>52,312</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2018</td>
<td>Stock Option[4]</td>
<td>75,349</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td></td>
<td>03/15/2018</td>
<td>Stock Option[7]</td>
<td>37,674</td>
<td>18,838</td>
<td>111.00</td>
</tr>
<tr>
<td></td>
<td>03/15/2019</td>
<td>Stock Option[9]</td>
<td>162,500</td>
<td>—</td>
<td>135.42</td>
</tr>
<tr>
<td></td>
<td>03/15/2019</td>
<td>Stock Option[10]</td>
<td>162,500</td>
<td>—</td>
<td>117.76</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>01/02/2013</td>
<td>STAP Award[11]</td>
<td>100,000</td>
<td>—</td>
<td>53.83</td>
</tr>
<tr>
<td></td>
<td>03/15/2013</td>
<td>STAP Award[3]</td>
<td>18,600</td>
<td>—</td>
<td>61.06</td>
</tr>
<tr>
<td></td>
<td>03/14/2014</td>
<td>STAP Award[3]</td>
<td>40,000</td>
<td>—</td>
<td>94.96</td>
</tr>
<tr>
<td></td>
<td>03/13/2015</td>
<td>STAP Award[3]</td>
<td>37,200</td>
<td>—</td>
<td>163.30</td>
</tr>
<tr>
<td></td>
<td>03/15/2016</td>
<td>Stock Option[3]</td>
<td>39,200</td>
<td>—</td>
<td>120.26</td>
</tr>
<tr>
<td></td>
<td>06/24/2016</td>
<td>Stock Option[3]</td>
<td>52,500</td>
<td>—</td>
<td>102.11</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[4]</td>
<td>63,000</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[5]</td>
<td>26,250</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[7]</td>
<td>42,940</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2017</td>
<td>Stock Option[5]</td>
<td>69,750</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td></td>
<td>03/15/2018</td>
<td>Stock Option[4]</td>
<td>85,531</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td>Name and Grant Date</td>
<td>Award Type</td>
<td>Number of Securities Underlying Unexercised Options or STAP Awards</td>
<td>Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</td>
<td>Option or STAP Award Exercise Price ($)</td>
<td>Option or STAP Award Expiration Date</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------</td>
<td>-----------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>03/15/2018</td>
<td>Stock Option(7)</td>
<td>42,765</td>
<td>21,383</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td>03/15/2019</td>
<td>Stock Option(9)</td>
<td>—</td>
<td>187,500</td>
<td>—</td>
<td>135.42</td>
</tr>
<tr>
<td>03/15/2019</td>
<td>Stock Option(10)</td>
<td>—</td>
<td>187,500</td>
<td>—</td>
<td>117.76</td>
</tr>
</tbody>
</table>

**Paul Mahon**

<table>
<thead>
<tr>
<th>Name and Grant Date</th>
<th>Award Type</th>
<th>Number of Securities Underlying Unexercised Options or STAP Awards</th>
<th>Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</th>
<th>Option or STAP Award Exercise Price ($)</th>
<th>Option or STAP Award Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/14/2014</td>
<td>STAP Award(3)</td>
<td>89,500</td>
<td>—</td>
<td>—</td>
<td>94.96</td>
</tr>
<tr>
<td>03/13/2015</td>
<td>STAP Award(3)</td>
<td>116,250</td>
<td>—</td>
<td>—</td>
<td>163.30</td>
</tr>
<tr>
<td>03/15/2016</td>
<td>Stock Option(3)</td>
<td>122,500</td>
<td>—</td>
<td>—</td>
<td>120.26</td>
</tr>
<tr>
<td>03/15/2017</td>
<td>Stock Option(4)</td>
<td>75,000</td>
<td>—</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td>03/15/2017</td>
<td>Stock Option(5)</td>
<td>31,250</td>
<td>—</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td>03/15/2017</td>
<td>Stock Option(7)</td>
<td>42,940</td>
<td>—</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td>03/15/2017</td>
<td>Stock Option(5)</td>
<td>69,750</td>
<td>—</td>
<td>—</td>
<td>146.03</td>
</tr>
<tr>
<td>03/15/2018</td>
<td>Stock Option(10)</td>
<td>—</td>
<td>81,458</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td>03/15/2018</td>
<td>Stock Option(7)</td>
<td>40,729</td>
<td>20,365</td>
<td>—</td>
<td>111.00</td>
</tr>
<tr>
<td>03/15/2019</td>
<td>Stock Option(9)</td>
<td>—</td>
<td>150,000</td>
<td>—</td>
<td>135.42</td>
</tr>
<tr>
<td>03/15/2019</td>
<td>Stock Option(10)</td>
<td>—</td>
<td>150,000</td>
<td>—</td>
<td>117.76</td>
</tr>
</tbody>
</table>

(1) These stock options were fully vested upon grant pursuant to Dr. Rothblatt’s employment agreement.
(2) For estate planning purposes, these stock options were held by trusts beneficially owned by Dr. Rothblatt and her spouse as of December 31, 2020. They have since been transferred back to Dr. Rothblatt.
(3) These stock options or STAP awards vest in one-fourth increments on each of the first four anniversaries of the date of grant.
(4) These stock options vest in one-third increments on each of the first three anniversaries of the date of grant.
(5) These stock options were subject to a three-year (2017-2019) performance threshold tied to average cash profit margin. These stock options were fully earned as of December 31, 2019 and vested at March 15, 2020.
(6) These stock options were subject to a three-year (2018-2020) performance threshold tied to average cash profit margin. These stock options were fully earned as of December 31, 2020 and vested at March 15, 2021.
(7) These stock options were subject to a one-year performance threshold tied to Company-Wide Milestone Performance. Once earned, shares vest in equal installments over a three-year period. The number of shares shown reflect the number of shares earned based on actual performance.
(8) One-time STAP award granted upon Mr. Edgemond’s commencement of employment, which vested in full on February 28, 2015.
(9) These stock options cliff vest (100%) on the fourth anniversary of the date of grant.
(10) These stock options vest in one-third increments on the second, third and fourth anniversaries of the date of grant.
(11) These STAP awards cliff vested (100%) on the fifth anniversary of the date of grant.
Option Exercises and Stock Vested in 2020

The following table shows (1) the number of shares of our common stock acquired upon exercise of stock options; and (2) the number of STAP awards exercised by each of our Named Executive Officers during the year ended December 31, 2020. We did not have any stock awards that vested in 2020.

<table>
<thead>
<tr>
<th>Name</th>
<th>Option Awards</th>
<th>STAP Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of Shares Acquired on Exercise (#)</td>
<td>Value Realized on Exercise ($)</td>
</tr>
<tr>
<td>Martine Rothblatt</td>
<td>364,834</td>
<td>20,564,777</td>
</tr>
<tr>
<td>James Edgemond</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

(1) Represents the difference between the exercise price of the stock options or STAP award and the fair market value of our common stock on the date of exercise, multiplied by the number of options or STAP awards exercised. STAP awards convey the right to receive an amount in cash equal to the positive difference between the exercise price and the closing price of our common stock on the date of exercise.

(2) All options exercised by Dr. Rothblatt during 2020 had been held for nearly 10 years, and were nearing their expiration date of December 31, 2020.

Pension Benefits in 2020

The table below describes the present value of the accumulated benefit for our Named Executive Officers under the SERP.

<table>
<thead>
<tr>
<th>Name</th>
<th>Plan Name</th>
<th>Number of Years of Credited Service (1)</th>
<th>Actual Years of Service (2)</th>
<th>Present Value of Accumulated Benefit ($) (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Rothblatt</td>
<td>SERP</td>
<td>15.0</td>
<td>24.5</td>
<td>19,079,967</td>
</tr>
<tr>
<td>James Edgemond</td>
<td>SERP</td>
<td>8.0</td>
<td>8.0</td>
<td>5,820,039</td>
</tr>
<tr>
<td>Michael Benkowitz</td>
<td>SERP</td>
<td>9.8</td>
<td>9.7</td>
<td>9,171,542</td>
</tr>
<tr>
<td>Paul Mahon</td>
<td>SERP</td>
<td>15.0</td>
<td>19.6</td>
<td>15,057,720</td>
</tr>
</tbody>
</table>

(1) Reflects the number of years (up to the maximum of 15 years under the terms of the SERP) since each Named Executive Officer commenced employment with us, through December 31, 2020.

(2) Reflects the number of years since each Named Executive Officer commenced employment with us, through December 31, 2020.

(3) The present values of accumulated benefits are based on assumptions used in the financial disclosures for the year ended December 31, 2020 including a discount rate of 1.49% and a lump sum interest rate of 2.25%. The present value represents the lump sum value of the accrued benefit which is based on service and earnings as of December 31, 2020, and assumes payment at age 60, the normal retirement date under the SERP. No preretirement death, disability, or termination is assumed. For a discussion of valuation assumptions, see Note 11 — Employee Benefit Plans to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Supplemental Executive Retirement Plan

In 2006, our Compensation Committee approved our SERP, which is a non-qualified supplemental defined benefit retirement plan for select key executives intended to enhance the long-term retention of individuals that have been and will continue to be vital to our success. Participants in the SERP generally must remain in the employ of United Therapeutics or one of its affiliates until age 60 to receive a benefit except in the event of death, disability or a change in control. If a participant terminates employment with us for any reason prior to age 60 (other than due to death or disability or following a change in control), no benefit will be paid. The benefit to be paid under the plan is based on when an executive commenced participation in the plan. In general, a participant will be eligible for an unreduced benefit under the plan after 15 years of service. Upon a change in control before a participant reaches age 60, they will immediately vest in and receive a prorated benefit based on years of service to date.

The SERP is administered by our Compensation Committee. Currently, our Named Executive Officers and two other members of senior management participate in the SERP. Each of our Named Executive Officers is eligible, upon retirement after the age of 60, to receive monthly payments equal to the monthly average of the total gross base salary received by the participant over their last 36 months of active employment (the Final Average Compensation), reduced by the participant’s estimated social security benefit (determined as provided under the SERP), for the remainder of the participant’s life (the aggregate amount of such payments, the Normal Retirement Benefit), commencing on the first day of the sixth month after retirement. For executives who began participating in the plan after July 1, 2006, the retirement benefit is generally calculated as 100% of the final three year average gross base salary reduced by the estimated
social security benefit they would receive in retirement, multiplied by a fraction (not to exceed one) the numerator of which is their years of service and the denominator of which is 15 (the **Normal Retirement Benefit**). This means that for participants who have less than 15 years of service with us, the retirement benefit is prorated by the number of years of actual service divided by 15 years. By age 60, all current participants will have had 15 years of service if they remain employed by us. In the event of termination of employment due to disability prior to the age of 60 or death prior to retirement, a participant or the participant’s beneficiary, as applicable, will be entitled to a percentage of the Normal Retirement Benefit, as determined under the SERP [the aggregate amount of such payments referred to as the **Disability Retirement Benefit**], commencing on the first day of the sixth month after termination of employment in the event of a Disability and as soon as administratively practicable in the event of death. All of our Named Executive Officers have elected to receive their benefit in the form of a lump sum, although they were also offered a choice of a single life annuity or an actuarially equivalent joint or survivor annuity.

In the event of a change in control, as defined in the SERP, a participant who is actively employed on the date of the change in control will be entitled to a lump sum payment equal to the actuarial equivalent present value of a monthly single life annuity equal to [1] the participant’s Final Average Compensation, reduced by the participant’s estimated future social security benefit (determined as provided under the SERP), multiplied by [2] a fraction (no greater than one), the numerator of which equals the participant’s years of service and the denominator of which equals 15, to be paid as soon as administratively practicable following the change in control. In the event that a participant is entitled to a Normal Retirement Benefit or Disability Retirement Benefit at the time of a change in control, all such payments (or any remaining payments, with respect to any participant who is receiving payments under the SERP at the time of the change in control) will be made in a lump sum as soon as administratively practicable following such change in control. Participants in the SERP will be prohibited from competing with us or soliciting its employees for a period of twelve months following their termination of employment (or, if earlier upon attainment of age 65). Violation of this covenant will result in forfeiture of all benefits under the SERP.

**Rabbi Trust**

In December 2007, our Compensation Committee adopted the United Therapeutics Corporation Supplemental Executive Retirement Plan Rabbi Trust Document ([Rabbi Trust Document]), providing for the establishment of a trust ([Rabbi Trust]), the assets of which will be contributed by us and used to pay benefits under the SERP. We entered into the Rabbi Trust Document with Wilmington Trust Company, which serves as trustee of the Rabbi Trust. The Rabbi Trust is irrevocable, and SERP participants will have no preferred claim on, nor any beneficial ownership interest in, any assets of the Rabbi Trust.

Currently, the Rabbi Trust does not contain any assets. Generally, we may contribute additional assets to the Rabbi Trust at our sole discretion. However, pursuant to the terms of the Rabbi Trust Document, within five days following the occurrence of a potential change in control (as defined in the Rabbi Trust Document), or if earlier, at least five days prior to the occurrence of a change in control (as defined in the Rabbi Trust Document), we will be obligated to make an irrevocable contribution to the Rabbi Trust in an amount sufficient to pay each SERP participant or beneficiary the benefits to which they would be entitled pursuant to the terms of the SERP on the date on which the change in control occurred. The Rabbi Trust will not terminate until the date on which SERP participants or their beneficiaries are no longer entitled to benefits pursuant to the terms of the SERP.
Potential Payments Upon Termination or Change in Control

Each of our Named Executive Officers is eligible to receive certain payments and benefits if their employment is involuntarily terminated without “Cause”, terminated by the executive for “Good Reason”, terminated by the executive voluntarily with continued status as a “Senior Advisor” to us, terminated due to disability or death, or terminated in connection with a “Change in Control” of our company in accordance with the applicable terms of their respective employment agreements, change in control severance agreements, the SERP, our equity compensation plans (the EIP and 2015 SIP) and related stock option agreements, as reported in the Potential Payments Upon Termination or Change in Control table below and described in the narrative table that follows. The summary of these benefits is qualified in its entirety by the specific language of the various agreements and plans that have been filed with the SEC. The amounts shown in the Potential Payments Upon Termination or Change in Control table below are estimates of the value of these payments and benefits, assuming that such termination or triggering event was effective as of December 31, 2020 (except as otherwise noted below with respect to those Named Executive Officers who terminated during the year). The actual compensation to be paid to a Named Executive Officer can only be determined at the time such Named Executive Officer’s employment is terminated and may vary based on factors such as the timing during the year of any such event, our stock price, the Named Executive Officer’s age, and any changes to our benefit arrangements and policies. In addition to the benefits described below, our Named Executive Officers will be eligible to receive any benefits accrued under our broad-based benefit plans, such as distributions under life insurance and disability benefit plans.

<table>
<thead>
<tr>
<th>Executive Benefits and Payments Upon Separation</th>
<th>Involuntary Termination Without Cause/Resignation for Good Reason/Resignation While Continuing as Senior Advisor(1)</th>
<th>Disability</th>
<th>Death</th>
<th>Termination upon a Change in Control</th>
<th>Change In Control without Termination of Employment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Martine Rothblatt</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salary and cash incentive</td>
<td>$11,508,750</td>
<td>$1,320,000</td>
<td>$1,320,000</td>
<td>$11,508,750</td>
<td>$—</td>
</tr>
<tr>
<td>Stock option vesting acceleration*(2)</td>
<td>$32,952,908</td>
<td>$32,952,908</td>
<td>$32,952,908</td>
<td>$32,952,908</td>
<td>$32,952,908</td>
</tr>
<tr>
<td>Supplemental Executive Retirement Plan</td>
<td>$19,079,967</td>
<td>$19,079,967</td>
<td>$12,858,615</td>
<td>$19,079,967</td>
<td>$19,079,967</td>
</tr>
<tr>
<td>Health and other benefits*(3)</td>
<td>$129,558</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$129,558</td>
</tr>
<tr>
<td>Total</td>
<td>$63,671,183</td>
<td>$53,352,875</td>
<td>$47,131,523</td>
<td>$63,671,183</td>
<td>$52,032,875</td>
</tr>
<tr>
<td><strong>James Edgemond</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salary and cash incentive</td>
<td>$138,082</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$2,665,626</td>
</tr>
<tr>
<td>Stock option vesting acceleration*(2)</td>
<td>$—</td>
<td>$10,239,011</td>
<td>$10,239,011</td>
<td>$10,239,011</td>
<td>$10,239,011</td>
</tr>
<tr>
<td>Supplemental Executive Retirement Plan</td>
<td>$—</td>
<td>$5,643,334</td>
<td>$3,748,236</td>
<td>$5,617,860</td>
<td>$5,617,860</td>
</tr>
<tr>
<td>Health and other benefits*(3)</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$72,231</td>
</tr>
<tr>
<td>Total</td>
<td>$138,082</td>
<td>$15,882,345</td>
<td>$13,987,247</td>
<td>$18,594,728</td>
<td>$15,856,871</td>
</tr>
<tr>
<td><strong>Michael Benkowitz</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salary and cash incentive</td>
<td>$443,712</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$3,710,626</td>
</tr>
<tr>
<td>Stock option vesting acceleration*(2)</td>
<td>$—</td>
<td>$11,775,880</td>
<td>$11,775,880</td>
<td>$11,775,880</td>
<td>$11,775,880</td>
</tr>
<tr>
<td>Supplemental Executive Retirement Plan</td>
<td>$—</td>
<td>$5,967,353</td>
<td>$3,546,240</td>
<td>$8,120,938</td>
<td>$8,120,938</td>
</tr>
<tr>
<td>Health and other benefits*(3)</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$72,231</td>
</tr>
<tr>
<td>Total</td>
<td>$443,712</td>
<td>$17,743,233</td>
<td>$15,322,120</td>
<td>$23,679,675</td>
<td>$19,896,818</td>
</tr>
<tr>
<td><strong>Paul Mahon</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salary and cash incentive</td>
<td>$3,250,125</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$3,250,125</td>
</tr>
<tr>
<td>Stock option vesting acceleration*(2)</td>
<td>$9,775,128</td>
<td>$9,775,128</td>
<td>$9,775,128</td>
<td>$9,775,128</td>
<td>$9,775,128</td>
</tr>
<tr>
<td>Supplemental Executive Retirement Plan</td>
<td>$—</td>
<td>$12,939,583</td>
<td>$8,393,936</td>
<td>$14,626,035</td>
<td>$14,626,035</td>
</tr>
<tr>
<td>Total</td>
<td>$13,025,253</td>
<td>$22,714,711</td>
<td>$18,169,064</td>
<td>$27,651,288</td>
<td>$24,401,163</td>
</tr>
</tbody>
</table>

(1) Benefits upon termination while continuing as a senior advisor are applicable only to employment agreements with Dr. Rothblatt and Mr. Mahon.
The value shown is based on the positive difference between the aggregate exercise price of all accelerated stock options and/or STAP awards and the aggregate market value of the underlying shares calculated based on the closing market price of our common stock on December 31, 2020, $151.79. Per the terms of awards containing performance vesting criteria, acceleration will result in the vesting of the “target” number of shares. As of March 15, 2021, all performance-based awards had vested at “maximum”. With respect to the four-year stock option grants in March 2019, both Dr. Rothblatt and Mr. Mahon have waived their contractual provision providing for stock option vesting acceleration if they resign while continuing as a senior advisor.

Dr. Rothblatt’s employment agreement provides for SERP benefits under her employment agreement upon reaching age 65, including three additional years of service. Given Dr. Rothblatt has attained retirement age and has already reached the maximum number of years of service under the SERP, this additional benefit is no longer applicable. As a result, the value included in this table represents the normal benefits Dr. Rothblatt would receive upon retirement, in accordance with the terms of the SERP.

Represents the estimated value of continued health care benefits for a three-year period after termination, outplacement services for 12 months and the fair value of one currently leased vehicle.

Represents the estimated value of continued health care benefits for a two-year period after termination and outplacement services equal to $10,000.

## Severance and Change in Control Payments to Named ExecutiveOfficers

<table>
<thead>
<tr>
<th>Provision</th>
<th>Terms Applicable to Chairman and CEO</th>
<th>Terms Applicable to Mr. Mahon</th>
</tr>
</thead>
</table>
| Payments Upon Involuntary Termination without Cause, or Resignation for Good Reason, or Resignation while Continuing as Senior Advisor |  - Lump sum prorated cash incentive and incentive payment*  
- Lump sum payment equal to 3.0 times base salary + 3.0 times annual cash incentive award*  
- Continuation of health care benefits for 36 months, outplacement services for 12 months and the transfer of one currently leased vehicle  
- Immediate vesting of unvested stock options**  |  - Lump sum payment equal to 2.0 times: [1] current base salary; plus [2] annual cash incentive award*  
- Immediate vesting of unvested stock options and STAP awards**  |
| Payments Upon Disability |  - Continued payment of current base salary through the end of the calendar year following such disability  
- Acceleration of SERP benefits  
- Immediate vesting of unvested stock options  |  - Immediate vesting of unvested stock options and STAP awards  
- Acceleration of SERP benefits  |
| Payments Upon Death |  - Continued payment of current base salary through the end of the calendar year following such death to Executive’s legal representatives  
- Acceleration of SERP benefits  
- Immediate vesting of unvested stock options  |  - Immediate vesting of unvested stock options and STAP awards  
- Acceleration of SERP benefits  |
| Payments Upon Termination Following Change in Control |  - Same as Payments Upon Involuntary Termination, etc., except that payment of SERP benefits occurs immediately, and is calculated as described above under Supplemental Executive Retirement Plan  |  - Same as Payments Upon Involuntary Termination, etc.  
- Acceleration of SERP benefits  |
| Payments Upon Change in Control without Termination |  - Acceleration of SERP benefits  
- Immediate vesting of unvested stock options [if not assumed]  |  - Immediate vesting of unvested stock options and STAP awards [if not assumed]  
- Acceleration of SERP benefits  |

* Payment is equal to greater of payment for the prior year, or the average of such payments for the prior two years

** Provision has been waived with respect to the 2019-2022 four-year stock options granted to Dr. Rothblatt and Mr. Mahon
## Executive Compensation

### Provision

<table>
<thead>
<tr>
<th>Provision</th>
<th>Terms Applicable to Mr. Edgemond and Mr. Benkowizt</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Payments Upon Involuntary Termination without Cause</strong></td>
<td>• Lump sum payment equal to base salary through the remainder of the agreement term</td>
</tr>
<tr>
<td><strong>Payments Upon Disability</strong></td>
<td>• Continued payment of current base salary through date of termination</td>
</tr>
<tr>
<td></td>
<td>• Immediate vesting of unvested stock options and STAP awards</td>
</tr>
<tr>
<td></td>
<td>• Acceleration of SERP benefits</td>
</tr>
<tr>
<td><strong>Payments Upon Death</strong></td>
<td>• Immediate vesting of unvested stock options and STAP awards</td>
</tr>
<tr>
<td></td>
<td>• Acceleration of SERP benefits</td>
</tr>
<tr>
<td><strong>Payments Upon Termination Following Change in Control</strong></td>
<td>• Payment of a lump sum cash amount equal to 2.0 times the sum of (x) base salary plus (y) the highest of (1) the cash incentive paid to the individual for the year immediately preceding the year in which the change in control occurs, (2) the cash incentive award payable to the individual for the year immediately preceding the year in which the termination of employment occurs, or (3) the individual’s annual target cash incentive award</td>
</tr>
<tr>
<td></td>
<td>• Immediate vesting of unvested stock options and STAP awards</td>
</tr>
<tr>
<td></td>
<td>• Acceleration of SERP benefits</td>
</tr>
<tr>
<td></td>
<td>• Continuation of medical benefits for 24 months</td>
</tr>
<tr>
<td></td>
<td>• Outplacement benefits with a value of $10,000</td>
</tr>
<tr>
<td><strong>Payments Upon Change in Control without Termination</strong></td>
<td>• Acceleration of SERP benefits</td>
</tr>
<tr>
<td></td>
<td>• Immediate vesting of unvested stock options and STAP awards [if not assumed]</td>
</tr>
</tbody>
</table>

* Payment is equal to greater of payment for the prior year, or the average of such payments for the prior two years

As used in the tables above, the following terms are generally defined as follows:

### Cause:

- In the case of Dr. Rothblatt, her willful and continued failure to substantially perform her duties, or willfully engaging in gross misconduct that is materially injurious to us
- In the case of the other Named Executive Officers, (2) failure to perform any of the material terms or provisions of his employment agreement; (2) negligent or unsatisfactory performance of duties, after notice and the opportunity to correct such performance; (3) employment or profession related misconduct; (4) conviction of a crime involving a felony, fraud or embezzlement; or (5) misappropriation of our funds or misuse of assets

### Good Reason:

- In the case of Dr. Rothblatt, without her consent, the occurrence of any of the following: (1) the assignment of any duties that are inconsistent with her position as Chairman and Chief Executive Officer; (2) a material adverse change in her reporting responsibilities, titles or offices; (3) failure to re-elect her to any position she held with us; (4) a reduction in her base salary or failure to increase her salary consistent with certain other executive salary increases; (5) relocation of 25 miles or more or additional substantially more burdensome travel requirements; (6) failure to continue her as a participant in any bonus or other incentive plans in which she was participating; (7) failure to keep in effect certain benefit plans and arrangements; (8) failure to obtain a successor entity’s assumption of the employment agreement; (9) failure to abide by certain provisions in the employment agreement; or (10) any other material breach of the employment agreement
- In the case of Mr. Mahon, his authority and responsibilities being materially diminished without cause

### Change in Control:

Transfer of control of our company (generally, as a result of an acquisition, merger, hostile takeover, or any other reason)

### Pay Ratio

As required by Section 953(b) of the Dodd Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are required to disclose the ratio of the 2020 compensation of our principal executive officer to that of our median compensated employee.

During 2020, our principal executive officer was our Chief Executive Officer, Dr. Martine Rothblatt. For purposes of this pay ratio disclosure, Dr. Rothblatt’s 2020 annual total compensation was $4,828,939, and the 2020 total annual compensation for our median employee, identified as discussed below, was $188,017, resulting in a pay ratio of approximately 26:1. Dr. Rothblatt’s total compensation for purposes of this disclosure differs from the total annual compensation reflected in the Summary Compensation Table because we included the value of employer paid non-discriminatory health and welfare benefits and basic life insurance premiums, which are not required to be disclosed in the Summary Compensation Table, but which we include here to give a more complete picture of our median employee’s total rewards compensation.
In accordance with Item 402(u) of Regulation S K, we identified our employee population as of October 1, 2020 and determined the median employee by (1) aggregating for each applicable employee [a] annual base salary determined as of October 1, 2020 for salaried employees (or hourly rate as of the same date, multiplied by estimated hours worked in 2020, for hourly employees), and [b] the target cash incentive, commissions, and overtime earned in 2020, and (2) ranking this compensation measure for our employees from lowest to highest. This calculation was performed for all employees except as disclosed in the following paragraph, excluding Dr. Rothblatt, whether employed on a full time, part time, or seasonal basis.

For purposes of identifying the median employee, all employees located outside of the United States as of October 1, 2020, totaling 16 individuals, were excluded from the determination of the median employee pursuant to the so-called de minimis exemption, which permits us to exclude foreign employees, up to 5% of our total employee population of 948, on a whole country basis. As of October 1, 2020, these employees were located in the following countries: Canada (9), Germany (2) and United Kingdom (5). Applying this de minimis exemption, as of October 1, 2020, we considered a total of 931 US based employees (excluding our CEO) and no employees located outside of the United States. Irrespective of the de minimis exemption, on this same date we had 931 U.S. based employees and 16 employees located outside of the United States.

The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation, allows companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.
Approval of The Amendment and Restatement of The United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan

We are asking our shareholders to approve an amendment and restatement (the 2021 Restatement) of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the Plan). On April 29, 2015, our Board of Directors unanimously adopted and approved the Plan. Our shareholders subsequently approved the Plan at our 2015 Annual Meeting of Shareholders. Our shareholders subsequently approved an amendment and restatement of the Plan at each of our 2018, 2019, and 2020 Annual Meetings of Shareholders. We refer to the 2020 amendment and restatement of the Plan as the 2020 Restatement.

Our Board of Directors adopted and approved the Plan to stimulate the efforts of non-employee directors, officers, employees, and other service providers, in each case who are selected to be participants in the Plan, by heightening the desire of such persons to continue working toward and contributing to our success and progress. The Plan allows grants of stock options, stock appreciation rights, restricted stock, restricted stock units, and stock awards, any of which may be performance-based, and for cash incentives.

We believe that a comprehensive equity compensation program serves as a necessary and powerful tool to attract, retain, and incentivize individuals essential to our financial success and accordingly benefits all of our shareholders by allowing us to retain individuals who are expected to make significant contributions to the creation of shareholder value.

The 2021 Restatement makes the following changes to the 2020 Restatement of the Plan:

• Increases the maximum number of shares of our common stock that may be issued under the Plan by 1,000,000 shares
• Extends the expiration date of the Plan to April 29, 2031
• Expressly prohibits the payment of dividends on unvested awards for all equity award types

Approval of the 2021 Restatement requires the affirmative vote of the holders of a majority of the outstanding shares present, online or by proxy, at our Annual Meeting and entitled to vote on this proposal.

Our Board of Directors recommends that you vote FOR the approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.

Why You Should Vote For the 2021 Restatement of the Plan

Our Board of Directors recommends that our shareholders approve the 2021 Restatement of the Plan.

• Reasonable Share Request. At the current burn rate for our equity awards, we expect that the existing limit of 10,000,000 shares available for issuance under the 2020 Restatement of the Plan may be insufficient to fund the annual issuance of awards to our employees in March 2022 and 2023.
• Market Competitiveness and Broad-Based Usage. We offer equity-based compensation to all of our full-time employees, executive officers, and non-employee directors. Like other similarly-situated biotech and pharmaceutical companies, many of which we compete with for talent, equity is an important part of our compensation program. Our ability to continue granting equity-based awards is crucial to ensure that we can attract, retain, motivate, and reward key talent so that we can continue to deliver exceptional performance.

If the 2021 Restatement is not approved, we may need to grant cash-based or other awards in order to remain competitive; these awards may not align the interests of our key employees and non-employee directors as closely with those of our shareholders as equity awards. In addition, the use of cash resources to deliver competitive pay would divert cash from use in running other aspects of our business and investing in future product development.

Promotion of Good Corporate Governance Practices

Our company and our Board of Directors have designed the Plan to include a number of provisions that we believe promote best practices by reinforcing the alignment between equity compensation arrangements for non-employee directors, officers, employees, and other service providers and shareholders’ interests. These provisions include, but are not limited to:

• the Plan allows for awards to be granted with performance-based vesting conditions;
• stock options and stock appreciation rights may not be granted with exercise prices lower than the fair market value of the underlying shares on the grant date;
• no award may vest prior to the first anniversary of grant, subject to limited exceptions for death, disability, or a change in control;
• the share pool under the Plan is not subject to liberal “recycling” provisions (among other things, shares used to pay the exercise price for stock options do not again become available for grant under the Plan);
• at any time when the exercise price of a stock option or stock appreciation right is above the market value of our common stock, we cannot, without shareholder approval, directly or indirectly “reprice” those awards;
• stock options granted under the Plan cannot be subject to a “reload” feature;
• we have the authority under the Plan to cancel outstanding awards (vested or unvested) in the event the applicable plan participant engages in an “act of misconduct” (as such term is defined in the Plan);
• no participant may receive dividends in respect of an unvested award; and
• the Plan specifies limits on cash and equity compensation that may be provided annually to our non-employee directors.

Key Data

The following table includes information regarding all of our outstanding equity awards (under all of our equity-based compensation plans under which shares of common stock may be issued, other than our Employee Stock Purchase Plan) and shares available for future awards under the Plan as of March 17, 2021:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total shares underlying all outstanding stock options</td>
<td>7,594,984</td>
</tr>
<tr>
<td>Weighted average exercise price of outstanding stock options</td>
<td>$126.27</td>
</tr>
<tr>
<td>Weighted average remaining contractual life of outstanding stock options</td>
<td>5.39 years</td>
</tr>
<tr>
<td>Total shares of common stock outstanding</td>
<td>44,755,429</td>
</tr>
<tr>
<td>Total shares underlying all outstanding and unvested performance shares</td>
<td>0</td>
</tr>
<tr>
<td>Total shares underlying all outstanding and unvested restricted stock (excluding performance shares)</td>
<td>428,934</td>
</tr>
<tr>
<td>Shares available for future awards that could be issued under Prior Plan(1)</td>
<td>0</td>
</tr>
<tr>
<td>Shares available for future awards that could be issued under the 2015 Stock Incentive Plan(2)</td>
<td>2,041,358</td>
</tr>
<tr>
<td>Shares available for future awards that could be issued under the 2019 Inducement Stock Incentive Plan(3)</td>
<td>77,437</td>
</tr>
</tbody>
</table>

(1) Certain outstanding stock options were issued under our Amended and Restated Equity Incentive Plan (the Prior Plan), which was approved by security holders in 1997. Information regarding this plan is contained in Note 8 — Share Based Compensation to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. No further awards may be granted pursuant to the Prior Plan following shareholder approval of the Plan in June 2015 (but outstanding awards under the Prior Plan will continue to be governed by the Prior Plan). Any shares subject to awards that are forfeited under the Prior Plan will not become available for the issuance of future awards under either the Plan or the Prior Plan.

(2) This is the Plan being amended and restated and does not include the additional shares to be made available for issuance if the 2021 Restatement is approved. The fungible share ratio of 1.35:1 will apply to full-value awards granted under the 2021 Restatement.

(3) The fungible share ratio of 2.14:1 will apply to full-value awards granted under the 2019 Inducement Stock Incentive Plan.

The potential dilution from the additional 1,000,000 shares to be made available for issuance under the Plan is approximately 2.2% (calculated as the additional shares requested divided by shares outstanding as of March 17, 2021). Our Board of Directors has considered this potential dilution level in the context of competitive data from our peer group and believes that the resulting dilution levels would be within normal competitive ranges. Actual dilution from the Plan will depend on several factors, including the type of awards made under the Plan. This is because the Plan uses a fungible share design, under which each share issued pursuant to a stock option or stock appreciation right will reduce the number of shares available under the Plan by one share, and each share issued pursuant to other awards will reduce the number of shares available by 1.35 shares. If all of the shares available under the Plan were to be granted in the form of restricted stock units, the total potential dilution from the Plan would be approximately 1.7% as of March 17, 2021 (calculated as the additional shares requested divided first by 1.35 and then by the total shares outstanding as of March 17, 2021).
We manage our long-term dilution goal by limiting the number of shares subject to equity awards that we grant annually, commonly referred to as burn rate. Burn rate shows how rapidly a company is depleting its shares reserved for equity compensation plans and is defined as the number of shares granted under our equity incentive plans divided by the weighted average number of common shares outstanding at the end of the year. We have calculated the burn rate under the Plan for the past three years, as set forth in the following table:

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Options Granted</th>
<th>Full-Value Shares Granted</th>
<th>Total Granted</th>
<th>Weighted Average Number of Common Shares Outstanding</th>
<th>Burn Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiscal 2020</td>
<td>78,559</td>
<td>284,303</td>
<td>362,862</td>
<td>44,224,671</td>
<td>0.8 %</td>
</tr>
<tr>
<td>Fiscal 2019</td>
<td>2,081,047</td>
<td>225,218</td>
<td>2,306,265</td>
<td>43,818,811</td>
<td>5.3 %</td>
</tr>
<tr>
<td>Fiscal 2018</td>
<td>996,775</td>
<td>198,888</td>
<td>1,195,663</td>
<td>43,493,497</td>
<td>2.7 %</td>
</tr>
<tr>
<td>Three-Year Average</td>
<td>1,052,127</td>
<td>236,136</td>
<td>1,288,263</td>
<td>43,845,660</td>
<td>2.9 %</td>
</tr>
</tbody>
</table>

(1) These figures reflect time-based full-value awards granted during the applicable fiscal year and both time-based and performance-based stock option awards granted during the applicable fiscal year.

An additional metric that we use to measure the cumulative impact of our equity program is overhang (the number of shares subject to equity awards outstanding but not exercised or settled, plus the number of shares available to be granted, divided by the sum of the total number of shares of our common stock outstanding, plus the number of shares subject to equity awards outstanding but not exercised or settled, plus the number of shares available to be granted). Of the shares subject to outstanding awards under our equity plans as of March 17, 2021, approximately 155,000 shares, or approximately 2.0% of the total shares subject to outstanding awards, were subject to stock options with exercise prices greater than $171.17. If the Plan is approved, our overhang calculated on this basis would increase to approximately 20%, and then would be expected to decline as awards are exercised and/or become vested.

When considering the Plan, our Board of Directors also reviewed, among other things, projected future share usage and projected future forfeitures. The projected future usage of shares for long-term incentive awards under the Plan was reviewed under scenarios based on a variety of assumptions. Depending on assumptions, with the 1,000,000 additional shares to be made available under the Plan, the 2021 Restatement of the Plan is expected to satisfy our equity compensation needs for approximately 2-3 years of similar levels of awards based on current utilization levels. Our Board of Directors is committed to effectively managing the number of shares reserved for issuance under the Plan while minimizing shareholder dilution.

Plan Summary

The following summary of the material terms of the Plan is qualified in its entirety by reference to the complete statement of the Plan, which is set forth in Annex A to this Proxy Statement.

Administration

The Plan will be administered by our Compensation Committee. Subject to the express provisions of the Plan, the administrator is authorized and empowered to do all things that it determines to be necessary or appropriate in connection with the administration of the Plan. All decisions, determinations, and interpretations by our Compensation Committee regarding the Plan and awards granted under the Plan will be final and binding on all participants and other persons holding or claiming rights under the Plan or an award under the Plan. Our Compensation Committee may authorize one or more of our officers to perform any or all things that the administrator is authorized and empowered to do or perform under the Plan. Our Compensation Committee may delegate any or all aspects of the day-to-day administration of the Plan to one or more of our officers or employees, and/or to one or more agents.

Participants

Any person who is a current or prospective officer or employee of United Therapeutics or of any subsidiary may be eligible for selection by the administrator for the grant of awards under the Plan. In addition, non-employee directors and any service providers who have been retained to provide consulting, advisory or other services to us may be eligible for the grant of awards under the Plan. Options intended to qualify as “incentive stock options” [ISOs] within the meaning of Section 422 of the Code may be granted only to our employees. Approximately 961 officers and employees and eleven non-employee directors currently qualify to participate in the Plan.

Stock Options and RSUs Granted under the Plan

No awards made under the Plan prior to the date of the Annual Meeting were granted subject to shareholder approval. The number and types of awards that will be granted under the Plan in the future are not determinable, as the Compensation Committee will make these
determinations in its discretion. The following table sets forth information with respect to the number of stock options and RSUs that have been granted to our NEOs, directors, and the specified groups set forth below under the Plan as of March 17, 2021. No other award types have been granted under the Plan. On March 17, 2021, the closing price of the underlying shares of our common stock traded on the Nasdaq was $171.17 per share.

<table>
<thead>
<tr>
<th>Name and Principal Position</th>
<th>Stock Options</th>
<th>Restricted Stock Units</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Martine Rothblatt</strong></td>
<td>2,560,144</td>
<td>—</td>
</tr>
<tr>
<td>Chairperson and Chief Executive Officer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>James Edgemond</strong></td>
<td>661,157</td>
<td>—</td>
</tr>
<tr>
<td>Chief Financial Officer and Treasurer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Michael Benkowitz</strong></td>
<td>827,691</td>
<td>—</td>
</tr>
<tr>
<td>President and Chief Operating Officer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Paul Mahon</strong></td>
<td>793,364</td>
<td>—</td>
</tr>
<tr>
<td>Executive Vice President and General Counsel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All executive officers as a group (4 persons)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All non-executive directors as a group (11 persons)</td>
<td>393,940</td>
<td>99,160</td>
</tr>
<tr>
<td>Each associate of the above-mentioned directors or executive officers</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Each other person who received or is to receive 5% of such options, warrants or rights</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>All employees (other than current executive officers) as a group (2,246 persons)</td>
<td>1,691,333</td>
<td>812,667</td>
</tr>
</tbody>
</table>

(1) Reflects the actual number of shares of common stock subject to restricted stock units, without applying the fungible share ratio of 1.35:1 or 2.14:1, as applicable

(2) Excludes former executive officers

(3) Includes current and former employees and former executive officers

### Shares Subject to the Plan and to Awards

Subject to changes in our capitalization, the aggregate number of shares of our common stock issuable pursuant to all awards under the Plan will not exceed 11,000,000 shares; provided that (1) any shares granted under options or stock appreciation rights will be counted against this limit on a one-for-one basis; (2) any shares granted prior to March 17, 2020, as awards other than options or stock appreciation rights will be counted against this limit as 2.14 shares for every one share subject to such award; and (3) any shares granted on or after March 17, 2020, as awards other than options or stock appreciation rights shall be counted against this limit as 1.35 shares for every one share subject to such award. The shares issued pursuant to awards granted under the Plan may be shares that are authorized and unissued or issued shares that were reacquired by us, including shares purchased in the open market.

For purposes of determining the share limits described in the paragraph above, the aggregate number of shares issued under the Plan at any time will equal only the number of shares actually issued upon exercise or settlement of an award. Notwithstanding the foregoing, shares subject to an award under the Plan may not again be made available for issuance under the Plan if such shares are: (1) shares that were subject to a stock-settled stock appreciation right and were not issued upon the net settlement or net exercise of such stock appreciation right; (2) shares used to pay the exercise price of an option; (3) shares delivered to or withheld by us to pay the withholding taxes related to an award; or (4) shares repurchased on the open market with the proceeds of an option exercise.

Shares subject to awards that have been canceled, expired, forfeited or otherwise not issued under an award and shares subject to awards settled in cash will not count as shares issued under the Plan. Any shares that were subject to options or stock appreciation rights and that again become available for awards under the Plan will be added as one share for every one share subject to such options or stock appreciation rights. Any shares that were subject to awards other than options or stock appreciation rights that again become available for awards under the Plan shall: (1) prior to March 17, 2020 be added as 1.35 shares for every one share subject to such awards; and (2) from and after March 17, 2020, be added as 1.35 shares for every one share subject to such awards.

Subject to certain adjustments, the aggregate number of shares subject to awards granted under the Plan during any calendar year to any one participant will not exceed 1,000,000 and the aggregate number of shares that may be issued pursuant to the exercise of ISOs granted under the Plan will not exceed 11,000,000. The maximum amount payable pursuant to that portion of a cash incentive award granted in any calendar year to any participant under the Plan will not exceed $5 million.

In addition, the aggregate dollar value of awards (based on the aggregate accounting value on the date of grant) granted pursuant to the Plan during any calendar year to any non-employee director may not exceed $400,000 for annual equity grants (plus, for the year an individual first becomes a non-employee director [(x) an initial equity grant valued at $400,000, plus (y) a pro-rata portion of the $400,000 annual equity-based award value based on the number of months remaining in the Board of Directors service year at the date of grant]. The annual equity award may be payable in options, restricted stock units, or a combination, as elected by the non-employee director. The
Plan further provides that the cash compensation paid or payable to a non-employee director with respect to any calendar year may not exceed $60,000 (with additional cash compensation of $35,000 for the lead independent director, $25,000 for each committee chair, and $15,000 for each other committee membership), plus a pro-rated portion of the aggregate cash compensation for the roles in which the non-employee director serves for the year an individual first becomes a non-employee director.

Option Awards

The administrator will establish the exercise price per share under each option, which, other than in the event of options granted in connection with a merger or other acquisition, will not be less than the fair market value (or 110 percent of the fair market value in the case of ISOs granted to individuals who own more than 10 percent of our common stock) of a share on the date the option is granted. The administrator will establish the term of each option, which in no case may exceed a period of ten years from the date of grant or five years in the case of ISOs granted to individuals who own more than 10 percent of our common stock. Options granted under the Plan may either be ISOs or options which are not intended to qualify as ISOs, or nonqualified stock options (NQSOs). Unless the administrator determines otherwise: (1) upon termination of employment other than due to death, disability, or termination for cause, participants may continue to exercise their options for ninety (90) days (or until the expiration date of the option, if earlier) to the extent that they were exercisable upon the date of termination; (2) upon death or disability, options become fully vested and remain exercisable for one year (or until the expiration date of the option, if earlier) following such event; and (3) upon termination of employment for cause, all options are forfeited. Stock options may not include any “reload” feature. In no event shall any stock option fully vest before the first anniversary of the date of grant; provided that, if so determined by the administrator, an option may fully vest before such anniversary in the event of the participant’s death or disability or a change in control. No participant will have any rights as a shareholder with respect to any shares subject to options until such shares have been issued, including, for avoidance of doubt, no voting rights and no rights to receive dividends, distributions, or dividend equivalents in respect of an option or any shares subject to an option until the participant has become the holder of record of such shares.

Stock Appreciation Rights

A stock appreciation right provides the right to receive the monetary equivalent of the increase in value of a specified number of the shares over a specified period of time after the right is granted. Stock appreciation rights may be granted to participants either in tandem with or as a component of other awards granted under the Plan (tandem SARs) or not in conjunction with other awards (freestanding SARs). All freestanding SARs will be granted subject to the same terms and conditions applicable to options as set forth above and in the Plan, and all tandem SARs will have the same exercise price, vesting, exercisability, forfeiture, and termination provisions as the award to which they relate. Participants will have no voting rights and will have no rights to receive dividends, distributions, or dividend equivalents in respect of stock appreciation rights or any shares subject to stock appreciation rights until the participant has become the holder of record of such shares.

Restricted Stock and Restricted Stock Units

Restricted stock is an award or issuance of shares the grant, issuance, retention, vesting, and/or transferability of which is subject during specified periods of time to such conditions [including continued employment or performance conditions] and terms as the administrator deems appropriate. Restricted stock units are awards denominated in units of shares under which the issuance of shares is subject to such conditions [including continued employment or performance conditions] and terms as the administrator deems appropriate. Notwithstanding the satisfaction of any performance goals, the number of shares granted, issued, retainable, and/or vested under a restricted stock award or restricted stock units because of either financial performance or personal performance evaluations may be reduced, but not increased, by the administrator based on such further consideration as the administrator may determine.

In no event shall any restricted stock or restricted stock units fully vest before the first anniversary of the date of grant; provided that, if so determined by the administrator, restricted stock or restricted stock units may fully vest before such anniversary in the event of the participant’s death or disability or a change in control. Unless the administrator determines otherwise, (1) upon termination of employment for any reason other than death or disability, all restricted stock and restricted stock units still subject to restrictions as of the date of termination will be forfeited; and (2) upon death or disability, the restrictions remaining on a participant’s restricted stock and restricted stock units will lapse.

Unless otherwise determined by the administrator, participants holding shares of restricted stock granted under the Plan may exercise full voting rights with respect to those shares during the period of restriction, and participants will have no voting rights with respect to shares underlying restricted stock units unless and until such shares are reflected as issued and outstanding shares in our stock ledger. Participants in whose name restricted stock is granted will be entitled to receive all dividends and other distributions paid with respect to those shares, unless determined otherwise by the administrator. Participants will be entitled to receive dividends or dividend equivalents with respect to shares underlying restricted stock units only to the extent provided by the administrator. However, in no event will dividends, distributions, or dividend equivalents be payable with respect to unvested or unearned awards until such awards vest.
Stock Awards

The administrator may grant stock awards under the Plan, which will be subject to the terms and conditions determined by the administrator. Participants will have all voting, dividend, liquidation, and other rights with respect to shares underlying a stock award, subject to any restrictions on transfer determined by the administrator, provided that in no event will dividends, distributions, or dividend equivalents be currently payable with respect to unvested or unearned stock awards until such awards vest. In no event shall any stock award fully vest before the first anniversary of the date of grant; provided that, if so determined by the administrator, a stock award may fully vest before such anniversary in the event of the participant’s death or disability or a change in control.

Incentive Awards

Each incentive award will confer upon the participant the opportunity to earn a future payment tied to the level of achievement with respect to one or more performance criteria established for a performance period of not less than one year. The administrator will establish the performance criteria and level of achievement of these criteria that will determine the target and maximum amount payable under an incentive award, which criteria may be based on financial performance and/or personal performance evaluations. Notwithstanding the satisfaction of any performance goals, the amount paid under an incentive award because of either financial performance or personal performance evaluations may be reduced, but not increased, by the administrator based on such further consideration as the administrator may determine. Payment of the amount due under an incentive award may be made in cash or in shares, as determined by the administrator, provided that no participant will have any rights as a shareholder with respect to any shares payable in respect of an incentive award until said shares have been issued, including, for avoidance of doubt, no voting rights and no rights to receive dividends, distributions, or dividend equivalents in respect of an incentive award or any shares subject to an incentive award until the participant has become the holder of record of such shares.

Suspension or Termination of Awards

Unless otherwise determined by the administrator, (1) if our Chief Executive Officer or any other person designated by the administrator reasonably believes that a participant may have committed an act of misconduct (as defined in the Plan), then the participant’s rights to exercise any option, vest in any award and/or receive payment for or shares in settlement of an award may be suspended pending a determination of whether an act of misconduct has been committed; and (2) if the administrator, our Chairman and Chief Executive Officer or any other person designated by the administrator determines that a participant has committed an act of misconduct, then the participant (a) may not exercise any option or stock appreciation right, vest in, have restrictions on an award lapse or otherwise receive payment of an award; (b) will forfeit all outstanding awards; and (c) may be required, at the discretion of the committee, to return or repay any then-unvested shares previously issued under the Plan.

Amendment and Termination

Our Board of Directors may amend, alter or discontinue the Plan, and the administrator may amend or alter any agreement or other document evidencing an award made under the Plan, except no such amendment may, without the approval of our shareholders: (1) increase the maximum number of shares for which awards may be granted under the Plan; (2) reduce the minimum price set forth in the Plan at which options or stock appreciation rights may be granted; (3) reduce the exercise price of outstanding options or stock appreciation rights; (4) extend the term of the Plan; (5) change the class of persons eligible to be participants; (6) otherwise amend the Plan in any manner requiring shareholder approval by law or under Nasdaq listing requirements or the listing requirements of any successor exchange that is the primary stock exchange for trading of our shares; or (7) increase the individual maximum limits set forth in the Plan.

No amendment or alteration to the Plan or an award or agreement may be made that would impair the rights of the holder of an award without such holder’s consent, provided that no such consent will be required if the administrator determines in its sole discretion and prior to the date of any change in control that such amendment or alteration either is required or advisable in order for us, the Plan, or the award to satisfy any law or regulation or to meet the requirements of or avoid adverse financial accounting consequences under any accounting standard. In addition, the Plan may not be amended in any way that causes the Plan to fail to comply with or be exempt from Section 409A of the Code, unless our Board expressly determines to amend the Plan to be subject to Section 409A of the Code.

Change in Control

The administrator may determine the effect of a change in control (as defined in the Plan) on outstanding awards in a manner that is fair and equitable to participants (as determined by the administrator in its reasonable discretion). These effects, which need not be the same for all participants, may include, but are not limited to: (1) substituting for the shares subject to an outstanding award or portion thereof the stock or securities of the surviving corporation or any successor corporation, in which event the aggregate exercise price of the award will remain the same; and/or (2) converting any outstanding award or portion thereof into a right to receive cash or other property following the consummation of the change in control in an amount equal to the value of consideration to be received for one share of our
common stock in connection with such transaction less the purchase or exercise price of the shares subject to the award, multiplied by the number of shares subject to the award or portion thereof.

Adjustments

The number and kind of shares available for issuance under the Plan, and the number and kind of shares subject to the individual and ISO limits set forth under the Plan, will be equitably adjusted by the administrator to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend, or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares outstanding. The terms of any outstanding award will also be equitably adjusted by the administrator as to price, number, or kind of shares subject to such award and other terms to reflect the foregoing events, which adjustments need not be uniform as between different awards or different types of awards.

In the event there is a change in the number or kind of outstanding shares under the Plan as a result of a change of control, other merger, consolidation, or otherwise, then the administrator will determine the appropriate and equitable adjustment to be effected. In addition, in the event of such a change, the administrator may accelerate the time or times at which any award may be exercised and may provide for cancellation of such accelerated awards that are not exercised within a time prescribed by the administrator in its sole discretion.

Transferability

Unless the administrator determines otherwise, awards may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by a participant other than by will or the laws of descent and distribution, and each option or stock appreciation right may be exercisable only by the participant during their lifetime. To the extent permitted by the administrator, the person to whom an award is initially granted may make certain limited transfers to certain family members, family trusts, or family partnerships.

Effective Date and Termination of the Plan

The Plan was initially adopted by our Board on April 29, 2015 and approved by our shareholders at the 2015 Annual Meeting of shareholders. The 2018 Restatement was adopted by our Board on April 25, 2018 and approved by our shareholders at the 2018 Annual Meeting of Shareholders. The 2019 Restatement was adopted by our Board on April 25, 2019 and approved by our shareholders at the 2019 Annual Meeting of Shareholders. The 2020 Restatement was adopted by our Board on April 29, 2020 and approved by our shareholders at the 2020 Annual Meeting of Shareholders. The 2021 Restatement was adopted by our Board on April 26, 2021 and will become effective upon approval by our shareholders at the 2021 Annual Meeting. The Plan will remain available for the grant of awards until April 29, 2031.

Federal Income Tax Treatment

The following tax discussion is a general summary as of the date of this Proxy Statement of the U.S. federal income tax consequences to us and the participants in the Plan. The discussion is intended solely for general information and does not make specific representations to any participant. The discussion does not address state, local, or foreign income tax rules or other U.S. tax provisions, such as estate or gift taxes. A recipient’s particular situation may be such that some variation of the basic rules is applicable to him or her. In addition, the federal income tax laws and regulations frequently have been revised and may be changed again at any time. Therefore, each recipient is urged to consult a tax advisor before exercising any award or before disposing of any shares acquired under the Plan both with respect to federal income tax consequences as well as any foreign, state or local tax consequences.

Stock Options

ISOs and NQSOs are treated differently for federal income tax purposes. ISOs are intended to comply with the requirements of Section 422 of the Code. NQSOs need not comply with such requirements.

An optionee is not taxed on the grant or exercise of an ISO. The difference between the exercise price and the fair market value of the shares on the exercise date will, however, be a preference item for purposes of the alternative minimum tax. If an optionee holds the shares acquired upon exercise of an ISO until the later of two years following the option grant date and one year following exercise, the optionee’s gain, if any, upon a subsequent disposition of such shares is long term capital gain. The measure of the gain is the difference between the proceeds received on disposition and the optionee’s basis in the shares (which generally equals the exercise price). If an optionee disposes of stock acquired pursuant to exercise of an ISO before satisfying these holding periods, the optionee will recognize ordinary income in the year of disposition an amount equal to the excess of the fair market value of the shares at the time of exercise (or, if less, the amount realized on the disposition of the shares), over the exercise price paid for the shares, and capital gain or loss for any other difference between the sale price and the exercise price. Our company is not entitled to an income tax deduction on the grant or exercise of an ISO or on the optionee’s disposition of the shares after satisfying the holding period requirement described above. If the holding periods are not satisfied, we will be entitled to a deduction in the year the optionee disposes of the shares in an amount equal to the ordinary income recognized by the optionee.
In order for an option to qualify for ISO tax treatment, the grant of the option must satisfy various other conditions more fully described in the Code. We do not guarantee that any option will qualify for ISO tax treatment even if the option is intended to qualify for such treatment. In the event an option intended to be an ISO fails to so qualify, it will be taxed as an NQSO described below.

An optionee is not taxed on the grant of an NQSO. On exercise, the optionee recognizes ordinary income equal to the difference between the exercise price and the fair market value of the shares acquired on the date of exercise. Our company is entitled to an income tax deduction in the year of exercise in the amount recognized by the optionee as ordinary income. The optionee’s gain (or loss) on subsequent disposition of the shares is long-term capital gain (or loss) if the shares are held for at least one year following exercise, and otherwise is short-term capital gain (or loss). Our company does not receive a deduction for any such capital gain.

Stock Appreciation Rights

Generally, the recipient of a freestanding SAR will not recognize any taxable income at the time the freestanding SAR is granted. If the freestanding SAR is settled in cash, the cash will be taxable as ordinary income to the recipient at the time that it is received. If the freestanding SAR is settled in shares, the recipient will recognize ordinary income equal to the excess of the fair market value of the shares on the day they are received over any amounts paid by the recipient for the shares.

With respect to tandem SARs, if a holder elects to surrender the underlying option in exchange for cash or stock equal to the appreciation inherent in the underlying option, the tax consequences to the employee will be the same as discussed above relating to freestanding SARs. If the employee elects to exercise the underlying option, the holder will be taxed at the time of exercise as if they had exercised an NQSO (discussed above).

Our company generally is entitled to a deduction with respect to a SAR at the same time the recipient recognizes ordinary income with respect thereto.

Restricted Stock and Restricted Stock Units

Grantees of restricted stock or restricted stock units do not recognize income at the time of the grant. When the award vests or is paid, grantees generally recognize ordinary income in an amount equal to the fair market value of the stock or units at such time, and we will receive a corresponding deduction. Dividends (if any) paid with respect to unvested shares of restricted stock generally will be taxable as ordinary income to the participant at the time the dividends are received.

Subject to Section 162(m) of the Code, we generally will be entitled to a deduction with respect to restricted stock and restricted stock units at the same time the recipient recognizes ordinary income with respect thereto.

Stock Awards

Grantees of stock awards generally are required to recognize ordinary income in an amount equal to the excess of the fair market value of the shares on the date the shares are granted over the purchase price (if any) paid for the shares. Subject to Section 162(m) of the Code, we generally will be entitled to a deduction with respect to stock awards at the same time the recipient recognizes ordinary income with respect thereto.

Cash Incentive Awards

A participant will have taxable income at the time a cash incentive award is paid or, if the participant has timely elected deferral to a later date, such later date. At that time, the participant will recognize ordinary income equal to the value of the amount then payable and, subject to Section 162(m) of the Code, we will be entitled to a corresponding deduction.

Company Deduction and Section 162(m)

Our company generally will be entitled to a deduction for federal income tax purposes as described above with respect to each type of award. However, pursuant to the Tax Cuts and Jobs Act that was signed into law in December 2017, for taxable years beginning on or after January 1, 2018, the compensation deductible with respect to the Chief Executive Officer, the Chief Financial Officer, and the individuals serving as our officers at the end of such year who are among the three highest compensated executive officers [other than the Chief Executive Officer and Chief Financial Officer] for proxy reporting purposes, as well as for individuals who were proxy officers for any taxable year beginning after December 31, 2016, Section 162(m) limits the amount of compensation otherwise deductible by us and our subsidiaries for such year to $1,000,000. The “performance-based compensation” exception to this limitation generally is no longer applicable for awards granted after November 3, 2017 (but may be available for tax deductions for grants made on or prior to that date).
New Plan Benefits

The benefits that will be awarded or paid under the Plan are not currently determinable. Awards granted under the Plan are within the discretion of our Compensation Committee, and our Compensation Committee has not determined future awards or who might receive them. Information about awards granted in fiscal year 2020 under our prior plans to our Named Executive Officers can be found in the table under the heading Grants of Plan-Based Awards. As of March 17, 2021, the closing price of a share of our common stock on the Nasdaq was $171.17.

Securities Authorized for Issuance Under Equity Compensation Plans

The following table presents information as of December 31, 2020, regarding our securities authorized for issuance under equity compensation plans:

<table>
<thead>
<tr>
<th>Plan category</th>
<th>Number of securities to be issued upon exercise of outstanding options and restricted stock units [a][3]</th>
<th>Weighted average exercise price of outstanding options [b][4]</th>
<th>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column [a]) [c][5]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity compensation plan approved by security holders [1]</td>
<td>8,112,693</td>
<td>126.27</td>
<td>5,446,154</td>
</tr>
<tr>
<td>Equity compensation plans not approved by security holders [2]</td>
<td>8,029</td>
<td>—</td>
<td>79,383</td>
</tr>
<tr>
<td>Total</td>
<td>8,120,722</td>
<td>126.27</td>
<td>5,525,537</td>
</tr>
</tbody>
</table>

(1) All outstanding stock options were issued under our two equity incentive plans approved by security holders in 1999 [the 1999 Plan] and 2015 [the 2015 Plan]. The majority of outstanding restricted stock units (RSUs) were issued under the 2015 Plan. In addition, our employees have outstanding rights to purchase our common stock at a discount as part of our Employee Stock Purchase Plan (ESPP), which was approved by security holders in 2011. No further awards will be issued under the 1999 Plan. Information regarding these plans is contained in Note 8 — Share-Based Compensation to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

(2) We have one equity incentive plan, the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan (the 2019 Inducement Plan), that has not been approved by our shareholders, as permitted by the Nasdaq Stock Market rules. The 2019 Inducement Plan was approved by our Board of Directors in February 2019 and provides for the issuance of up to 99,000 shares of our common stock in the aggregate under awards granted to newly-hired employees. Currently, we grant only restricted stock units to newly-hired employees under the 2019 Inducement Plan. Information regarding this plan is contained in Note 8 — Share-Based Compensation to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

(3) Column (a) includes 7,680,194 shares of our common stock issuable upon the exercise of outstanding stock options issued under the 1999 Plan and 2015 Plan; 432,499 shares issuable upon the vesting of outstanding RSUs issued under the 2019 Inducement Plan. The 2015 Plan and 2019 Inducement Plan use a share counting formula for determining the number of shares available for issuance under the plans. In accordance with this formula, each option issued under the 2015 Plan counts as one share, while each RSU issued under the 2019 Inducement Plan counts as 1.35 shares and 2.14 shares, respectively. The number under column (a) represents the actual number of shares issuable under our outstanding awards without giving effect to the share counting formula.

(4) Column (b) represents the weighted average exercise price of the outstanding stock options only. The outstanding RSUs are not included in this calculation because they do not have an exercise price.

(5) Column (c) includes 79,383, 2,813,190, and 2,632,946 of shares available for future issuance under the 2019 Inducement Plan, the 2015 Plan, and the ESPP, respectively. Under the ESPP, employees may purchase shares based upon a 6-month offering period at an amount equal to the lesser of (1) 85 percent of the closing market price of the Common Stock on the first day of the offering period, or (2) 85 percent of the closing market price of the Common Stock on the last day of the offering period. Refer to Note 8 — Share-Based Compensation—Employee Stock Purchase Plan in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 for more information. The number under column (c) assumes that all 440,528 outstanding RSUs included in column (a) vest. Each RSU is only counted as one share in column (a) because only one share is issuable upon vesting. However, if any RSU does not vest, the number of shares available for future issuance will increase by 1.35 and 2.14, under the 2015 Plan and 2019 Plan, respectively, because of the share counting formula described in note (3) above.
Ratification of The Appointment of Ernst & Young LLP as United Therapeutics Corporation’s Independent Registered Public Accounting Firm for 2021

The Audit Committee of our Board has appointed Ernst & Young LLP (EY) as our independent registered public accounting firm for the year 2021. Services provided to us and our subsidiaries by EY in 2020 are described under the section entitled Principal Accountant Fees and Services below.

We ask that our shareholders vote to ratify the appointment of EY as our independent registered public accounting firm. Although ratification is not required by our bylaws or otherwise, our Board has chosen to submit the ratification of EY’s appointment to our shareholders as a matter of good corporate practice. In the event our shareholders do not ratify the appointment of EY, such appointment will be reconsidered by our Audit Committee and our Board. Following such reconsideration, our Audit Committee may still appoint EY if it determines doing so to be in the best interests of the company and our shareholders. Even if the appointment of EY is ratified, our Audit Committee, in its discretion, may select a different independent registered public accounting firm at any time during the year if it determines that such a change would be in our best interests and those of our shareholders.

The affirmative vote of the holders of a majority of the outstanding shares of common stock present, online or by proxy, at our Annual Meeting, and entitled to vote on the matter, is required for approval of this proposal. Abstentions have the same effect as an “against” vote. If you hold your shares through brokerage accounts, brokers will have the discretion to vote on this item in the absence of your instructions.

Representatives of EY are expected to be present at our Annual Meeting to respond to appropriate shareholder questions and to make such statements as they may desire.

Our Board of Directors recommends that you vote FOR the ratification of the appointment of EY as our independent registered public accounting firm for 2021.

Report of our Audit Committee

As the members of the Audit Committee, we oversee United Therapeutics’ financial reporting process on behalf of our Board of Directors. We are all independent directors under the applicable Nasdaq listing standards and the independence standards set forth in Rule 10A-3(b)(1) under the Exchange Act. Our Board has determined that Richard Giltner, our Audit Committee Chair, is an audit committee financial expert as defined under the rules and regulations of the SEC (based on the relevant experience described in his biography above) and that each member of our Audit Committee meets the financial sophistication requirement of the Nasdaq listing standards. Our Audit Committee operates under a written charter, which we review periodically, and which was adopted by our Board. Our charter is consistent with the provisions of the Sarbanes-Oxley Act of 2002, as well as the corporate governance rules issued by the SEC and Nasdaq, as they relate to audit committee requirements.

We have met and held discussions with management and our independent auditors regarding financial reporting. Management is responsible for the financial reporting process and preparation of United Therapeutics’ quarterly and annual consolidated financial statements, including maintaining a system of internal controls and disclosure controls and procedures. Our Audit Committee is directly responsible for the appointment, compensation, retention, oversight, and termination of our independent auditors. EY functioned as our independent auditors for 2019 and has served as our auditor since 2003. EY is responsible for expressing an opinion on [1] the conformity of our consolidated financial statements with generally accepted accounting principles; and [2] our internal control over financial reporting. Our Audit Committee does not prepare financial statements or conduct audits.

In conjunction with the December 31, 2020, audited consolidated financial statements, we have:

- reviewed and discussed United Therapeutics’ 2020 audited consolidated financial statements with our management and EY, including discussions about critical accounting policies, other financial accounting and reporting principles and practices appropriate for us, and the reasonableness of significant judgments
- reviewed and discussed management’s assessments of the effectiveness of internal controls over financial reporting and EY’s related assessments and auditing procedures
- discussed with EY the overall scope of and plans for our audits and reviews. Our Audit Committee has met with EY, with and without management present, to discuss our financial reporting processes and internal accounting controls. We have reviewed all important audit findings prepared by EY
Audit Matters

• discussed with EY matters that are required to be discussed by applicable Public Company Accounting Oversight Board (PCAOB) requirements. EY also provided to our Audit Committee the written disclosures and the letter required by applicable requirements of the PCAOB regarding its communications with our Audit Committee concerning independence. We also discussed with EY their independence, including any relationships that may have an impact on their objectivity and independence, and satisfied ourselves as to EY’s independence. We also reviewed and pre-approved the scope and fees for all audit and other services performed by EY for us.

• met and reviewed with members of senior management and EY the certifications provided by our Chairman and Chief Executive Officer and our Chief Financial Officer under the Sarbanes-Oxley Act of 2002 and the rules and regulations of the SEC relating to these certifications and the overall certification process.

Based on these reviews and discussions, our Audit Committee recommended to our Board of Directors that our audited consolidated financial statements for 2020 be included in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC.

Submitted by the Audit Committee:

RICHARD GILTNER (Chair)
CHRISTOPHER CAUSEY
JUDY OLIAN
CHRISTOPHER PATUSKY
TOMMY THOMPSON

Principal Accountant Fees and Services

Fees for professional services provided by EY in each of the last two years in each of the following categories were:

<table>
<thead>
<tr>
<th>Category</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Audit fees</td>
<td>$2,088,155</td>
<td>$2,076,749</td>
</tr>
<tr>
<td>Audit-related fees</td>
<td>19,142</td>
<td>—</td>
</tr>
</tbody>
</table>
| Tax fees:
  - Fees for tax compliance services    | 329,997       | 423,672       |
  - Fees for tax consulting services (including tax advice and tax planning) | 107,041       | 104,422       |
| Total tax fees                         | 437,038       | 528,094       |
| All other fees                         | 5,005         | 6,965         |
| **Total**                              | $2,549,340    | $2,611,808    |

Audit fees include the aggregate fees billed for the audit of our consolidated annual financial statements, reviews of our interim consolidated financial statements included in quarterly reports, accounting and financial reporting consultations and services in connection with registration statements. Audit-related fees include the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported as audit fees. Tax fees include the aggregate fees billed for professional services for tax compliance, tax advice and tax planning. All other fees included license fees for an accounting research online software tool.

The Audit Committee of our Board of Directors has considered and determined that the provision of non-audit services by EY is compatible with maintaining EY’s independence. Since EY’s appointment as our independent registered public accounting firm, our Audit Committee has pre-approved all of the services performed by EY.

Policy on Audit Committee Pre-Approval of Audit Services and Permissible Non-Audit Services of our Independent Auditors

Our Audit Committee’s policy is to pre-approve all audit and permissible non-audit services performed by our independent auditors. These services may include audit services, audit-related services, tax services, and other services. For audit services, our independent auditor provides an engagement letter to our Audit Committee prior to commencing its second quarter review work, which outlines the scope of the proposed audit and audit-related fees. Our Audit Committee reviews the letter and negotiates with and formally engages the auditor.

For non-audit services, our senior management may from time to time recommend to our Audit Committee that it engage our independent auditor to provide non-audit services, and request our Audit Committee to approve such engagement. Our senior management and our independent auditor will each confirm to our Audit Committee that each non-audit service is permissible under all applicable legal requirements. A budget estimating non-audit service spending for the fiscal year will be provided to our Audit Committee along with the request. Our Audit Committee must approve the permissible non-audit services and the budget for such services. The Audit Committee has delegated authority to the Audit Committee Chair to pre-approve Audit and permissible non-audit services below a certain threshold. Our Audit Committee will be informed periodically as to the non-audit services actually provided by our independent auditor pursuant to this pre-approval process.
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Review and Approval of Related Party Transactions

We have adopted a written policy for the review of transactions, arrangements and relationships between our company and our directors, director nominees, executive officers, greater than 5% shareholders, and their immediate family members where the amount involved exceeds $100,000. The policy requires our Audit Committee to review certain transactions subject to the policy and determine whether to approve or ratify those transactions. In doing so, our Audit Committee considers, among other things, whether the transaction is on terms that are no less favorable to our company than terms generally available to an unaffiliated third party under similar circumstances and the extent of the related person’s interest in the transaction. The policy also provides the Chair of our Audit Committee with the authority to approve or ratify transactions in which the amount involved is expected to be less than $500,000. Information on transactions approved or ratified by the Chair of our Audit Committee is provided to our Audit Committee at its next regularly scheduled meeting.

Our Audit Committee has considered and adopted standing pre-approvals under the policy for certain limited transactions with related persons that meet specific criteria. Information on transactions subject to pre-approval is provided to our Audit Committee at its next regularly scheduled meeting. Pre-approved transactions are limited to:

- executive officers’ compensation that is subject to required Proxy Statement disclosure or Compensation Committee approval
- non-employee director compensation that is subject to required Proxy Statement disclosure
- certain transactions with other companies and certain charitable contributions that do not exceed the greater of $200,000 or 5% of the other company’s or non-profit organization’s total annual revenues or receipts
- transactions where all shareholders receive proportional benefits

OTHER RELATIONSHIPS

From time to time, we employ family members of certain executive officers. During 2020, Dr. Rothblatt’s daughter, Jenesis Rothblatt, was employed as Project Leader, Corporate Telepresence & Robotics, and received total compensation valued at approximately $150,000.
Beneficial Ownership of Common Stock

The following table sets forth certain information as of April 10, 2021 (unless otherwise noted), with respect to the beneficial ownership of our common stock by: (1) each person or entity who we know beneficially owns more than 5% of the outstanding shares of our common stock; (2) each director and director nominee; (3) each of our Named Executive Officers (which, for 2020, included our Chairman and Chief Executive Officer, our Chief Financial Officer and Treasurer, our President and Chief Operating Officer and our Executive Vice President and General Counsel); and (4) all of our directors and executive officers as a group. Unless otherwise noted, the address of each person listed below is our co-headquarters address at 1040 Spring Street, Silver Spring, Maryland 20910. In accordance with SEC rules, the number of shares of common stock beneficially owned and the percentage of outstanding shares shown in this table exclude any STAP awards held by our directors and executive officers because they are cash settled awards that do not involve the issuance of shares of common stock.

<table>
<thead>
<tr>
<th>Name</th>
<th>Number of Shares of Common Stock Beneficially Owned</th>
<th>Percentage of Outstanding Shares</th>
<th>Vested STAP Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Beneficial Owners</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BlackRock, Inc. (4)</td>
<td>4,273,124</td>
<td>9.6 %</td>
<td>—</td>
</tr>
<tr>
<td>55 East 52nd Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York, NY 10055</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Vanguard Group (5)</td>
<td>3,964,001</td>
<td>8.9 %</td>
<td>—</td>
</tr>
<tr>
<td>100 Vanguard Boulevard</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malvern, PA 19355</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renaissance Technologies LLC (6)</td>
<td>3,607,291</td>
<td>8.1 %</td>
<td>—</td>
</tr>
<tr>
<td>800 Third Avenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York, NY 10022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avoro Capital Advisors LLC (7)</td>
<td>2,850,000</td>
<td>6.4 %</td>
<td>—</td>
</tr>
<tr>
<td>110 Greene Street, Suite 800</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York, NY 10012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FMR LLC (8)</td>
<td>2,322,683</td>
<td>5.2 %</td>
<td>—</td>
</tr>
<tr>
<td>245 Summer Street</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston, Massachusetts 02210</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Executive Officers, Directors and Nominees</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martine Rothblatt (9)</td>
<td>4,152,531</td>
<td>8.6 %</td>
<td>—</td>
</tr>
<tr>
<td>Paul Mahon (10)</td>
<td>570,361</td>
<td>1.3 %</td>
<td>163,750</td>
</tr>
<tr>
<td>Michael Benkowitz (11)</td>
<td>508,054</td>
<td>1.1 %</td>
<td>195,600</td>
</tr>
<tr>
<td>James Edgmond (12)</td>
<td>384,523</td>
<td>*</td>
<td>47,571</td>
</tr>
<tr>
<td>Tommy Thompson (13)</td>
<td>60,190</td>
<td>*</td>
<td>40,709</td>
</tr>
<tr>
<td>Katherine Klein (14)</td>
<td>55,080</td>
<td>*</td>
<td>29,375</td>
</tr>
<tr>
<td>Judy Olian (15)</td>
<td>45,410</td>
<td>*</td>
<td>—</td>
</tr>
<tr>
<td>Christopher Patusky (16)</td>
<td>43,270</td>
<td>*</td>
<td>27,000</td>
</tr>
<tr>
<td>Ray Kurzweil (17)</td>
<td>42,590</td>
<td>*</td>
<td>30,000</td>
</tr>
<tr>
<td>Christopher Causey (18)</td>
<td>41,885</td>
<td>*</td>
<td>—</td>
</tr>
<tr>
<td>Louis Sullivan (19)</td>
<td>39,850</td>
<td>*</td>
<td>30,000</td>
</tr>
<tr>
<td>Richard Giltner (20)</td>
<td>23,350</td>
<td>*</td>
<td>30,000</td>
</tr>
<tr>
<td>Nilda Mesa (21)</td>
<td>17,830</td>
<td>*</td>
<td>—</td>
</tr>
<tr>
<td>Raymond Dwek (22)</td>
<td>15,000</td>
<td>*</td>
<td>51,000</td>
</tr>
<tr>
<td>Linda Maxwell</td>
<td></td>
<td>*</td>
<td>—</td>
</tr>
<tr>
<td>All directors and executive officers as a group (15 persons) (23)</td>
<td>5,999,924</td>
<td>12.0 %</td>
<td>645,005</td>
</tr>
</tbody>
</table>

* Less than one percent.

(1) Beneficial ownership is determined in accordance with the rules of the SEC and generally includes ownership of those shares over which the person has sole or shared voting or investment power. Beneficial ownership also includes ownership of shares of our common stock subject to rights and options currently exercisable or convertible, or exercisable or convertible within 60 days after April 10, 2021. Except where indicated otherwise, and subject to community property laws where applicable, to our knowledge, the persons listed in the table above have sole voting and investment power with respect to their shares of our common stock.
Ownership percentage is based on 44,794,869 shares of our common stock outstanding on April 10, 2021, plus, as to the holder thereof and no other person, the number of shares [if any] that the person has the right to acquire as of April 10, 2021, or within 60 days thereafter, through the exercise of stock options or other similar rights.

Represents the number of outstanding, vested STAP awards on April 10, 2021. None of the individuals in the table above have STAP awards scheduled to vest within 60 days after April 10, 2021. Because STAP awards are cash settled and do not involve the issuance of shares of stock, they are excluded from the other columns of this table.

Beneficial ownership information obtained from a Schedule 13G/A filed by BlackRock, Inc. on February 1, 2021 reporting beneficial ownership as of December 31, 2020. According to the Schedule 13G/A, BlackRock, Inc. has sole voting power over 4,117,594 shares and sole investment power over 4,273,124 shares.

Beneficial ownership information obtained from a Schedule 13G/A filed by The Vanguard Group on February 10, 2021, reporting beneficial ownership as of December 31, 2020. According to the Schedule 13G/A, The Vanguard Group has shared voting power over 31,550 shares, sole investment power over 3,894,427 shares, and shared investment power over 69,574 shares.


Beneficial ownership information obtained from a Schedule 13G filed by Avoro Capital Advisors LLC [Avoro] and Behzad Aghazadeh, who serves as the portfolio manager and controlling person of Avoro, on February 12, 2021, reporting beneficial ownership as of December 31, 2020.

Beneficial ownership information obtained from a Schedule 13G/A filed by FMR LLC [FMR] and Abigail P. Johnson on February 8, 2021, reporting beneficial ownership as of December 31, 2020. According to the Schedule 13G/A, FMR has sole voting power over 227,162 shares and sole investment power over 2,322,683 shares, while Ms. Johnson has sole investment power over 2,322,683 shares. According to the Schedule 13G/A, neither FMR nor Ms. Johnson has sole power to vote or direct the voting of shares owned directly by various investment companies registered under the Investment Company Act advised by Fidelity Management & Research Company, a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds’ Board of Trustees.

Includes currently exercisable options held by Dr. Rothblatt to purchase 3,473,363 shares. Also includes 662,366 shares held indirectly by trust, 166 shares held by Dr. Rothblatt’s spouse and 16,496 shares held by charitable organizations, and over which Dr. Rothblatt has investment and voting power.

Includes currently exercisable options to purchase 533,992 shares.

Includes currently exercisable options to purchase 505,819 shares.

Includes currently exercisable options to purchase 383,294 shares.

Includes currently exercisable options to purchase 41,350 shares.

Includes currently exercisable options to purchase 55,080 shares.

Includes currently exercisable options to purchase 39,620 shares.

Includes currently exercisable options to purchase 39,670 shares. Also includes 1,300 shares held in a family trust with Mr. Patusky as trustee.

Includes currently exercisable options to purchase 35,050 shares.

Includes currently exercisable options to purchase 41,060 shares.

Includes currently exercisable options to purchase 30,430 shares.

Includes currently exercisable options to purchase 15,000 shares.

Includes currently exercisable options to purchase 12,870 shares.

Includes currently exercisable options to purchase 15,000 shares.

Includes currently exercisable options to purchase 5,221,598 shares.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our directors, officers and greater than 10% shareholders to file reports of ownership and changes in ownership of our equity securities with the SEC. We routinely assist our officers and directors in preparing and filing these reports. Based solely on a review of the copies of reports furnished to us and related written representations from reporting persons, we believe that for the fiscal year ended December 31, 2020, all reporting persons filed the required reports on a timely basis under Section 16(a), except that one Form 4 reporting the vesting of performance-based stock options for Dr. Rothblatt and Messrs. Edgemond, Benkowitz, and Mahon was filed late due to an administrative error.
Shareholder Proposals and Director Nominations

Proposals for Inclusion in the Proxy Statement for the 2022 Annual Meeting

Shareholder proposals intended for inclusion in our Proxy Statement and form of proxy for our 2022 Annual Meeting of Shareholders pursuant to Rule 14a-8 of the Exchange Act must be received by us at the address indicated below no later than 5:00 p.m. Eastern Time on January 7, 2022, unless the date of the 2022 Annual Meeting is more than 30 days before or after the anniversary of the Annual Meeting, in which case the deadline is a reasonable time before we begin to print and send our proxy materials. In addition, proposals must otherwise comply with the rules of the SEC for inclusion in our Proxy Statement and form of proxy relating to that meeting. The submission of a shareholder proposal does not guarantee that it will be included in our Proxy Statement and form of proxy.

Director Nominees for Inclusion in the Proxy Statement for the 2022 Annual Meeting

In 2015, we amended our bylaws to implement proxy access, which allows a shareholder or a group of up to 20 shareholders owning shares representing at least 3% of our outstanding voting stock entitled to vote in the election of directors continuously for at least three years, to nominate and include in our Proxy Statement their own director nominees constituting up to 20% of the total number of directors then serving on our Board (or up to 25% if fewer than 10 directors are then serving on our Board), provided that the shareholder(s) and the nominee(s) satisfy the requirements in our bylaws. Notice of director nominees submitted under these bylaw provisions must include the information required under our bylaws. Such notice must be received by our Corporate Secretary at the address indicated below no earlier than the close of business on December 8, 2021 and no later than the close of business on January 7, 2022 unless the date of the 2022 Annual Meeting is more than 30 days before or 45 days after the anniversary of the Annual Meeting, in which case such notice must be received by our Corporate Secretary no later than the close of business on the later of the 120th day prior to the 2022 Annual Meeting or the close of business on the tenth day following the day on which public announcement of the date of the 2022 Annual Meeting is first made.

Other Proposals or Nominees for Presentation at the 2022 Annual Meeting

In order for a shareholder to properly bring other business before the 2022 Annual Meeting of Shareholders, including shareholder proposals and director nominations that are not submitted for inclusion in our Proxy Statement, our bylaws require that the shareholder give timely notice of the proposal or nomination, as applicable, to our Corporate Secretary at the address indicated below in advance of the meeting. Such notice must be delivered to or mailed and received by no less than 90 days nor more than one hundred and 120 days prior to the anniversary of the Annual Meeting unless the date of the 2022 Annual Meeting is advanced by more than 30 days or delayed (other than as a result of adjournment) by more than 30 days from the anniversary of the Annual Meeting, in which case notice of a proposal or nomination, as applicable, must be delivered no later than the close of business on the later of the 90th day prior to the 2022 Annual Meeting or the tenth day following the date on which public announcement of the date of the 2022 Annual Meeting of Shareholders is first made. Accordingly, for the 2022 Annual Meeting, notice of a proposal or nomination, as applicable, must be received by our Corporate Secretary no later than March 27, 2022 and no earlier than February 25, 2022. In addition, the notice of such proposal or nomination must meet all other requirements contained in our bylaws. These requirements are separate from the requirements a shareholder must meet to have a proposal or director nomination included in our Proxy Statement. If a shareholder fails to meet these requirements or fails to satisfy the requirements of Rule 14a-4 under the Exchange Act, we may exercise discretionary voting authority under proxies that we solicit to vote on any such proposal or nomination in accordance with our best judgment.

All notices of proposals or nominations, as applicable, must be given in writing to our Corporate Secretary by overnight mail, acceptance signature required, to United Therapeutics Corporation, Attention: Corporate Secretary, 1735 Connecticut Avenue N.W., Washington, D.C. 20009.
Other Business

Management knows of no matters to be presented for action at the Annual Meeting other than as described above. However, if any other matter properly comes before the meeting, it is intended that the persons named in the accompanying form of proxy will vote on such matters in accordance with their judgment of the best interests of our company.

Shareholders Sharing the Same Address

SEC rules permit the delivery of a single copy of a company’s annual report and Proxy Statement, or Notice of Internet Availability, as applicable, to any household at which two or more shareholders reside. Each shareholder will continue to receive a separate proxy card. This procedure, referred to as householding, reduces the volume of duplicate information shareholders receive, reduces mailing and printing expenses, and benefits the environment.

The bank, broker, trust, or other holder of record for any shareholder who is a beneficial owner, but not the record holder, of United Therapeutics shares may deliver only one copy of our 2020 Annual Report on Form 10-K and this Proxy Statement, or one copy of the Notice of Internet Availability, as applicable, to multiple shareholders who share the same address, unless the bank, broker, trust, or other holder of record has received contrary instructions from one or more of the shareholders. Beneficial owners sharing an address who are receiving multiple copies of the 2020 Annual Report on Form 10-K and this Proxy Statement, or the Notice of Internet Availability, as applicable, and who would prefer to receive a single copy in the future should contact their bank, broker, trust, or other holder of record to request delivery of a single copy in the future.

Our 2020 Annual Report on Form 10-K and this Proxy Statement are available at our website at ir.unither.com/annual-and-proxy. We will deliver promptly upon written or oral request a separate copy of the 2020 Annual Report on Form 10-K and this Proxy Statement, or the Notice of Internet Availability, as applicable, to any shareholder of record at a shared address to which a single copy of any of those documents was delivered. To receive a separate copy of these materials, now or in the future, write to: Investor Relations, 1040 Spring Street, Silver Spring, Maryland 20910 or call (301) 608-9292 and ask for Investor Relations. Shareholders of record sharing an address who are receiving multiple copies of proxy materials and annual reports and wish to receive a single copy of such materials in the future should submit their request by contacting us in the same manner.

Annual Report

A copy of our Annual Report on Form 10-K for the year ended December 31, 2020, has been delivered or made available concurrently with this Proxy Statement to all shareholders entitled to notice of and to vote at our Annual Meeting. The Annual Report is not incorporated into this Proxy Statement and is not considered proxy soliciting material. Shareholders may obtain printed copies of our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC, without charge by mailing a request to United Therapeutics Corporation, Attention: Investor Relations, 1040 Spring Street, Silver Spring, Maryland 20910. Our copying costs will be charged if copies of exhibits to the Annual Report on Form 10-K are requested. An electronic copy is available on our website: ir.unither.com/annual-and-proxy.
INFORMATION ABOUT THE MEETING, VOTING, AND PROXIES

Attending the Annual Meeting

This year’s Annual Meeting will be held solely online as a virtual live audio webcast on Friday, June 25, 2021, beginning at 10:30 a.m. Eastern Time, and will be accessible through the Internet at virtualshareholdermeeting.com/UTHR2021. Our Board reached this decision after careful consideration and in light of the ongoing COVID-19 pandemic. A virtual format will enable shareholders to participate from any location and at no cost, while safeguarding the health of our shareholders, management, and Board. Information regarding how shareholders can attend the meeting, vote their shares, and submit questions are described below.

Admission. The Annual Meeting is limited to shareholders of United Therapeutics as of April 30, 2021 (the Record Date) or holders of a valid proxy for the Annual Meeting. In order to be admitted to the Annual Meeting online, you must enter the 16-digit control number provided in the Notice of Internet Availability, proxy card, or voting instruction form. To avoid any delay due to technical issues, we encourage shareholders to log in to the website and access the webcast 15 minutes before the virtual Annual Meeting’s start time. To attend the meeting online, vote your shares electronically, submit questions, go to virtualshareholdermeeting.com/UTHR2021. Our list of shareholders as of the Record Date will also be available for inspection for the ten days prior to the Annual Meeting. To inspect the list, please email our Investor Relations department at IR@unither.com.

Questions. The Annual Meeting will include a question and answer session, and you may submit appropriate questions before and live during the Annual Meeting. Questions may be submitted in advance at investorvote.com/uthr after logging in with your unique control number provided in your Notice. Questions may be submitted during the Annual Meeting through virtualshareholdermeeting.com/UTHR2021. We will post questions and answers on our website shortly after the Annual Meeting. We will address questions during the Q&A session portion of the Annual Meeting. We will try to answer as many stockholder-submitted questions that comply with the meeting rules of conduct as time permits. However, we reserve the right to edit profanity or other inappropriate language, or to exclude questions that are not pertinent to meeting matters or that are otherwise inappropriate. If we receive substantially similar questions, we will summarize such questions and provide a single response to avoid repetition.

Technical Support. For help with technical difficulties on the meeting day you can call (844) 986-0822 (U.S.) or (303) 562-9302 (International) for assistance. Technical support will be available starting at 10:00 a.m. Eastern Time and until the meeting has finished.

Future Meetings. Future Annual Meetings may be held virtually or in person in various locations, including without limitation locations where United Therapeutics has operations.

General

This Proxy Statement and the accompanying proxy card are being furnished to shareholders of United Therapeutics Corporation in connection with the solicitation by our Board of Directors of proxies to be voted at our 2021 Annual Meeting of Shareholders and any adjournment or postponement thereof. Proxy materials or a Notice of Internet Availability of Proxy Materials were first sent to shareholders on or about May 7, 2021.

Record Date and Outstanding Shares

On the Record Date, there were approximately 44,795,671 shares of our common stock outstanding and entitled to vote at our Annual Meeting. Only shareholders of record on the Record Date will be entitled to vote, either online or by proxy, at our Annual Meeting, and each share will have one vote for each director nominee and one vote for each other matter to be voted on.

Internet Availability of Proxy Materials

As permitted by the rules of the Securities and Exchange Commission, we are making our proxy materials available to shareholders primarily via the Internet, rather than mailing printed copies of these materials to shareholders. On or about May 7, 2020, we sent to many of our shareholders a Notice containing instructions on how to access and review our proxy materials, including our Proxy Statement and our 2020 Annual Report on Form 10-K, and vote online.

This process is designed to expedite shareholders’ receipt of proxy materials, lower the cost of the Annual Meeting, and help conserve natural resources. If you received a Notice by mail, you will not receive a printed copy of the proxy materials unless you request one. If you would prefer to receive printed proxy materials, please follow the instructions included in the Notice. Shareholders who requested paper copies of the proxy materials did not receive the Notice and will receive the proxy materials in the format requested.
Solicitation

We will bear the cost of soliciting proxies. Our directors, officers, and employees may solicit proxies in person or by telephone, fax, email, or regular mail, and they will receive no additional compensation for such work. Copies of solicitation materials may be furnished to brokers, custodians, nominees, and other fiduciaries for forwarding to beneficial owners of shares of our common stock, and normal handling charges may be paid for such forwarding service. We have also retained Georgeson Inc. to assist in soliciting proxies for a fee of approximately $12,000 plus customary expenses.

Voting Rights and Quorum

Shares can be voted at our Annual Meeting only by shareholders who are present online at our virtual Annual Meeting or represented by proxy. Whether or not you plan to attend our Annual Meeting online, you are encouraged to vote your shares. The representation online at the virtual Annual Meeting or by proxy of at least a majority of the outstanding shares entitled to vote is necessary to achieve a quorum for the transaction of business at the Annual Meeting.

If you are a shareholder of record (that is, you hold shares in your own name), you may revoke any proxy given pursuant to this solicitation at any time before it is exercised at the Annual Meeting by delivering to the Corporate Secretary of United Therapeutics Corporation at 1735 Connecticut Avenue N.W., Washington, D.C. 20009 a written notice of revocation or a fully executed proxy bearing a later date, voting online before the meeting at proxyvote.com at a date after the date of your previous proxy, or by attending the Annual Meeting and voting during the meeting at virtualshareholdermeeting.com/UTHR2021. See the section entitled Attending the Annual Meeting for information regarding how to attend the Annual Meeting online.

If you are a beneficial owner, your broker, bank, trust, or other nominee has the discretion to vote on routine corporate matters presented in the proxy materials without your specific voting instructions. Your broker, bank, trust, or other nominee does not have the discretion to vote on non-routine matters. Only Proposal No. 4 (ratification of the appointment of our independent registered public accounting firm) is considered a routine matter. Proposals No. 1, 2, and 3 are not considered routine matters, and without your specific voting instructions your shares will not be voted on these proposals.

Abstentions and “broker non votes” (i.e., shares held by brokers, banks, trusts, or other nominees that are represented at the meeting but with respect to which they have no discretionary power to vote on a particular matter and have received no instructions from the beneficial owners thereof) will be counted as present in determining whether the quorum requirement is satisfied.

Proxy

If the enclosed proxy card is properly executed and returned prior to the Annual Meeting, the shares represented by the proxy card will be voted in accordance with the shareholder’s directions. If the proxy card is signed and returned without any direction given, shares of our common stock represented by the proxy will be voted in accordance with our Board’s recommendations as follows: (1) FOR the election of each of the three director nominees named on the proxy card; (2) FOR the advisory resolution to approve executive compensation; (3) FOR the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan; and (4) FOR the ratification of the appointment of EY as our independent registered public accounting firm for 2021.
1. Purpose

The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and other service providers, in each case who are selected to be participants, by heightening the desire of such persons to continue working toward and contributing to the success and progress of the Company. This Plan amends and restates, effective June 25, 2021 (the “Effective Date”), the Amended and Restated United Therapeutics Corporation 2015 Stock Incentive Plan, which was approved by stockholders on June 26, 2020, and which amended and restated the United Therapeutics Corporation 2015 Stock Incentive Plan (the “Original 2015 Plan”). The Original 2015 Plan was approved by shareholders on June 26, 2015 (the “Original Effective Date”), and superseded the Company’s Amended and Restated Equity Incentive Plan (as amended effective as of September 24, 2004) (the “Prior Plan”). This Plan provides for the grant of Incentive and Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Stock Awards, any of which may be performance based, and for Incentive Bonuses, which may be paid in cash or stock or a combination thereof, as determined by the Administrator. No new awards were to be issued under the Prior Plan following the Original Effective Date, but outstanding awards under the Prior Plan as of the Original Effective Date shall continue to be governed by the Prior Plan. The Plan is hereby amended and restated effective as of the Effective Date to increase the number of Shares issuable pursuant to Awards.

2. Definitions

As used in the Plan, the following terms shall have the meanings set forth below:


(b) “Administrator” means the Administrator of the Plan in accordance with Section 19.

(c) “Affiliate” means, with respect to any entity, any other corporation, organization, association, partnership, sole proprietorship or other type of entity, whether incorporated or unincorporated, directly or indirectly controlling or controlled by or under direct or indirect common control with such entity.

(d) “Award” means an Incentive Stock Option, Nonqualified Stock Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Stock Award or Incentive Bonus granted to a Participant pursuant to the provisions of the Plan, any of which the Administrator may structure to qualify in whole or in part as a Performance Award.

(e) “Award Agreement” means a written agreement or other instrument as may be approved from time to time by the Administrator implementing the grant of each Award. An Agreement may be in the form of an agreement to be executed by both the Participant and the Company (or an authorized representative of the Company) or certificates, notices or similar instruments as approved by the Administrator.

(f) “Board” means the board of directors of the Company.

(g) “Cause” has the meaning specified in the Participant’s employment agreement (if any) or otherwise means (1) any act of personal dishonesty taken by the Participant in connection with their responsibilities as an employee or other service provider and intended to result in substantial personal enrichment of the Participant; (2) the Participant’s conviction of a felony; (3) an act by the Participant which constitutes willful or gross misconduct and which is demonstrably and materially injurious to the Company; or (4) continued substantial willful violations by the Participant of the Participant’s duties after there has been delivered to the Participant a written demand for performance from the Company which specifically sets forth the factual basis for the Company’s belief that the Participant has not substantially performed their duties.

(h) “Change in Control” means, and shall be deemed to have occurred:

(1) if any person or group (as used in Section 13(d) of the Act) (other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company, or any company owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Act) of securities of the Company representing more than 30% of [a] the Shares then outstanding or [b] the combined voting power [other than in the election of directors] of all voting securities of the Company then outstanding; or
if, during any period of 24 consecutive months, individuals who at the beginning of such period constituted the Board, and any
director whose election or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds
(2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination
for election was previously so approved [the “Incumbent Board”], cease for any reason (other than death or disability) to
constitute at least a majority thereof; or

upon the consummation of a reorganization, merger, statutory share exchange or consolidation or similar transaction involving
the Company or any of its subsidiaries unless, following such event, (A) all or substantially all of the individuals and entities that
were the beneficial owners of the Company’s common stock or the combined voting power of all voting securities of the Company
immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the then outstanding shares of
common stock [or, for a non-corporate entity, equivalent securities] and the combined voting power of the then-outstanding
voting securities entitled to vote generally in the election of directors [or, for a non-corporate entity, equivalent governing body],
as the case may be, of the entity resulting from such transaction [including, without limitation, an entity that, as a result of such
transaction, owns the Company either directly or through one or more subsidiaries] in substantially the same proportions as
their ownership immediately prior to such transaction of the Company’s common stock or voting securities, as the case may be,
(B) no person [excluding any corporation resulting from such transaction or any employee benefit plan (or related trust) of the
Company or such corporation resulting from such transaction] beneficially owns, directly or indirectly, 30% or more of,
respectively, the then-outstanding shares of common stock of the corporation resulting from such transaction or the combined
voting power of the then-outstanding voting securities of such corporation, except to the extent that such ownership existed prior
to the transaction, and (C) at least a majority of the members of the board of directors [or, for a non-corporate entity, equivalent
governing body] of the entity resulting from such transaction were members of the Incumbent Board at the time of the execution
of the initial agreement or of the action of the Board providing for such transaction; or

upon the complete liquidation of the Company or the sale or disposition by the Company of all or substantially all of the
Company's assets, other than a liquidation of the Company into a wholly-owned subsidiary.

"Code" means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.
"Company” means United Therapeutics Corporation.
"Disability" means, in the Company’s reasonable judgment, either (a) the Participant has been unable to perform the Participant’s
duties because of a physical or mental impairment for 80% or more of the normal working days during six consecutive calendar
months or 50% or more of the normal working days during twelve consecutive calendar months, or (b) the Participant has become
totally and permanently incapable of performing the usual duties of their employment with the Company on account of a physical or
mental impairment.
"Fair Market Value" means, as of any date, the closing price of a Share on the principal exchange on which Shares are then trading, if
any [or as reported on any composite index which includes such principal exchange]. If Shares are not traded as of a particular date,
the Fair Market Value of a Share as of such date shall be the closing price on the preceding trading date. If Shares not publicly traded
on an exchange and not quoted on Nasdaq or a successor quotation system, the Fair Market Value of a Share shall be established by
the Administrator in good faith.
"Incentive Bonus" means a bonus opportunity awarded under Section 10 pursuant to which a Participant may become entitled to
receive an amount based on satisfaction of such performance criteria as are specified in the Award Agreement or otherwise.
"Incentive Stock Option" means a stock option that is intended to qualify as an “incentive stock option” within the meaning of
Section 422 of the Code.
"Nonemployee Director” means each person who is, or is elected to be, a member of the Board and who is not an employee of the
Company or any Subsidiary.
"Nonqualified Stock Option” means a stock option that is not intended to qualify as an “incentive stock option” within the meaning of
Section 422 of the Code.
"Option” means an Incentive Stock Option and/or a Nonqualified Stock Option granted pursuant to Section 6 of the Plan.
"Participant” means any individual described in Section 3 to whom Awards have been granted from time to time by the Administrator
and any authorized transferee of such individual.
"Person” has the same meaning as set forth in Sections 13(d) and 14(d)(2) of the Act.
"Performance Award” means an Award, the grant, issuance, retention, vesting or settlement of which is subject to satisfaction of one
or more Qualifying Performance Criteria established pursuant to Section 14.
"Plan” means the 2015 United Therapeutics Corporation Stock Incentive Plan as set forth herein and as amended from time to time.
"Qualifying Performance Criteria” has the meaning set forth in Section 14(b).
"Restricted Stock” means Shares granted pursuant to Section 8 of the Plan.
"Restricted Stock Unit” means an Award granted to a Participant pursuant to Section 8 pursuant to which Shares or cash in lieu
thereof may be issued in the future.
“Share” means a share of the Company’s par value common stock, subject to adjustment as provided in Section 13.
"Stock Appreciation Right" means a right granted pursuant to Section 7 of the Plan that entitles the Participant to receive, in cash or Shares or a combination thereof, as determined by the Administrator, value equal to or otherwise based on the excess of (i) the Fair Market Value of a specified number of Shares at the time of exercise over (ii) the exercise price of the right, as established by the Administrator on the date of grant.

"Stock Award" means an award of Shares to a Participant pursuant to Section 9 of the Plan.

"Substitute Awards" means Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines.

"Subsidiary" means any corporation (other than the Company), limited liability company or other form of entity in an unbroken chain of entities beginning with the Company where each of the entities in the unbroken chain other than the last entity owns stock possessing at least 50 percent or more of the total combined voting power of all classes of stock in one of the other entities in the chain, and if specifically determined by the Administrator in the context other than with respect to Incentive Stock Options, may include an entity in which the Company has a significant ownership interest or that is directly or indirectly controlled by the Company.

"Termination of Employment" means ceasing to serve as an employee of the Company and its Subsidiaries or, with respect to a Nonemployee Director or other non-employee service provider, ceasing to serve as such for the Company, except that with respect to all or any Awards held by a Participant (i) the Administrator may determine that a transition of employment to service with a partnership, joint venture or corporation not meeting the requirements of a Subsidiary in which the Company or a Subsidiary is a party is not considered a Termination of Employment, (ii) unless otherwise determined by the Administrator, service as a member of the Board or other service provider shall not be deemed to constitute continued employment with respect to Awards granted to a Participant while they served as an employee, (iii) service as an employee of the Company or a Subsidiary shall constitute continued employment with respect to Awards granted to a Participant while they served as a member of the Board or other service provider, and (iv) the Administrator may determine that an approved leave of absence or approved employment on a less than full-time basis is considered a Termination of Employment. The Administrator shall determine whether any corporate transaction, such as a sale or spin-off of a division or subsidiary that employs a Participant, shall be deemed to result in a Termination of Employment with the Company and its Subsidiaries for purposes of any affected Participant’s Awards, and the Administrator’s decision shall be final and binding.

3. Eligibility

Any person who is a current or prospective officer or employee of the Company or of any Subsidiary shall be eligible for selection by the Administrator for the grant of Awards hereunder. In addition, Nonemployee Directors and any other service providers who have been retained to provide consulting, advisory or other services to the Company or to any Subsidiary shall be eligible for the grant of Awards hereunder as determined by the Administrator. Options intended to qualify as Incentive Stock Options may only be granted to employees of the Company or any Subsidiary, as selected by the Administrator.

4. Effective Date and Termination of Plan

The Original 2015 Plan was adopted by the Board as of April 29, 2015 and approved by shareholders on the Original Effective Date. This Plan hereby amends and restates the Plan as previously amended and restated effective as of June 26, 2020 as of the Effective Date. All Awards granted under this Plan in excess of the aggregate limitation approved by shareholders at the 2020 annual meeting of shareholders are subject to, and may not be exercised before, the approval of this Plan by the shareholders prior to the first anniversary of the date the Board adopts the Plan, by the affirmative vote of the holders of a majority of the outstanding Shares of the Company present, or represented by proxy, and entitled to vote, at a meeting of the Company's shareholders or by written consent in accordance with the laws of the State of Delaware; provided that if such approval by the shareholders of the Company is not forthcoming, all Awards previously granted under this Plan in excess of the aggregate limitation approved by shareholders at the 2020 annual meeting of shareholders shall be void. The Plan shall remain available for the grant of Awards until April 29, 2031. Notwithstanding the foregoing, the Plan may be terminated at such earlier time as the Board may determine. Termination of the Plan will not affect the rights and obligations of the Participants and the Company arising under Awards theretofore granted and then in effect.

5. Shares Subject to the Plan and to Awards

(a) Aggregate Limits. The aggregate number of Shares issuable pursuant to all Awards shall not exceed 11,000,000; provided that (i) any Shares granted under Options or Stock Appreciation Rights shall be counted against this limit on a one-for-one basis, and (ii) any Shares granted prior to March 17, 2020, as Awards other than Options or Stock Appreciation Rights shall be counted against this limit as 2.14 Shares for every one [1] Share subject to such Award and [ii] any Shares granted on or after March 17, 2020, as Awards other than Options or Stock Appreciation Rights shall be counted against this limit as 1.35 Shares for every one [1] Share subject to such Award. The aggregate number of Shares available for grant under this Plan and the number of Shares subject to outstanding Awards shall be subject to adjustment as provided in Section 13. The Shares issued pursuant to Awards granted under this Plan may be shares that are authorized and unissued or shares that were reacquired by the Company, including shares purchased in the open market.
Issuance of Shares. For purposes of Section 5(a), the aggregate number of Shares issued under this Plan at any time shall equal only the number of Shares actually issued upon exercise or settlement of an Award. Notwithstanding the foregoing, Shares subject to an Award under the Plan may not again be made available for issuance under the Plan if such Shares are: (i) Shares that were subject to a stock-settled Stock Appreciation Right and were not issued upon the net settlement or net exercise of such Stock Appreciation Right, (ii) Shares used to pay the exercise price of an Option, (iii) Shares delivered to or withheld by the Company to pay the withholding taxes related to an Award, or (iv) Shares repurchased on the open market with the proceeds of an Option exercise. Shares subject to Awards that have been canceled, expired, forfeited or otherwise not issued under an Award and Shares subject to Awards settled in cash shall not count as Shares issued under this Plan. Any Shares that were subject to Options or Stock Appreciation Rights and that again become available for Awards under the Plan pursuant to this Section shall be added as one (1) Share for every one (1) Share subject to such Options or Stock Appreciation Rights. Any Shares that were subject to Awards other than Options or Stock Appreciation Rights that again become available for Awards under the Plan pursuant to this Section shall be added as 2.14 Shares for every one (1) Share subject to such Awards and (ii) from and after March 17, 2020, be added as 1.35 Shares for every one (1) Share subject to such Awards.

Individual and Tax Code Limits. The aggregate number of Shares subject to Awards granted under this Plan during any calendar year to any one Participant shall not exceed 1,000,000, which number shall be calculated and adjusted pursuant to Section 13, but which number shall not count any tandem SARs (as defined in Section 7). The aggregate number of Shares that may be issued pursuant to the exercise of Incentive Stock Options granted under this Plan shall not exceed 11,000,000, which number shall be calculated and adjusted pursuant to Section 13 only to the extent that such calculation or adjustment will not affect the status of any option intended to qualify as an Incentive Stock Option under Section 422 of the Code. The maximum cash amount payable pursuant to that portion of an Incentive Bonus granted in any calendar year to any Participant under this Plan shall not exceed $5,000,000.

Director Awards.

(1) The aggregate dollar value of Awards (based on the aggregate accounting value on the date of grant) granted pursuant to this Plan during any calendar year to any Nonemployee Director shall not exceed $400,000 for annual equity grants (plus, for the year an individual first becomes a Nonemployee Director (x) an initial equity grant valued at $400,000, plus (y) a pro-rata portion of the $400,000 annual equity-based award value based on the number of months remaining in the Board service year at the date of grant), payable in Options, Restricted Stock Units, or a split evenly between Options and Restricted Stock Units, based on an election by the Nonemployee Director. Such dollar limits shall be converted into a number of Awards as follows:

(A) Options: The number of Options shall be calculated by dividing the equity value (e.g., $400,000) by the fair value of each Option, calculated in accordance with the Black-Scholes methodology utilized by the Company in calculating share-based compensation for financial reporting purposes. Black-Scholes inputs shall be the same as those used in the Company’s most recent quarterly report on Form 10-Q or Annual Report on Form 10-K, except that the Share price input shall be the average closing price of the Shares over a recent time period prior to the date of grant (May 10 through June 10, in the case of annual grants made in June).

(B) Restricted Stock Units: The number of Restricted Stock Units shall be calculated by dividing the equity value (e.g., $400,000) by the average closing price of the Shares over a recent time period prior to the date of grant (May 10 through June 10, in the case of annual grants paid in June).

(C) Rounding: The resulting number of Options and/or Restricted Stock Units, calculated as above, shall be rounded to the nearest 10 Shares.

(2) In addition, the amount of cash compensation paid or payable by the Company to a Nonemployee Director with respect to any calendar year shall not exceed $60,000 (with additional cash compensation of $35,000 for the lead independent director, $25,000 for each committee chair, and $15,000 for each other committee membership), plus a prorated portion of the aggregate cash compensation for the roles in which the Nonemployee Director serves for the year an individual first becomes a Nonemployee Director, to reflect the number of months then remaining in the Board service year as of the date the individual becomes a Nonemployee Director. For the avoidance of doubt, cash compensation shall be counted towards the limit specified in this subclause in the year earned (regardless of whether deferred), and any interest or other earnings on such compensation shall not count towards the limit.

Substitute Awards. Substitute Awards shall not reduce the Shares authorized for issuance under the Plan or authorized for grant to a Participant in any calendar year. Additionally, in the event that a company acquired by the Company or any Subsidiary, or with which the Company or any Subsidiary combines, has shares available under a pre-existing plan approved by shareholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for issuance under the Plan; provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were employees, directors or other service providers of such acquired or combined company before such acquisition or combination.
6. Options

(a) Option Awards. Options may be granted at any time and from time to time prior to the termination of the Plan to Participants as determined by the Administrator. No Participant shall have any rights as a shareholder with respect to any Shares subject to Options hereunder until said Shares have been issued, including, for avoidance of doubt, no voting rights and no rights to receive dividends, distributions or dividend equivalents in respect of an Option or any Shares subject to an Option until the Participant has become the holder of record of such Shares. Each Option shall be evidenced by an Award Agreement. Options granted pursuant to the Plan need not be identical but each Option must contain and be subject to the terms and conditions set forth below.

(b) Price. The Administrator will establish the exercise price per Share under each Option, which, in no event will be less than the Fair Market Value of the Shares on the date of grant; provided, however, that the exercise price per Share with respect to an Option that is granted in connection with a merger or other acquisition as a substitute or replacement award for options held by optionees of the acquired entity may be less than 100% of the Fair Market Value of the Shares on the date such Option is granted if such exercise price is based on a formula set forth in the terms of the options held by such optionees or in the terms of the agreement providing for such merger or other acquisition. The exercise price of any Option may be paid in Shares, cash or a combination thereof, as determined by the Administrator, including an irrevocable commitment by a broker to pay over such amount from a sale of the Shares issuable under an Option, the delivery of previously owned Shares and withholding of Shares deliverable upon exercise, or in such other form as is acceptable to the Administrator.

(c) Provisions Applicable to Options. The date on which Options become exercisable shall be determined at the sole and absolute discretion of the Administrator and set forth in an Award Agreement. However, in no event shall any Option vest before the first anniversary of the date of grant; provided that, if so determined by the Committee, an Option may fully or partially vest before such anniversary in the event of the Participant’s death or disability or a Change in Control. Unless otherwise determined by the Administrator, an approved leave of absence or employment on a less than full-time basis shall not result in an adjustment to the vesting period and/or exercisability of an Option to reflect the effects of any period during which the Participant is on an approved leave of absence or is employed on a less than full-time basis. In no event may any Option include a reload feature.

(d) Term of Options and Termination of Employment: The Administrator shall establish the term of each Option, which in no case shall exceed a period of ten (10) years from the date of grant. Unless an Option earlier expires upon the expiration date established pursuant to the foregoing sentence, upon the Participant’s Termination of Employment, their rights to exercise an Option then held shall be only as follows, unless the Administrator specifies otherwise:

1. General. If a Participant’s Termination of Employment is for any reason other than the Participant’s death, Disability, or termination for Cause, Options granted to the Participant may continue to be exercised in accordance with their terms for a period of ninety (90) days after such Termination of Employment, but only to the extent the Participant was entitled to exercise the Options on the date of such termination.

2. Death. If a Participant dies either while an employee or officer of the Company or a Subsidiary or member of the Board, or after the Termination of Employment other than for Cause but during the time when the Participant could have exercised an Option, the Options issued to such Participant shall become fully vested and exercisable by the personal representative of such Participant or other successor to the interest of the Participant for one year after the Participant’s death.

3. Disability. If a Participant’s Termination of Employment is due to Disability, then all of the Participant’s Options shall immediately vest, and the Options held by the Participant at the time of such Termination of Employment shall be exercisable by the Participant or the personal representative of such Participant for one year following such Termination of Employment.

4. Termination for Cause. If a Participant is terminated for Cause, the Participant shall have no further right to exercise any Options previously granted. The Administrator or one or more officers designated by the Administrator shall determine whether a termination is for Cause.

(e) Incentive Stock Options. Notwithstanding anything to the contrary in this Section 6, in the case of the grant of an Option intending to qualify as an Incentive Stock Option: (i) if the Participant owns stock possessing more than 10 percent of the combined voting power of all classes of stock of the Company, the exercise price of such Option must be at least 110 percent of the Fair Market Value of the Shares on the date of grant and the Option must expire within a period of not more than five (5) years from the date of grant, and (ii) Termination of Employment will occur when the person to whom an Award was granted ceases to be an employee (as determined in accordance with Section 3401(c) of the Code and the regulations promulgated thereunder) of the Company and its corporate Subsidiaries. Notwithstanding anything in this Section 6 to the contrary, options designated as Incentive Stock Options shall not be eligible for treatment under the Code as Incentive Stock Options and will be deemed to be Nonqualified Stock Options to the extent that either (a) the aggregate Fair Market Value of Shares (determined as of the time of grant) with respect to which such Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any corporate Subsidiary) exceeds $100,000, taking Options into account in the order in which they were granted, or (b) such Options otherwise remain exercisable but are not exercised within three (3) months of Termination of Employment (or such other period of time provided in Section 422 of the Code).
7. Stock Appreciation Rights

Stock Appreciation Rights may be granted to Participants from time to time either in tandem with or as a component of other Awards granted under the Plan (“tandem SARs”) or not in conjunction with other Awards (“freestanding SARs”) and may, but need not, relate to a specific Option granted under Section 6. The provisions of Stock Appreciation Rights need not be the same with respect to each grant or each recipient. Any Stock Appreciation Right granted in tandem with an Award may be granted at the same time such Award is granted or at any time thereafter before exercise or expiration of such Award. All freestanding SARs shall be granted subject to the same terms and conditions applicable to Options as set forth in Section 6 (including, without limitation, the vesting provisions of Section 6(c)) and all tandem SARs shall have the same exercise price, vesting, exercisability, forfeiture and termination provisions as the Award to which they relate. Subject to the provisions of Section 6 and the immediately preceding sentence, the Administrator may impose such other conditions or restrictions on any Stock Appreciation Right as it shall deem appropriate. Participants shall have no voting rights and will have no rights to receive dividends, distributions or dividend equivalents in respect of Stock Appreciation Rights or any Shares subject to Stock Appreciation Rights until the Participant has become the holder of record of such Shares. Stock Appreciation Rights may be settled in Shares, cash or a combination thereof, as determined by the Administrator and set forth in the applicable Award Agreement.

8. Restricted Stock and Restricted Stock Units

(a) Restricted Stock and Restricted Stock Unit Awards. Restricted Stock and Restricted Stock Units may be granted at any time and from time to time prior to the termination of the Plan to Participants as determined by the Administrator. Restricted Stock is an award or issuance of Shares the grant, issuance, retention, vesting and/or transferability of which is subject during specified periods of time to such conditions (including continued employment or performance conditions) and terms as the Administrator deems appropriate. Restricted Stock Units are Awards denominated in units of Shares under which the issuance of Shares is subject to such conditions (including continued employment or performance conditions) and terms as the Administrator deems appropriate. Each grant of Restricted Stock and Restricted Stock Units shall be evidenced by an Award Agreement. Unless determined otherwise by the Administrator, each Restricted Stock Unit will be equal to one Share and will entitle a Participant to either the issuance of Shares or payment of an amount of cash determined with reference to the value of Shares. To the extent determined by the Administrator, Restricted Stock and Restricted Stock Units may be satisfied or settled in Shares, cash or a combination thereof. Restricted Stock and Restricted Stock Units granted pursuant to the Plan need not be identical but each grant of Restricted Stock and Restricted Stock Units must contain and be subject to the terms and conditions set forth below.

(b) Contents of Agreement. Each Award Agreement shall contain provisions regarding (i) the number of Shares or Restricted Stock Units subject to such Award or a formula for determining such number, (ii) the purchase price of the Shares, if any, and the means of payment, (iii) the performance criteria, if any, and level of achievement versus these criteria that shall determine the number of Shares or Restricted Stock Units granted, issued, retailable and/or vested, (iv) such terms and conditions on the grant, issuance, vesting and/or forfeiture of the Shares or Restricted Stock Units as may be determined from time to time by the Administrator, (v) the term of the performance period, if any, as to which performance will be measured for determining the number of such Shares or Restricted Stock Units, and (vi) restrictions on the transferability of the Shares or Restricted Stock Units. Shares issued under a Restricted Stock Award may be issued in the name of the Participant and held by the Participant or held by the Company, in each case as the Administrator may provide.

(c) Vesting and Performance Criteria. The grant, issuance, retention, vesting and/or settlement of shares of Restricted Stock and Restricted Stock Units will occur when and in such installments as the Administrator determines or under criteria the Administrator establishes, which may include Qualifying Performance Criteria. However, in no event shall any shares of Restricted Stock or Restricted Stock Units vest before the first anniversary of the date of grant; provided that, if so determined by the Committee, shares of Restricted Stock and Restricted Stock Units may fully or partially vest before such anniversary in the event of the Participant’s death or disability or a Change in Control.

(d) Termination of Employment. Unless the Administrator provides otherwise:

(i) General. In the event of Termination of Employment for any reason other than death or Disability, any Restricted Stock or Restricted Stock Units still subject in full or in part to restrictions at the date of such Termination of Employment shall automatically be forfeited and returned to the Company.

(ii) Death or Disability. In the event a Participant’s Termination of Employment is because of death or Disability, the restrictions remaining on any or all Shares remaining subject to a Restricted Stock or Restricted Stock Unit Award shall lapse.

(e) Voting Rights. Unless otherwise determined by the Administrator, Participants holding shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those shares during the period of restriction. Participants shall have no voting rights with respect to Shares underlying Restricted Stock Units unless and until such Shares are reflected as issued and outstanding shares on the Company’s stock ledger.
Dividends and Distributions. Participants in whose name Restricted Stock is granted shall be entitled to receive all dividends and other distributions paid with respect to those Shares, unless determined otherwise by the Administrator. The Administrator will determine whether any such dividends or distributions will be automatically reinvested in additional shares ofRestricted Stock and subject to the same restrictions on transferability as the Restricted Stock with respect to which they were distributed or whether such dividends or distributions will be paid in cash. Shares underlying Restricted Stock Units shall be entitled to dividends or dividend equivalents only to the extent provided by the Administrator. Notwithstanding anything herein to the contrary, in no event shall dividends, distributions or dividend equivalents be currently payable with respect to unvested or unearned Restricted Stock and Restricted Stock Unit awards.

Payment of Restricted Stock Units. In all events, unless payment with respect to a Restricted Stock Unit is deferred in a manner consistent with Section 409A of the Code, the Shares and/or cash underlying such Restricted Stock Unit shall be paid to the Participant no later than two and one-half months following the end of the year in which the Restricted Stock Unit is no longer subject to a substantial risk of forfeiture.

Legend of Restricted Stock. The Administrator may also require that certificates representing shares of Restricted Stock be retained and held in escrow by a designated employee or agent of the Company or any Subsidiary until any restrictions applicable to shares of Restricted Stock so retained have been satisfied or lapsed. Any certificates evidencing shares of Restricted Stock awarded pursuant to the Plan shall bear the following legend:

The shares represented by this certificate were issued subject to certain restrictions under the United Therapeutics Corporation 2015 Stock Incentive Plan (the “Plan”). This certificate is held subject to the terms and conditions contained in a restricted stock agreement that includes a prohibition against the sale or transfer of the stock represented by this certificate except in compliance with that agreement and that provides for forfeiture upon certain events. Copies of the Plan and the restricted stock agreement are on file in the office of the Secretary of the Company.

9. Stock Awards

(a) Grant. Stock Awards may be granted at any time and from time to time prior to the termination of the Plan to Participants as determined by the Administrator. Stock Awards shall be subject to such terms and conditions, consistent with the other provisions of the Plan, as may be determined by the Administrator. However, in no event shall any Stock Award vest before the first anniversary of the date of grant; provided that, if so determined by the Committee, a Stock Award may fully or partially vest before such anniversary in the event of the Participant’s death or disability or a Change in Control.

(b) Rights as a Shareholder. A Participant shall have all voting, dividend, liquidation and other rights with respect to Shares issued to the Participant as a Stock Award under this Section 9 upon the Participant becoming the holder of record of the Shares granted pursuant to such Stock Award; provided, that, the Administrator may impose such restrictions on the assignment or transfer of Shares awarded pursuant to a Stock Award as it considers appropriate. Notwithstanding anything herein to the contrary, in no event shall dividends, distributions or dividend equivalents be currently payable with respect to unvested or unearned Stock Awards.

10. Incentive Bonuses

(a) General. Each Incentive Bonus Award will confer upon the Participant the opportunity to earn a future payment tied to the level of achievement with respect to one or more performance criteria established for a performance period of not less than one year.

(b) Incentive Bonus Document. Unless otherwise determined by the Administrator, the terms of any Incentive Bonus will be set forth in an Award Agreement. Each Award Agreement evidencing an Incentive Bonus shall contain provisions regarding (i) the target and maximum amount payable to the Participant as an Incentive Bonus, (ii) the performance criteria and level of achievement versus these criteria that shall determine the amount of such payment, (iii) the term of the performance period as to which performance shall be measured for determining the amount of any payment, (iv) the timing of any payment earned by virtue of performance, (v) restrictions on the alienation or transfer of the Incentive Bonus prior to actual payment, (vi) forfeiture provisions and (vii) such further terms and conditions, in each case not inconsistent with this Plan as may be determined from time to time by the Administrator.

(c) Performance Criteria. The Administrator shall establish the performance criteria and level of achievement versus these criteria that shall determine the target and maximum amount payable under an Incentive Bonus, which criteria may be based on financial performance and/or personal performance evaluations.

(d) Timing and Form of Payment. The Administrator shall determine the timing of payment of any Incentive Bonus. Payment of the amount due under an Incentive Bonus may be made in cash or in Shares, as determined by the Administrator. No Participant shall have any rights as a shareholder with respect to any Shares payable in respect of an Incentive Bonus until said Shares have been issued, including, for avoidance of doubt, no voting rights and no rights to receive dividends, distributions or dividend equivalents in respect of an Incentive Bonus or any Shares subject to an Incentive Bonus until the Participant has become the holder of record of such Shares. The Administrator may provide for or, subject to such terms and conditions as the Administrator may specify, may permit a Participant to elect for the payment of any Incentive Bonus to be deferred to a specified date or event. In all events, unless payment of an Incentive Bonus is deferred in a manner consistent with Section 409A of the Code, any Incentive Bonus shall be paid to the Participant no later than two and one-half months following the end of the year in which the Incentive Bonus is no longer subject to a substantial risk of forfeiture.
Discretionary Adjustments. Notwithstanding satisfaction of any performance goals, the amount paid under an Incentive Bonus on account of either financial performance or personal performance evaluations may, to the extent specified in the Award Agreement or other document evidencing the Award, be adjusted by the Administrator on the basis of such further considerations as the Administrator shall determine.

11. Deferral of Awards

The Administrator may, in an Award Agreement or otherwise, provide for the deferred delivery of Shares upon settlement, vesting or other events with respect to Restricted Stock or Restricted Stock Units, or in payment or satisfaction of an Incentive Bonus. Notwithstanding anything herein to the contrary, in no event will any deferral of the delivery of Shares or any other payment with respect to any Award be allowed if the Administrator determines, in its sole and absolute discretion, that the deferral would result in the imposition of the additional tax under Section 409A(a)(1)(B) of the Code. No award shall provide for deferral of compensation that does not comply with Section 409A of the Code, unless the Board, at the time of grant, specifically provides that the Award is not intended to comply with Section 409A of the Code. The Company shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not so exempt or compliant or for any action taken by the Board.

12. Conditions and Restrictions Upon Securities Subject to Awards

The Administrator may provide that the Shares issued upon exercise of an Option or Stock Appreciation Right or otherwise subject to or issued under an Award shall be subject to such further agreements, restrictions, conditions or limitations as the Administrator in its sole and absolute discretion may specify prior to the exercise of such Option or Stock Appreciation Right or the grant, vesting or settlement of such Award, including without limitation, conditions on vesting or transferability, forfeiture or repurchase provisions and method of payment for the Shares issued upon exercise, vesting or settlement of such Award (including the actual or constructive surrender of Shares already owned by the Participant) or payment of taxes arising in connection with an Award. Without limiting the foregoing, such restrictions may address the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any Shares issued under an Award, including without limitation (i) restrictions under an insider trading policy or pursuant to applicable law, (ii) restrictions designed to delay and/ or coordinate the timing and manner of sales by Participant and holders of other Company equity compensation arrangements, (iii) restrictions as to the use of a specified brokerage firm for such resales or other transfers and (iv) provisions requiring Shares to be sold on the open market or to the Company in order to satisfy tax withholding or other obligations.

13. Adjustment of and Changes in the Stock

(a) General. The number and kind of Shares available for issuance under this Plan (including under any Awards then outstanding), and the number and kind of Shares subject to the limits set forth in Section 5 of this Plan, shall be equitably adjusted by the Administrator to reflect any reorganization, recategorization, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of Shares outstanding. Such adjustment shall be designed to comply with Sections 409A and 424 of the Code as applicable, or, except as otherwise expressly provided in Section 5(c) of this Plan, may be designed to treat the Shares available under the Plan and subject to Awards as if they were all outstanding on the record date for such event or transaction or to increase the number of such Shares to reflect a deemed reinvestment in Shares of the amount distributed to the Company’s securityholders. The terms of any outstanding Award shall also be equitably adjusted by the Administrator as to price, number or kind of Shares subject to such Award, vesting, and other terms to reflect the foregoing events, which adjustments need not be uniform as between different Awards or different types of Awards.

In the event there shall be any other change in the number or kind of outstanding Shares, or any stock or other securities into which such Shares shall have been changed, or for which it shall have been exchanged, by reason of a change of control, other merger, consolidation or otherwise, then the Administrator shall determine the appropriate and equitable adjustment to be effected.

No right to purchase fractional shares shall result from any adjustment in Awards pursuant to this Section 13. In case of any such adjustment, the Shares subject to the Award shall be rounded up to the nearest whole share for Awards other than Options and Stock Appreciation Rights, and shall be rounded down to the nearest whole Share with respect to Options and Stock Appreciation Rights. The Company shall notify Participants holding Awards subject to any adjustments pursuant to this Section 13 of such adjustment, but whether or not notice is given such adjustment shall be effective and binding for all purposes of the Plan.

(b) Change in Control. The Administrator may determine the effect of a Change in Control on outstanding Awards in a manner that, in the Administrator’s discretion, is fair and equitable to Participants. Such effects, which need not be the same for every Participant, may include, without limitation: (x) the substitution for the Shares subject to any outstanding Award, or portion thereof, of stock or other securities of the surviving corporation or any successor corporation to the Company, or a parent or subsidiary thereof, in which event the aggregate purchase or exercise price, if any, of such Award, or portion thereof, shall remain the same, and/or (y) the conversion of any outstanding Award, or portion thereof, into a right to receive cash or other property upon or following the consummation of the Change in Control in an amount equal to the value of the consideration to be received by holders of Shares in connection with such transaction for one Share, less the per share purchase or exercise price of such Award, if any, multiplied by the number of Shares subject to such Award, or a portion thereof.
14. Qualifying Performance-Based Compensation

(a) General. The Administrator may establish performance criteria and level of achievement versus such criteria that shall determine the number of Shares to be granted, retained, vested, issued or issuable under or in settlement of or the amount payable pursuant to an Award, which criteria may be based on Qualifying Performance Criteria or other standards of financial performance and/or personal performance evaluations.

(b) Qualifying Performance Criteria. For purposes of this Plan, the term “Qualifying Performance Criteria” shall mean any one or more of the following performance criteria, or derivations of such performance criteria, either individually, alternatively or in any combination, applied to either the Company as a whole or to a business unit or Subsidiary, either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a pre-established target, to previous years’ results or to a designated comparison group, in each case as specified by the Administrator: (i) net earnings or earnings per share (including earnings before interest, taxes, depreciation, license fees, share-based compensation, and/or amortization, or other non-GAAP profitability measures), (ii) income, net income or operating income, (iii) revenues, (iv) net sales, (v) return on sales, (vi) return on equity, (vii) return on capital (including return on total capital or return on invested capital), (viii) return on assets or net assets, (ix) economic value added measurements, (x) return on invested capital, (xi) return on operating revenue, (xii) cash flow (before or after dividends), (xiii) stock price, (xiv) total shareholder return, (xv) market capitalization, (xvi) economic value added, (xvii) debt leverage (debt to capital), (xviii) operating profit or net operating profit, (xix) operating margin or profit margin, (xx) cash from operations, (xxi) market share, (xxii) product development or release schedules, (xxiii) new product innovation, (xxiv) cost reductions, (xxv) customer service, or (xxvi) customer satisfaction. The Committee shall appropriately adjust any evaluation of performance under a Qualifying Performance Criterion to eliminate the effects of charges for restructuring, discontinued operations, extraordinary items and all items of gain, loss or expense determined to be extraordinary or unusual in nature or related to the disposal of a segment of a business or related to a change in accounting principle all as determined in accordance with applicable accounting provisions, as well as the cumulative effect of accounting changes, in each case as determined in accordance with generally accepted accounting principles or identified in the Company’s financial statements or notes to the financial statements, and may appropriately adjust any evaluation of performance under a Qualifying Performance Criterion to exclude any of the following events that occurs during a performance period: (i) asset write-downs, (ii) litigation, claims, judgments or settlements, (iii) the effect of changes in tax law or other such laws or provisions affecting reported results, and (iv) accruals of any amounts for payment under this Plan or any other compensation arrangement maintained by the Company.

15. Transferability

Unless the Administrator determines otherwise, each Award may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution, and each Option or Stock Appreciation Right shall be exercisable only by the Participant during their lifetime. To the extent permitted by the Administrator, the person to whom an Award is initially granted (the “Grantee”) may transfer an Award to any “family member” of the Grantee (as such term is defined in Section 1(a)[5] of the General Instructions to Form S-8 under the Securities Act of 1933, as amended (“Form S-8”), to trusts solely for the benefit of such family members and to partnerships in which such family members and/or trusts are the only partners; provided that, (i) as a condition thereof, the transferor and the transferee must execute a written agreement containing such terms as specified by the Administrator, and (ii) the transfer is pursuant to a gift or a domestic relations order to the extent permitted under the General Instructions to Form S-8. Except to the extent specified otherwise in the agreement the Administrator provides for the Grantee and transferee to execute, all vesting, exercisability and forfeiture provisions that are conditioned on the Grantee’s continued employment or service shall continue to be determined with reference to the Grantee’s employment or service (and not to the status of the transferee) after any transfer of an Award pursuant to this Section 15, and the responsibility to pay any taxes in connection with an Award shall remain with the Grantee notwithstanding any transfer other than by will or intestate succession.

16. Suspension or Termination of Awards

Except as otherwise provided by the Administrator, if at any time (including after a notice of exercise has been delivered or an award has vested) the Company’s chief executive officer or any other person designated by the Administrator (each such person, an “Authorized Officer”) reasonably believes that a Participant may have committed an Act of Misconduct as described in this Section 16, the Authorized Officer, Administrator or the Board may suspend the Participant’s rights to exercise any Option, to vest in an Award, and/or to receive payment for or receive Shares in settlement of an Award pending a determination of whether an Act of Misconduct has been committed.
If the Administrator or an Authorized Officer determines a Participant has committed an act of embezzlement, fraud, dishonesty, nonpayment of any obligation owed to the Company or any Subsidiary, breach of fiduciary duty, violation of Company ethics policy or code of conduct, or deliberate disregard of the Company or Subsidiary rules resulting in loss, damage or injury to the Company or any Subsidiary, or if a Participant makes an unauthorized disclosure of any Company or Subsidiary trade secret or confidential information, solicits any employee or service provider to leave the employ or cease providing services to the Company or any Subsidiary, breaches any intellectual property or assignment of inventions covenant, engages in any conduct constituting unfair competition, breaches any non-competition agreement, induces any Company or Subsidiary customer to breach a contract with the Company or any Subsidiary or to cease doing business with the Company or any Subsidiary, or induces any principal for whom the Company or any Subsidiary acts as agent to terminate such agency relationship (any of the foregoing acts, an “Act of Misconduct”), then except as otherwise provided by the Administrator, (i) neither the Participant nor their estate nor transferee shall be entitled to exercise any Option or Stock Appreciation Right whatsoever, vest in or have the restrictions on an Award lapse, or otherwise receive payment of an Award, (ii) the Participant will forfeit all outstanding Awards and (iii) the Participant may be required, at the Administrator’s sole and absolute discretion, to return and/or repay to the Company any then unvested Shares previously issued under the Plan. In making such determination, the Administrator or an Authorized Officer shall give the Participant an opportunity to appear and present evidence on their behalf at a hearing before the Administrator or its designee or an opportunity to submit written comments, documents, information and arguments to be considered by the Administrator.

17. Compliance with Laws and Regulations

This Plan, the grant, issuance, vesting, exercise and settlement of Awards thereunder, and the obligation of the Company to sell, issue or deliver Shares under such Awards, shall be subject to all applicable foreign, federal, state and local laws, rules and regulations, stock exchange rules and regulations, and to such approvals by any governmental or regulatory agency as may be required. The Company shall not be required to register in a Participant’s name or deliver any Shares prior to the completion of any registration or qualification of such shares under any foreign, federal, state or local law or any ruling or regulation of any government body which the Administrator shall determine to be necessary or advisable. To the extent the Company is unable to or the Administrator deems it infeasible to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, the Company and its Subsidiaries shall be relieved of any liability with respect to the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained. No Option shall be exercisable and no Shares shall be issued and/or transferable under any other Award unless a registration statement with respect to the Shares underlying such Option is effective and current or the Company has determined that such registration is unnecessary.

In the event an Award is granted to or held by a Participant who is employed or providing services outside the United States, the Administrator may, in its sole and absolute discretion, modify the provisions of the Plan or of such Award as they pertain to such individual to comply with applicable foreign law or to recognize differences in local law, currency or tax policy. The Administrator may also impose conditions on the grant, issuance, exercise, vesting, settlement or retention of Awards in order to comply with such foreign law and/or to minimize the Company’s obligations with respect to tax equalization for Participants employed outside their home country.

18. Withholding

To the extent required by applicable federal, state, local or foreign law, a Participant shall be required to satisfy, in a manner satisfactory to the Company, any withholding tax obligations that arise by reason of an Option exercise, disposition of Shares issued under an Incentive Stock Option, the vesting of or settlement of an Award, an election pursuant to Section 83(b) of the Code or otherwise with respect to an Award. To the extent a Participant makes an election under Section 83(b) of the Code, within ten days of filing such election with the Internal Revenue Service, the Participant must notify the Company in writing of such election. The Company and its Subsidiaries shall not be required to issue Shares, make any payment or to recognize the transfer or disposition of Shares until all such obligations are satisfied. The Administrator may provide for or permit these obligations to be satisfied through the mandatory or elective sale of Shares and/or by having the Company withhold a portion of the Shares that otherwise would be issued to him or her upon exercise of the Option or the vesting or settlement of an Award, or by tendering Shares previously acquired.

19. Administration of the Plan

(a) Administrator of the Plan. The Plan shall be administered by the Administrator who shall be the Compensation Committee of the Board or, in the absence of a Compensation Committee, the Board itself. Any power of the Administrator may also be exercised by the Board, except to the extent that the grant or exercise of such authority would cause any Award or transaction to become subject to (or lose an exemption under) the short-term stock recovery provisions of Section 16 of the Act. To the extent that any permitted action taken by the Board conflicts with action taken by the Administrator, the Board action shall control. The Compensation Committee may by resolution authorize one or more officers of the Company to perform any or all things that the Administrator is authorized and empowered to do or perform under the Plan, and for all purposes under this Plan, such officer or officers shall be treated as the Administrator; provided, however, that no such officer shall designate himself or herself as a recipient of any Awards granted under authority delegated to such officer. The Compensation Committee may delegate any or all aspects of the day-to-day administration of the Plan to one or more officers or employees of the Company or any Subsidiary, and/or to one or more agents.
[b] Powers of Administrator. Subject to the express provisions of this Plan, the Administrator shall be authorized and empowered to do all things that it determines to be necessary or appropriate in connection with the administration of this Plan, including, without limitation: (i) to prescribe, amend and rescind rules and regulations relating to this Plan and to define terms not otherwise defined herein; (ii) to determine which persons are Participants, to which of such Participants, if any, Awards shall be granted hereunder and the timing of any such Awards; (iii) to grant Awards to Participants and determine the terms and conditions thereof, including the number of Shares subject to Awards and the exercise or purchase price of such Shares and the circumstances under which Awards become exercisable or vested or are forfeited or expire, which terms may but need not be conditioned upon the passage of time, continued employment, the satisfaction of performance criteria, the occurrence of certain events (including a Change in Control), or other factors; (iv) to establish and verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, exercisability, vesting and/or ability to retain any Award; (v) to prescribe and amend the terms of the agreements or other documents evidencing Awards made under this Plan (which need not be identical) and the terms of or form of any document or notice required to be delivered to the Company by Participants under this Plan; (vi) to determine the extent to which adjustments are required pursuant to Section 13; (vii) to interpret and construe this Plan, any rules and regulations under this Plan and the terms and conditions of any Award granted hereunder, and to make exceptions to any such provisions if in the Administrator, in good faith, determines that it is necessary to so do in light of extraordinary circumstances and for the benefit of the Company (provided that nothing in this Section 19(b) permits the Committee to provide that any Award may vest before the first anniversary of the date of grant other than in connection with the Participant’s death or disability or a Change in Control); (viii) to approve corrections in the documentation or administration of any Award; and (ix) to make all other determinations deemed necessary or advisable for the administration of this Plan. The Administrator may, in its sole and absolute discretion, without amendment to the Plan, waive or amend the operation of Plan provisions respecting exercise after termination of employment or service to the Company or an Affiliate and, except as otherwise provided herein, adjust any of the terms of any Award (subject to the proviso in item (viii) of the immediately preceding sentence). Except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether in the form of cash, Shares, other securities or other property), stock split, extraordinary cash dividend, recapitalization, Change in Control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of Shares or other securities, or similar transaction(s)), the Company may not, without obtaining shareholder approval: (w) amend the terms of outstanding Options or Stock Appreciation Rights to reduce the exercise price of such outstanding Options or Stock Appreciation Rights; (x) cancel outstanding Options or Stock Appreciation Rights in exchange for Options or Stock Appreciation Rights with an exercise price that is less than the exercise price of the original Options or Stock Appreciation Rights; (y) cancel outstanding Options or Stock Appreciation Rights with an exercise price above the current stock price in exchange for cash or other securities; or (z) otherwise amend, exchange or reprice Options or Stock Appreciation Rights.

c) Determinations by the Administrator. All decisions, determinations and interpretations by the Administrator regarding the Plan, any rules and regulations under the Plan and the terms and conditions of or operation of any Award granted hereunder, shall be final and binding on all Participants, beneficiaries, heirs, assigns or other persons holding or claiming rights under the Plan or any Award. The Administrator shall consider such factors as it deems relevant, in its sole and absolute discretion, to making such decisions, determinations and interpretations including, without limitation, the recommendations or advice of any officer or other employee of the Company and such attorneys, consultants and accountants as it may select.

d) Subsidiary Awards. In the case of a grant of an Award to any Participant employed by a Subsidiary, such grant may, if the Administrator so directs, be implemented by the Company issuing any subject Shares to the Subsidiary, for such lawful consideration as the Administrator may determine, upon the condition or understanding that the Subsidiary will transfer the Shares to the Participant in accordance with the terms of the Award specified by the Administrator pursuant to the provisions of the Plan. Notwithstanding any other provision hereof, such Award may be issued by and in the name of the Subsidiary and shall be deemed granted on such date as the Administrator shall determine.

e) Indemnification of Administrator. Neither any member nor former member of the Administrator nor any individual to whom authority is or has been delegated shall be personally responsible or liable for any act or omission in connection with the performance of powers or duties or the exercise of discretion or judgment in the administration and implementation of the Plan. Each person who is or shall have been a member of the Administrator shall be indemnified and held harmless by the Company from and against any cost, liability or expense imposed or incurred in connection with such person’s or the Administrator’s taking or failing to take any action under the Plan. Each such person shall be justified in relying on information furnished in connection with the Plan’s administration by any employee, officer, agent or expert employed or retained by the Administrator or the Company.

20. Amendment of the Plan or Awards

The Board may amend, alter or discontinue this Plan and the Administrator may amend or alter any agreement or other document evidencing an Award made under this Plan but, except as provided pursuant to the provisions of Section 13, no such amendment shall, without the approval of the shareholders of the Company:

(a) increase the maximum number of Shares for which Awards may be granted under this Plan;
(b) reduce the price at which Options or Stock Appreciation Rights may be granted below the price provided for in Section 6(a);
(c) amend the last sentence of Section 19(b) (relating to direct and indirect repricings of outstanding Options and Stock Appreciation Rights);
(d) amend the proviso in Section 19(b)(vii);
(e) extend the term of this Plan;
(f) change the class of persons eligible to be Participants;
(g) otherwise amend the Plan in any manner requiring shareholder approval by law or under Nasdaq Global Select Market listing requirements or the listing requirements of any successor exchange or market that is the primary stock exchange or market for trading of Shares; or
(h) increase the individual maximum limits in Sections 5(c) and (d).

No amendment or alteration to the Plan or an Award or Award Agreement shall be made which would impair the rights of the holder of an Award, without such holder’s consent, provided that no such consent shall be required if the Administrator determines in its sole and absolute discretion and prior to the date of any Change in Control that such amendment or alteration either is required or advisable in order for the Company, the Plan or the Award to satisfy any law or regulation or to meet the requirements of or avoid adverse financial accounting consequences under any accounting standard. In addition, the Plan may not be amended in any way that causes the Plan to fail to comply with or be exempt from Section 409A of the Code, unless the Board expressly determines to amend the Plan to be subject to Section 409A of the Code.

21. No Liability of Company

The Company and any Subsidiary or Affiliate which is in existence or hereafter comes into existence shall not be liable to a Participant or any other person as to: (a) the non-issuance or sale of Shares as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder; and (b) any tax consequence expected, but not realized, by any Participant or other person due to the receipt, exercise or settlement of any Award granted hereunder.

22. Non-Exclusivity of Plan

Neither the adoption of this Plan by the Board nor the submission of this Plan to the shareholders of the Company for approval shall be construed as creating any limitations on the power of the Board or the Administrator to adopt such other incentive arrangements as either may deem desirable, including without limitation, the granting of restricted stock or stock options otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases.

23. Governing Law

This Plan and any agreements or other documents hereunder shall be interpreted and construed in accordance with the laws of the Delaware and applicable federal law. Any reference in this Plan or in the agreement or other document evidencing any Awards to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.

24. No Right to Employment, Reelection or Continued Service

Nothing in this Plan or an Award Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and/ or its Affiliates to terminate any Participant’s employment, service on the Board or service for the Company at any time or for any reason not prohibited by law, nor shall this Plan or an Award itself confer upon any Participant any right to continue their employment or service for any specified period of time. Neither an Award nor any benefits arising under this Plan shall constitute an employment contract with the Company, any Subsidiary and/or its Affiliates. Subject to Sections 4 and 20, this Plan and the benefits hereunder may be terminated at any time in the sole and exclusive discretion of the Board without giving rise to any liability on the part of the Company, its Subsidiaries and/or its Affiliates.

25. Unfunded Plan

The Plan is intended to be an unfunded plan. Participants are and shall at all times be general creditors of the Company with respect to their Awards. If the Administrator or the Company chooses to set aside funds in a trust or otherwise for the payment of Awards under the Plan, such funds shall at all times be subject to the claims of the creditors of the Company in the event of its bankruptcy or insolvency.
ANNEX B - NON-GAAP FINANCIAL INFORMATION

This Proxy Statement contains the following financial measures that do not comply with United States generally accepted accounting principles (GAAP):

- **Non-GAAP Diluted EPS** (see the 2020 Performance in Review section above): Non-GAAP earnings is defined as net income, adjusted for: (1) share-based compensation expense (including expenses relating to stock options, restricted stock units, share tracking awards, and our employee stock purchase plan); (2) unrealized gains on investments in privately-held companies; (3) impairments of investments in privately-held companies; (4) asset impairment charges; (5) license-related fees; (6) net changes in recurring fair value measurements; and (7) tax impact on non-GAAP earnings adjustments. Non-GAAP earnings is divided by diluted weighted average shares outstanding to derive non-GAAP diluted earnings per share (EPS). A reconciliation of net income to non-GAAP earnings is presented below:

<table>
<thead>
<tr>
<th>In millions, except per share data</th>
<th>Year Ended December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income, as reported</td>
<td>$ 514.8</td>
</tr>
<tr>
<td>Adjusted for the following:</td>
<td></td>
</tr>
<tr>
<td>Share-based compensation expense</td>
<td>163.8</td>
</tr>
<tr>
<td>Unrealized gains on investments in privately-held companies</td>
<td>(25.5)</td>
</tr>
<tr>
<td>Impairments of investments in privately-held companies</td>
<td>9.1</td>
</tr>
<tr>
<td>Asset impairment charges</td>
<td>6.9</td>
</tr>
<tr>
<td>License-related fees</td>
<td>33.6</td>
</tr>
<tr>
<td>Net changes in recurring fair value measurements</td>
<td>(25.7)</td>
</tr>
<tr>
<td>Tax benefit</td>
<td>(32.3)</td>
</tr>
<tr>
<td><strong>Non-GAAP earnings</strong></td>
<td>$ 644.7</td>
</tr>
<tr>
<td>Non-GAAP earnings per share</td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>$ 14.59</td>
</tr>
<tr>
<td>Diluted</td>
<td>$ 14.46</td>
</tr>
<tr>
<td>Weighted average number of common shares outstanding:</td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>44.2</td>
</tr>
<tr>
<td>Diluted</td>
<td>44.6</td>
</tr>
</tbody>
</table>

- **EBITDASO** (see the 2020 Compensation Decisions section above): EBITDASO is defined as net income, adjusted for: (1) interest income, net; (2) income tax expense; (3) depreciation and amortization expense; and (4) share-based compensation expense (including expenses relating to stock options, restricted stock units, share tracking awards, and our employee stock purchase plan). EBITDASO is divided by total revenues to derive EBITDASO margin. A reconciliation of net income to EBITDASO is presented below:

<table>
<thead>
<tr>
<th>In millions, except percentages</th>
<th>Year Ended December 31, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income, as reported</td>
<td>$ 514.8</td>
</tr>
<tr>
<td>Adjusted for the following:</td>
<td></td>
</tr>
<tr>
<td>Interest income, net</td>
<td>(5.1)</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>124.1</td>
</tr>
<tr>
<td>Depreciation &amp; amortization expense</td>
<td>49.9</td>
</tr>
<tr>
<td>Share-based compensation expense</td>
<td>163.8</td>
</tr>
<tr>
<td><strong>EBITDASO (Non-GAAP)</strong></td>
<td>$ 847.5</td>
</tr>
<tr>
<td>Total revenues</td>
<td>$ 1,483.3</td>
</tr>
<tr>
<td>Net income margin</td>
<td>34.7 %</td>
</tr>
<tr>
<td>EBITDASO margin</td>
<td>57.1 %</td>
</tr>
</tbody>
</table>
We use these non-GAAP financial measures to assist us in: [1] planning, including the preparation of our annual operating budget; [2] allocating resources in an effort to enhance the financial performance of our business; [3] evaluating the effectiveness of our operational strategies; and [4] assessing our capacity to fund capital expenditures and expand our business. We believe these non-GAAP financial measures improve investors’ understanding of our financial results by excluding certain income and expenses that we do not consider when evaluating and comparing the performance of our core operations and making operating decisions. However, there are limitations in the use of these non-GAAP financial measures in that they exclude certain operating expenses that are recurring in nature. In addition, our calculation of these non-GAAP financial measures may differ from the methodologies used by other companies. The presentation of these non-GAAP financial measure should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.